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The hallmarks of cancer have paved the way for the development of target approached 
agents which are more selective and active towards cancer cells. Irrespective of this 
paradigm shift, there are still many hindrances to effective drug treatment which cause drug 
resistance such as hypoxia and mild acidity which are found in the tumour microenvironment 
(TME). One way to circumvent this issue is by the use of hypoxia activated prodrugs (HAPs), 
but with over 40 years of research there is still no HAP that is approved for use in humans. A 
new strategy to overcome this barrier is to apply a phenotypic screening approach to test 
compounds under those conditions which are favourable to the TME such as the 
combination of hypoxia and mild acidity.  
The aim of this study is to evaluate a series of compounds using a phenotypic evaluation 
strategy based upon testing compounds under (i) normoxia / pHe 7.4, (ii) normoxia / pHe 
6.5, (iii) hypoxia / pHe 7.4 and (iv) hypoxia / pHe 6.5 and (v) compare activity in cancer cells 
to non-cancer cells. The objective of this study is to identify compounds that preferentially 
and selectively kill cancer cells that reside within the TME that would not have been 
identified using standard cell culture conditions.  
In this study, a series of novel compounds (i) ruthenium, iridium and rhodium based 
napthyridines, thiourea derivatives, benzylthiourea ligands and aroylthiourea compounds, (ii) 
Bromo-hexitol prodrugs, (iii) NHC-Ag based complexes, (iv) Minor groove binders and (v) 
Tyrosine kinase inhibitor (dasatinib) with the attachment of 2-nitroimidazole have been 
provided by collaborators which will be screened under TME conditions to determine the 
potency (IC50), under hypoxic conditions (0.1% O2)  and in combination of mild acidity (pHe 
6.5). As well as potency the selectivity index (SI) which is defined as the ratio of IC50 values 
in non-cancer cells divided by the IC50 of cancer cells will also be determined. Those 
compounds that pass these tests are then to be subjected for further mechanistic studies. 
The initial studies focused on screening three classic chemotherapeutic drugs, cisplatin, 5-
FU, etoposide and the classic HAP tirapazamine under the TME conditions. All three classic 
chemotherapeutic drugs displayed high activity under normoxic conditions but showed 
resistance under TME conditions (i.e. hypoxia, mild acidity and the combination of both) with 
moderate to poor selectivity towards cancer cells. As expected, tirapazamine displayed HAP 
like abilities. These results were set as the ‘gold standard’ throughout this PhD study and 
were used to compare with the new novel compounds that were screened. A total of 72 
compounds were tested using this screen where 40 (55%) compounds were selective 
towards the cancer cell lines, 8 (11%) compounds were further activated under normoxic 
extracellular pH (pHe) 6.5 conditions, 24 (33%) compounds exhibited HAP like properties 
and finally 3 (4.1%) compounds displayed enhanced toxicity with the combination of hypoxia 
and pHe 6.5 conditions. The compounds screened in some instances did display superior 
selectivity and preferential activity towards cells under TME conditions in comparison to the 
classic chemotherapeutic  drugs which is promising.  
In conclusion, the phenotypic based screen employed throughout this study demonstrates 
potential in identifying compounds that show preferential activity and resistance to cells 
under TME conditions. Both results are valuable in terms of the decision making process for 
the selection of lead compounds and further studies are required to develop this concept 
further.   
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Chapter 1: General introduction 
1.1 Introduction to cancer  
Cancer is characterised by the abnormal proliferation of cells caused by multiple 
changes in gene expression which leads to an imbalance between cell growth and 
cell death. These cells ultimately become a population that have the ability to 
metastasize and invade other tissues causing significant morbidity and if left 
untreated, may lead to mortality (Ruddon, 2007). This can be caused by several 
different factors including smoking, overweight and obesity, alcohol, lack of physical 
activity, poor diet, sun and UV (ultra-violet) light, air pollution, hormones and 
inherited genes (Ruddon, 2007). During the development of cancer, cells acquire a 
number of characteristics or ‘hallmarks’, details of which are summarised below. 
 
1.2 The hallmarks of cancer 
With the emergence of the field of molecular biology in the 1980’s, a rich and 
complex body of knowledge has been generated revealing cancer to be a disease 
involving dynamic changes in the genome leading to the acquisition of multiple 
genetic and/or epigenetic lesions. In a landmark review article, Hanahan and 
Weinberg (2000), have described the development of cancer as the acquisition of a 
series of characteristics or ‘Hallmarks’. This concept essentially describes the key 
features that tumours acquire during their journey from normal to malignant cells 
(Hanahan and Weinberg, 2000, 2011). The six original hallmarks are illustrated in 
figure 1.1 and they include: (i) sustained proliferative signalling (ii) evading growth 
suppressors (iii) enabling replicative immortality (iv) activating invasion and 




Figure 1.1 The hallmarks of cancer as defined by Hanahan and Weinberg 
(Hanahan and Weinberg, 2000).  
 
Following on from their original review article, Hanahan and Weinberg reviewed the 
progress that had been made in the following decade and in 2011, they published 
the ‘next generation’ of hallmarks (Hanahan and Weinberg, 2011). As illustrated in 
figure 1.2, they identified two emerging hallmarks of cancer and two enabling 
characteristics that aid the development of cancers. In this article, they also illustrate 
the importance of how understanding of tumour biology has led to the development 
of novel therapeutics and describe the challenges posed by the emergence of new 
mechanisms of drug resistance caused by an unstable genome and tumour cell 






Figure 1.2 The next generation of the hallmarks of cancer as defined by 
Hanahan and Weinberg (Hanahan and Weinberg, 2011). This concept is built 
upon their original paper in 2000 with the addition of two emerging hallmarks 
(avoiding immune destruction and deregulating cellular energetics) and two enabling 
characteristics (genome instability and mutation and tumour promoting 
inflammation).  
1.3 Treatment of cancer 
The treatment of cancer involves three main strategies; surgery, radiotherapy and 
chemotherapy. Chemotherapy is typically used in combination with surgery or 
radiotherapy and in some instances both. Chemotherapy is given alone to leukaemia 
patients where the disease is blood borne from the onset and therefore not 
amendable to surgery. Chemotherapy is defined as the use of drugs to eradicate 
cancer cells that may have spread around the body or to treat disease that is 
disseminated from the onset.    
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Chemotherapy drugs can be categorised into two main groups: (i) traditional 
cytotoxic drugs and (ii) the more modern targeted therapeutics. Cytotoxic drugs 
consist of chemicals which target various aspects of DNA synthesis and cell 
replication and therefore have preferential activity against dividing cells. Targeted 
therapeutics target specific biochemical pathways that are implicated in the growth 
and survival of cancer cells. Cytotoxic drugs are classified based upon (i) their 
mechanism of action and (ii) their effect on cells at different stages of the cell cycle. 
Both classifications are illustrated in figure 1.3.  
 
Figure 1.3 The cell cycle and the different types of chemotherapeutic agents 
targeting specific check points of the cell cycle. There are four main stages of 
the cell cycle which are (i) G0 – cell growth and preparation for new cells, (ii) S – 
DNA and RNA synthesis, (iii) G2 – checkpoint for DNA error and (iv) M – Microtubule 
assembly (Mills et al., 2018). 
 
The cell cycle is divided into different stages, namely G1, S, G2 and M phases. The 
four stage cell cycle is coordinated accurately by cyclin-dependent kinases (CDKs), 
5 
 
checkpoint proteins as well as regulatory cyclins which all detect if there are any 
errors in order to preserve genome integrity (Hsieh and Yamane, 2008). The 
cytotoxic chemotherapy drugs target different phases of the cell cycle as illustrated in 
table 1.1 but their ability to target replicating cells is a fundamental characteristic of 
the majority of cytotoxic drugs. It is known however that certain alkylating agents are 
equally effective against dividing and non-dividing cells but in general, these drugs 
typically target dividing cells. 
 







































































Table 1.1 Therapies designed to target the cell cycle (Mills et al., 2018). There 
are some chemotherapy drugs which are not cell cycle specific such as alkylating 
and platinum-based agents. The remainder of the therapies preferentially kill cells in 
certain phases of the cell cycle but there is some overlap as illustrated in figure 1.3.  
 
Targeted therapeutics represent the product of modern-day approaches to drug 
discovery based upon the identification of biochemical targets and pathways that 
drive cancer progression and development (Jaibu et al., 2018). They can be broadly 
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characterised as being either small molecule inhibitors of key enzymes involved in 
aberrant cell signalling pathways (such as tyrosine kinase inhibitors) or large 
monoclonal antibodies that target either ligand or receptor biology. A detailed 
description of these therapeutics is beyond the scope of this thesis but for a more 
comprehensive review of targeted anti-cancer drugs, the reader is referred to 
excellent reviews on the topic (Seebacher et al., 2019), (Falzone et al., 2018).  
1.4 Chemotherapeutic side effects and resistance 
As stated above, one of the major characteristic features of tumours is unregulated 
cell proliferation and cytotoxic chemotherapy that work by targeting rapidly 
proliferating cells. Unfortunately, this class of anti-cancer agents are not able to 
distinguish between rapidly dividing normal and cancerous cells leading to unwanted 
side effects, many of which are dose limiting and potentially life threatening. The hair 
matrix keratinocytes, bone stem cells, immunocytes and gastrointestinal cells are 
some prime examples of normal cells that are rapidly dividing cells leading to 
unwanted side effects in these tissues and organs (Paus et al., 2013). Cytotoxic 
drugs therefore have poor selectivity for cancer cells and typically have a narrow 
therapeutic index.  
To circumvent this issue, the targeted therapeutics introduced above were 
developed with the aim of specifically targeting the cancer cells and widening their 
therapeutic index (A Baudino, 2015). Examples of these are small molecule 
inhibitors such as the tyrosine kinase inhibitors (TKI’s), monoclonal antibodies, 
naked monoclonal antibodies, conjugated monoclonal antibodies and bispecific 
monoclonal antibodies (Jaibu et al., 2018). Despite the promising concept of 
targeting cancerous cells specifically, these antibodies/ inhibitors also have their 
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limitations and are often associated with adverse effects. Examples of these adverse 
effects are, vomiting, rashes, diarrhoea and fever for the antibodies and bleeding, 
fever, hypertension, constipation, hypothyroidism for the small molecule inhibitors 
(Jaibu et al., 2018). However, their side effects are generally not as severe in 
comparison to conventional cytotoxic chemotherapeutic agents. 
As well as unwanted side effects, another limitation of both cytotoxic and targeted 
anti-cancer drugs is the problem of resistance. There are three major forms of 
resistance; (i) inherent resistance where cells are insensitive to drugs (ii) apparent 
resistance where cells are inherently sensitive to the drugs but don’t respond 
because of poor drug delivery and (iii) acquired resistance where cells initially 
respond to treatment but when relapse occurs, the tumours are not only resistant to 
the drugs they were originally treated with but have developed a multidrug resistance 
phenotype. Multiple mechanisms of resistance are known for cytotoxic drugs 
(increased drug efflux, decreased drug uptake, increased detoxification, increased 
DNA repair etc) and new mechanisms of resistance to targeted therapeutics are 
being reported including mutational changes to the target leading to steric hindrance 
of inhibitors etc (Barbuti and Chen, 2015) (Zhang et al., 2015).  
Whilst significant improvements in the treatment of cancer patients using drugs has 
been achieved, it is debatable as to whether there has been a paradigm shift in the 
successful treatment of cancer has occurred. In addition, the high cost of the new 
generation of targeted drugs has led to ‘financial toxicity’ with patients and clinicians 
having to make very difficult decisions based upon the availability of funds 
(Drummond and Mason, 2007). Furthermore, the dual problems of tumour cell 
heterogeneity and genomic instability are significant barriers to the successful 
treatment of cancer and there is therefore still a need to develop novel therapeutics 
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that addresses these key issues. There is a need to develop new therapies mainly to 
overcome the evolving nature of cancer and one way to overcome this is by the 
phenotypic screening of novel drugs for the identification of new therapies that target 
multiple pathways. Before discussing this in more detail, a general overview of the 
drug discovery process is provided below.  
 
1.5 The drug discovery process 
The drug discovery and development process are lengthy and inefficient and it is 
estimated that only one compound from tens of thousands tested will become 
licensed treatments. There is a vigorous screening process as illustrated in figure 1.4 
where new drugs can be rejected at any given time on the following basis, safety, 










Figure 1.4 Diagram of the major processes involved from getting a new drug 
from lab to approval (Lipsky and Sharp, 2001). The blue boxes represent the filtering 
process of the thousands of drugs which are screened. IND (investigational new drug) allows 
pharmaceutical companies to start human clinical trials. NDA (new drug application).  
 
There are two main approaches to the drug discovery process; (i) target orientated 
drug development and (ii) random screening or ‘phenotypic’ drug development. 
Target orientated drug discovery relies on an understanding of tumour biology to 
identify and validate key proteins or pathways that drive the cancer process as 
targets for therapeutic intervention. The synthesis of molecules or the screening of 
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compound libraries against the target will lead to the identification of ‘hits’ or lead 
compounds which then undergo optimisation steps to enhance their ‘drug like’ 
properties. These lead compounds are then evaluated in vivo and if successful, they 
enter phase I clinical evaluation. At all stages of the process, establishing ‘proof of 
principle’ is essential where any anti-cancer activity is assigned to drug target 
interactions. An example of targeted therapy are tyrosine kinase inhibitors such as 
imatinib (Jaibu et al., 2018). 
The second approach of random drug screening has been traditionally run by the 
National Cancer Institute (NCI) in the USA and it assumes that the ‘magic bullet’ has 
been either synthesised by chemists or is present somewhere in the natural world. 
By using high capacity cell screening approaches, the magic bullet will eventually be 
found. In simple terms, the active compound is found first and then the mechanism 
of action is determined later in a process called target deconvolution. The NCI’s 
approach to random drug screening has evolved over the years and currently relies 
on testing compounds against 60 cell lines, details of which are described below. 
1.6 The NCI60 approach to random drug screening 
The NCI60 screening method was first utilised in the 1990’s and consists of 9 
different distinct panels of cell lines including lung, brain, colon, ovary, prostate, 
breast, leukaemia, melanoma and kidney cells consisting of 60 cell lines in total 
(Shoemaker, 2006). Initial testing is done against 3 cell lines, the purpose of which is 
to eliminate those compounds that are inactive. If activity is obtained in the three-cell 
line panel, the compound progresses to the full 60 cell line panel and here, the test 
compound is added to cells for a 48hour time period using a 5-log concentration 
range. Upon completion, 60 dose response curves are obtained which can be 
analysed and three end point calculations are determined for each cell line. The 
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three end point calculations are (i) GI50 which is the concentration of test compound 
required to inhibit the growth of the cell line by 50% (ii) complete tumour growth 
inhibition (TGI) which is defined as the concentration of drug that completely 
prevents the growth of the cell line (i.e. the cell number at the end of the assay is the 
same as the starting cell number) and (iii) LC50 which is the concentration of 
compound required to kill 50% of the cells (Damia and D’Incalci, 2009). The 
completion of this study creates a unique ‘fingerprint’ of cellular response which 
allows the researcher to profile and characterise the data in terms of the sensitivity 
and resistance of each cell line to the test compound relative to the mean endpoint 
parameter used (GI50, TGI, LC50). The compounds which exhibit similar mechanism 
of actions will depict a similar pattern of growth inhibition across the 60 different cell 
lines screened against (Damia and D’Incalci, 2009). The COMPARE algorithm which 
was created by Paull et al., (1989) is a computer software programme that can be 
used to interpret chemosensitivity fingerprints by comparing the unique fingerprint of 
test compounds with that of established compounds for which the mechanism of 
action is known. If the unique fingerprint does not match the COMPARE algorithm 
database, then it is deemed as a COMPARE negative result which is more appealing 
to researchers as this is used for the identification of compounds with new 
mechanism of actions (Paull et al., 1989) (Damia and D’Incalci, 2009).  
 
The NCI60 screening strategy has been very successful in the identification of new 
therapies such as bortezomib which is used in the treatment of multiple myeloma 
(Shoemaker, 2006). As with all in vitro based assays however, there are limitations 
but the widely accepted view is that the NCI60 has provided useful information, 
particularly with regards to the identification of compounds with novel mechanisms of 
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action. In addition, the characterisation of molecular targets in the cell line panel has 
enabled comparisons to be made between target expression and chemosensitivity 
patterns which aids the process of target deconvolution (Paull et al., 1989) 
(Shoemaker, 2006). Once lead compounds have been identified, they progress into 
in vivo testing, details of which are outlined below.  
1.7 In vivo testing of novel compounds: The ‘hollow fibre’ assay 
The NCI developed the in vivo hollow fibre assay as a bridge between the in vitro 
assays and the human xenograft models in immune-deficient mice (Decker et al., 
2004; Hall et al., 2000). This intermediary assay was utilised for the better prediction 
of which lead compound observed in the in vitro study would be most appropriate to 
use in the subsequent xenograft models. The general cost of animals required, time 
constraints and the financial commitment essential for the in vivo studies justified the 
use of the hollow fibre assays as a faster means of screening these compounds 
(Damia and D’Incalci, 2009). The hollow fibre assay is devised in a manner where 
biocompatible hollow fibres are used as a ‘vessel’ for tumour cells to grow in an in 
vitro setting and later (24-48hours), these are implanted subcutaneously or 
intraperitoneally into nude mice. The pore size of the hollow fibres are not only small 
enough to prevent cancer cells escaping but they allow the entry of drug of interest 
with a molecular weight less than 500kDa (this also includes large proteins or 
peptides). The hollow fibre assay has also been used to investigate other important 
parameters such as the pharmacodynamics of the drug (Suggitt et al., 2006) 
(Temmink et al., 2007). The end point assays used in these pharmacodynamics 
studies are, apoptosis, comet assay and cell cycle analysis. If compounds are active 




1.8 In vivo testing of novel compounds: human tumour xenografts 
The in vivo studies are carried out in an animal model setting in order to demonstrate 
(i) that the test compound has activity (at the maximum tolerated dose) and (ii) the 
pharmacokinetic properties (i.e. drug distribution, excretion, metabolism, drug-drug 
interactions, and absorption) of the compound are satisfactory (Venditti et al., 1984). 
There are different types of in vivo models that can be used such as (i) tumour 
xenograft models which are important for the testing of efficacy where the target is 
known or present (Venditti et al., 1984) (ii) the hollow fibre assay which has been 
previously mentioned, (iii) the use of orthotopic and metastatic tumour models to 
overcome the limitation of tumour xenograft models which are grown in a tissue 
environment that is different to the origin organ of the tumour (Bibby, 2004) and (iv) 
the use of transgenic mice and genetically engineered (GEM) cancer models (Damia 
and D’Incalci, 2009). If compounds are active in vivo, they must obtain 
‘investigational new drug’ (IND) approval before any studies can take place in human 
subjects. As FDA highlights “safety first,” it is important that the first 4 stages or 
phases of a clinical trial is planned to assess the maximum tolerated dose and safety 
of a drug, the pharmacokinetics and pharmacodynamics involved in the process. 
1.9 Clinical testing: Phase I studies 
The purpose of a phase I trial is to (i) determine the maximum tolerated dose (ii) 
define the toxic side effects that are encountered (iii) analyse the pharmacokinetic 
properties of a drug and (iv) conduct biomarker studies to determine if the drug is 
targeting the desired biochemical pathway (Lipsky and Sharp, 2001). This study is 
small in number and usually consists of around 20-100 patients with cancerous 
disease (Lipsky and Sharp, 2001). 
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1.10 Clinical testing: Phase II studies 
The clinical phase II trial usually focuses on the efficacy of the drug against a cancer 
type (i.e. lung or breast) or tumours that carry a specific mutation/oncogenic driver 
that the drug targets. The primary objective is to establish whether or not the drug 
has anti-tumour activity (and if it works via the mechanism proposed). The number of 
patients in the phase II trials are normally larger than the phase I studies and involve 
patients with the disease of interest. The experimental design is also essential for 
planning the next phase (III studies) to determine, (i) optimum dose, (ii) how frequent 
the dose should be administered, (iii) the route of administration and (iv) endpoints 
(Umscheid et al., 2011). The number of participants in this trial limits the potential of 
a strong efficacy report and therefore warrants a study with a much larger participant 
number which is the clinical phase III studies (Umscheid et al., 2011). 
1.11 Clinical testing: Phase III studies 
The clinical phase III study focuses on confirming the data obtained from the 
previous studies which were focused on both safety and efficacy. The clinical phase 
III study also compares the results obtained with the test compound against the 
existing methods for treating patients, with the purpose of determining whether or not 
the new drug works better than existing therapies. This study is much larger and 
more diverse than the previous two and usually involves between 300-3000 
participants (Umscheid et al., 2011). The statistical power established from these 
numbers of participants based on Hanley’s ‘Rule of 3’ for an adverse event rate is no 
less than 1 in 100 participants (Eypasch et al., 1995). This signifies the importance of 
a clinical phase IV study as more than one clinical phase III study is sometimes 
required for the establishment of efficacy, drug safety and to identify less common 
adverse reactions (Umscheid et al., 2011). 
15 
 
1.12 Clinical testing: Phase IV studies 
By this stage the drug is usually approved and is required to go through some 
additional testing, (i) to determine if the common adverse reactions can be reduced, 
(ii) if there are any limitations in pre-marketing as previous statistics have shown that 
approximately 20% of new drugs require new warnings post-marketing and roughly 
4% of the drugs are consequently withdrawn due to safety reasons (iii) evaluate the 
costs of the drug and (iv) determine the effectiveness of the drug doses in diseases 
different to the original population (Bakke et al., 1995) (Lasser et al., 2002). 
1.13 Targeted or phenotypic drug discovery? 
Returning to the issue of preclinical drug development, the initial stages of the drug 
discovery process is challenging and each approach has its strengths and 
limitations. If the molecular target is known, then a much more focused targeted 
approach can be taken by using both cell-free and cell-based assays to identify new 
novel lead molecules which have a potent effect on either the pathway or 
biochemical target (Shoemaker et al., 2002). The cell-free based assay is (i) very 
amendable to high through put screening, (ii) precise, (iii) simple and (iv) target 
focused therefore able to generate many hit leads (Zhang et al., 1999) (Zhang et al., 
2000). Whereas the cell-based assay can (i) present other targets as well as the 
target in focus, (ii) include membrane bound receptors, (iii) characterization of the 
mechanistic of the drug and (iv) include cellular metabolism (Zhang et al., 1999). The 
molecular target of interest does not have to be limited to one specific site as some 
compounds may have the ability to target multiple proteins, a process that is known 
as poly-pharmacological (Ramsay et al., 2018). In our laboratory, Ag8 is a silver 
based compound that has this ability to target multiple sites in the cell which is very 
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attractive as it represents one approach to tackling the problem of tumour 
heterogeneity and biochemical plasticity (Allison et al., 2017).  
 
A review by Swinney and Anthony et al., (2011) have collated data from 1998-2011 
where 259 new compounds were approved by the food and drug administration 
(FDA). From these compounds 28 were discovered by the phenotypic approach 
whereas 17 of these were by the target drug discovery approach (Swinney and 
Anthony, 2011). It is also the case that more ‘first in class’ compounds have been 
identified using a phenotypic screening approach than target orientated approaches 
(Swinney and Anthony, 2011) and this is particularly attractive. Furthermore, the 
phenotypic screen is inherently flexible in its design and there is a strong case to re-
evaluate compounds using cell-based assays that more accurately reflect key 
features of tumour biology. This thesis addresses one such approach which is 
designed to identify compounds that selectively exploit physiological conditions that 
exist within the solid tumour, details of which are outlined below.  
1.14 The tumour microenvironment (TME) 
Solid tumours have been described as a complex ‘rogue’ organ which contain a 
heterogeneous population of tumour and non-malignant cells (Saggar et al., 2013). 
Within the tumour, there are microenvironments that can broadly be described as 
either cellular and/or physiological. Whilst the cellular tumour microenvironment 
(TME) is beyond the scope of this thesis, it is important to acknowledge that the 
cellular and physiological TME co-exist and ideally, they should not be viewed as 
distinct or isolated microenvironments. A brief overview of the cellular TME and its 
links to the physiological TME is provided below and summarised in figure 1.5.  
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1.15 The cellular TME 
Within tumours, the cellular TME consists of endothelial cells, smooth-muscle cells, 
pericytes, eosinophils and basophils, cancer associated fibroblasts (CAFs), 
myofibroblasts, T, B lymphocytes, myeloid cells, dendritic cells, macrophages, 
myeloid cells and mast cells (Albini and Sporn, 2007). The role that these cells play 
in the TME is complex and it is influenced by physiological conditions including 
hypoxia. A brief account of CAF cells and macrophages in the TME is provided 
below and summarised in figure 1.5. 
 
 
Figure 1.5 Cartoon illustration of the cells associated with the tumour 




1.16 The biological importance of CAFs  
As shown in figure 1.5, the tumour contains numerous CAF cells which play an 
important role in supporting the growth of the tumour. In normal tissues, fibroblasts 
are referred to as mesenchymal cells which are embedded in the physiological 
extracellular matrix (ECM). If there is an injury or wound to the tissue, these 
fibroblasts can be activated so that they can repair tissues and regeneration can 
occur during the healing process of tissue inflammation or fibrosis (Liu et al., 2019). 
CAFs when compared with quiescent fibroblasts are much larger in size and have 
distinct indented nuclei (De Wever et al., 2008). What also separates CAFs from 
their normal counterparts is that activated CAFs can inhibit migratory and 
proliferative properties (Chen and Song, 2019; Kobayashi et al., 2019). A small 
portion of CAFs also have the ability to trans-differentiate from a  fibroblastic cell to 
blood vessels, pericytes, epithelial cells, adipocytes and smooth muscle cells 
(Dulauroy et al., 2012; Jotzu et al., 2011; Potenta et al., 2008; Rhim et al., 2012; 
Wikström et al., 2009). 
CAFs are much more metabolically active in comparison to fibroblasts in normal 
tissue and are unique for their ability to produce an ECM (Kalluri, 2016). CAFs can 
also recruit immunosuppressive cells into the TME which can assist with immune 
evasion or promote angiogenesis by the secretion of the following pro-inflammatory 
cytokines: (i) vascular endothelial growth factor (VEGF), (ii) CXC-chemokine ligand 
(CXCL12), (iii) transforming growth factor-β (TGF-β) and (iv) interleukin-6 (IL-6) 
(Ahmadzadeh and Rosenberg, 2005; Feig et al., 2013). There is clear evidence that 
CAF cells are heterogeneous in population and these cells can either restrain or 
promote tumour growth (Chen and Song, 2019; Kalluri, 2016; Kobayashi et al., 
2019). CAFs also represent a novel approach for cancer therapeutic intervention due 
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to their exertion of anti-tumour immunity which itself makes them a promising 
therapeutic target.  
1.17 The role of macrophages in the TME  
The TME also contains macrophages (figure 1.5) which are phagocytic cells that are 
important effectors of innate immunity to pathogens. The other key duties of 
macrophages are their role in both chronic and acute inflammatory responses 
(Egners et al., 2016). Hypoxia (low O2 concentration - which will be covered in more 
depth later) is a key driver of multiple pathological processes involving the 
macrophages such as, (i) wound healing, (ii) tumour inflammation and (iii) 
atherosclerosis (Semenza, 2014). Hypoxia inducible factor (HIF) is a transcription 
factor, the alpha subunit of which is only stable under low levels of oxygen 
concentration. Previous studies have demonstrated that HIF-1 is stable in various 
stages in macrophages which are located in the hypoxic regions of the TME 
throughout. (Fang et al., 2009; Talks et al., 2000). Inhibiting HIF has an effect on 
various macrophage functions such as (i) aggregation and (ii) migration and invasion 
(Cramer et al., 2003; Peyssonnaux et al., 2005). 
1.18 Generation of the physiological TME  
The origin of the physiological TME stems from the tumour vasculature that develops 
within tumours. Angiogenesis is a hallmark of cancer which is a process that 
generates new blood vessels from existing blood vessels and it is required for the 
supply of oxygen, nutrients to tumours and for the removal of waste products 
(Folkman, 1971). Angiogenesis is stimulated by tumour tissues when there is a 
requirement of oxygen and nutrients (Nishida et al., 2006). Hypoxia-inducible factor 
(HIF-1α) which is a major transcription factor (discovered by the Nobel Prize laureate 
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Greg Semenza) that is stabilised at low levels (0.1-5%) of O2 and plays a vital role in 
tumour proliferation (Ziello et al., 2007). The development of new blood vessels from 
existing blood vessels can be induced by HIF-1α stabilisation under hypoxic 
conditions resulting in the formation of functional HIF1 complexes leading to the 
increased transcriptional activity of a variety of genes including those encoding for 
vascular endothelial growth factors (VEGF) and its receptors (Bottaro and Liotta, 
2003). The formation of the new blood supply to tumours not only enables the 
tumour to grow but provides the route for the metastatic spread of the disease to 
other organs (Folkman, 1971; Nishida et al., 2006).  
In contrast to capillary beds in normal tissues which are well organised and 
structured, the vascular supply that develops in tumours is chaotic and structurally 
abnormal (Balkwill et al., 2012) leading to regions that are poorly perfused with 
blood. Cells close to blood vessels are therefore able to receive nutrients and 
oxygen but as distance from a supporting blood vessel increase, gradients of oxygen 
tension, nutrients, extracellular pH (pHe), proliferation rates decrease which are all 
characteristic features of the TME (Phillips, 2016). These characteristics can affect 
tumour cell biology and therapeutic response to anti-cancer drugs (Vaupel and 















Figure 1.6 Depiction of the different fractions present in a TME.  This image 
includes details of the normoxic, hypoxic and necrotic regions of the TME as well the 
changes in extracellular pH (pHe) 
 
Figure 1.7 Tumour microenvironment and cross link of the hypoxic region in 
correspondence with the distance of the capillary. A) Diagram representation of 
tumour cells which are situated next to the capillary, showing the expression of 
hypoxia throughout the TME B) Graph representation of the level of hypoxia (dotted 
line) in relation with pH (dashed line) in a hypoxic and acidic tumour 
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As the distance from a supporting blood vessel increases, both acidic and pHe 
increases (Figure 1.7) (Vaupel and Harrison, 2004). In order to survive in these 
environments, cells have to biochemically adapt and numerous changes mediated 
primarily by HIF transcription factors occur (Semenza, 2012). This includes changes 
to cellular metabolism in order to generate sufficient ATP for cell survival (Ziello et 
al., 2007). Cells within the hypoxic regions proliferate slowly and this leads to 
resistance to cytotoxic anti-cancer drugs, many of which target the process of cell 
replication (Höckel and Vaupel, 2001). Hypoxic cells can remain viable due to their 
quiescent state which has been linked to the low levels of ATP production. These 
cells can re-enter cell proliferation following the eradication of aerobic cells by 
chemotherapy or radiotherapy caused by the improved supply of oxygen and 
nutrients (Saggar et al., 2013).  
Another feature of the hypoxic tumour microenvironment is the creation of an acidic 
extracellular pH (Kato et al., 2013). The Warburg effect which was first described by 
Otto Heinrich Warburg in 1924 states that tumours have the tendency of producing 
lactate through the anaerobic glycolytic pathway despite the presence of adequate 
amounts of oxygen for the production of energy (in form of ATP) (Warburg et al., 
1924). In aerobic glycolysis, the last step of which is the formation of lactate from 
pyruvate results in a build-up of lactate in tumour cells which is exported into the 
extracellular space by monocarboxylate transporters. High levels of lactate have 
been associated with poor clinical outcomes such as (i) poor prognosis in cancer 
patients, (ii) tumour reoccurrence and (iii) metastasis (Brizel et al., 2001; McFate et 
al., 2008; Walenta et al., 1997; Walenta et al., 2003). The molecular mechanisms for 
these poor clinical outcomes have been linked to effects on T cell function including 
effecting on the immune response, T-cells function themselves and also its 
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metabolism (Kato et al., 2013). The lactate produced by the tumour cells also has an 
effect on angiogenesis by the nuclear factor-KB (NF- KB) as well as the induction of 
VEGF (Végran et al., 2011).  
1.19 Therapeutic implications of the TME 
There is considerable evidence demonstrating that the presence of the TME 
adversely influences the response of tumours to chemotherapy. The causes or 
resistance can be either direct or indirect. As an example of a direct cause of 
resistance, drugs such as bleomycin require oxygen as a key component of their 
mechanism of action and therefore in hypoxic conditions, the efficacy of such drugs 
is reduced (Burger et al., 1981). The TME can also indirectly affect the efficacy of 
drugs, a key mechanism being the fact that the majority of cells that reside in the 
TME are not proliferating. As described earlier, most cytotoxic anti-cancer drugs 
work against dividing cells and therefore, non-proliferating tumour cells within the 
TME will inherently be less sensitive to chemotherapy than proliferating and well 
oxygenated cells. Another mechanism of resistance is poor drug delivery and 
reduced drug uptake. For an anti-cancer drug to be effective, it must have the ability 
to penetrate through the solid tumour by moving through multi-cell layers and be 
effectively taken up into cells within the TME (Minchinton and Tannock, 2006). This 
occurs best when the anti-cancer drug is in its uncharged form (Trédan et al., 2007). 
The mild acidic environment can mediate drug resistance as drug uptake into the 
cells is influenced by low pHe, leaving less chemotherapeutic drug to target tumour 
cells and produce the desired anti-tumour effect (Mayer et al., 1986). Whilst the 
intracellular pH (pHi) of tumour cells remains close to neutral or is slightly alkaline, 
the acidic pHe can have an effect on certain well-established anti-cancer drugs such 
mitoxantrone, vincristine, vinblastine and doxorubicin. All of these have pKa values 
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ranging between 7.5-9.5 meaning they become protonated under acidic conditions 
which in essence decreases their uptake ability into cells (Gerweck et al., 2006; 
Tannock and Rotin, 1989). If the pHe shifts towards (slightly) alkaline conditions, 
then the uptake of doxorubicin and mitoxantrone is enhanced (Raghunand et al., 
1999; Raghunand et al., 2003). The mild acidic pHe does not only affect drug uptake 
but also plays a critical role on drug efflux by upregulating the expression of p-
glycoprotein (Lotz et al., 2007).  
 
The pHe also has a direct impact on the expression of other genes which directly 
correlate with pro-metastatic factors (Kato et al., 2013). Rofstad et al., 2006, carried 
out in vivo studies to determine the influence of pHe on metastasis using athymic 
nude mice. These mice were injected (via the tail vein) with melanoma cells which 
were pre-treated with mildly acidic medium and the results demonstrated that a lot of 
these cells managed to metastasize to the lungs (Rofstad et al., 2006). This 
demonstrates that the acidic pHe is associated with tumour metastasis (Kato et al., 
2013). Tumour cells have to adapt to their environment (Swietach, 2019) and the 
presence of an acidic pHe is associated with not only resistance to certain drugs but 
it also appear to drive the malignant spread of the disease (Kato et al., 2013). There 
is therefore a need to develop therapeutic strategies that target hypoxic cells that 
reside within regions of tumours with acidic pHe.  
1.20 Therapeutic targeting of the tumour microenvironment 
As described above, there is evidence of poor clinical outcomes for tumours which 
are associated with hypoxia when compared to patients who lack hypoxic regions in 
their tumours (Höckel et al., 1996). Numerous well established anti-cancer drugs 
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have failed to adequately diminish tumour cells which reside within the hypoxic 
regions and this chemo/radiation resistance contributes to the poor outcome in the 
clinic  (Ikeda et al., 2016). The poor therapeutic outcome may also be explained by 
the following major biological factors; resistance to apoptosis (Welsh et al., 1996), 
increased invasion and metastasis and induction of angiogenesis which are all 
associated with the hypoxia-inducible factors (HIF-1) (Phillips, 2016). With the 
increasing evidence that hypoxia can unfavourably affect clinical outcome, new 
chemotherapeutic strategies have been evaluated to eradicate the tumour cells 
which reside in the hypoxic regions. One such approach is the development of 
bioreductive drugs or hypoxia activated prodrugs (HAPs). The seminal work 
conducted in this field was done by Sartorelli in the 1970’s following the 
demonstration that the activation of mitomycin C preferentially occurred under the 
reducing conditions present within the hypoxic regions of tumours (Lin et al., 1972) 
(Phillips, 2016). A brief account of HAPs and their efficacy against hypoxic cells is 
provided below.  
 
1.21 The discovery of Hypoxia activated prodrugs (HAPs) or Bioreductive 
drugs.  
As the prototypical bioreductive drug, mitomycin C is an anti-tumour antibiotic which 
is extracted from actinobacteria species Stretomyces caespitosus (Verweij and 
Pinedo, 1990). The mechanism of action of mitomycin C is by an initial enzymatic 
bioreduction which converts mitomycin C to a bi-electrophilic intermediate that is 
highly reactive leading to alkylation with cellular nucleophiles including DNA (Paz et 
al., 2012). The DNA-DNA interstrand cross link is the main cause for the cytotoxic 
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effect on tumour cells (Palom et al., 2002) and this has previously been reported to 








Figure 1.8. Chemical structure of mitomycin C (Paz et al., 2012) 
Mitomycin C is considered to be the first original bioreductive prodrug because of its 
preferential cytotoxic abilities under hypoxic conditions. This can be achieved by 
either the one or two electron reduction of mitomycin C (under hypoxia) which 
spontaneously loses methanol and leads to a very unstable but highly reactive 
intermediate (Verweij and Pinedo, 1990). An in vitro study carried out by Sartorelli 
showcased this cytotoxic ability of mitomycin C against S-180 and EMT-6 murine cell 
lines under hypoxic conditions (Kennedy et al., 1980). Interestingly under normoxic 
conditions, mitomycin C displayed increased levels of cytotoxicity at pHe 6.6 against 
the Chinese hamster ovary cells when compared to pHe 7.2. This effect was only 
observed under normoxic conditions and when repeated under hypoxic conditions 
using the same pHe levels there was no difference in cytotoxicity observed (Begleiter 
and Leith, 1993). The limitations of mitomycin C are its severe side effects such as 
bone marrow toxicity, myelosuppression, anaemia as well as other less severe 
adverse effects; alopecia, nausea and vomiting (Verweij and Pinedo, 1990). The 
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bioreductive properties of mitomycin C have nevertheless encouraged researchers 
to develop compounds that are activated under hypoxic conditions to circumvent the 
issue of targeting all the cells in the TME.  
1.22 Hypoxia activated prodrugs: General properties 
As well as mitomycin C, misonidazole has also been shown to exert selective toxicity 
towards cells under hypoxic conditions when compared to normoxic (Adams and 
Stratford, 1994). This has triggered extensive research into investigating a large 
series of compounds with different chemical attributes for their ability to work as bio-
reductive drugs or HAPs. Compounds within this class are typically inactive prodrugs 
in the presence of oxygen, but are enzymatically activated by reduction by either the 
one or two electron oxidoreductases which under hypoxic conditions, generate a 
cytotoxic agent (Denny et al., 1996). Denny has previously described a generalised 
modular design of HAPs which consists of a trigger, linker and an effector. 
Trigger – The trigger unit is vital for the selectivity of the compound and must be 
capable of undergoing efficient metabolism by precise tumour mechanisms (Denny 
et al., 1996). These reactions are typically reversible in the presence of oxygen.  
Linker – In the oxidised form the effector is inactive, however, when the trigger 
group is reduced under hypoxic conditions, the linker conveys this message to the 
effector leading to either its activation or release from the HAP which leads to the 
cytotoxic effects  (Denny et al., 1996). 
Effector – The effectors have been reported as being the cytotoxic module which 
has been previously reported as the potent DNA-interactive agents that produce the 
cytotoxicity (Phillips, 2016). 
28 
 
There are five different groups of HAPs which are able to selectively target the 
hypoxic cells and these include (i) aromatic and (ii) aliphatic N-oxides, (iii) transition 
metal compounds, (iv) nitro-cyclic compounds and (v) quinones (Guise et al., 2014). 
For a HAP to be successful it has to have the following properties; (i) penetrate to all 
those cells that are distant to the blood vessels within its pharmacokinetic lifetime, (ii) 
be selective enough to target only the tumour cells and not the normal tissue, (iii) to 
be able to target the aerobic fraction as well as the hypoxic fraction via a bystander 
effect and (iv) to be able to kill those hypoxic cells which are slow dividing which 
typically behave like quiescent cells (Phillips, 2016). The following sections describe 




Figure 1.9 Chemical structure of the HAP tirapazamine (Brown, 1993) 
 
Tirapazamine (figure 1.9) was developed back in the mid 1980’s and was the first 
HAP to be extensively evaluated both pre-clinically and clinically (Brown, 1993; 
Spiegelberg et al., 2019). Tirapazamine consists of an aromatic N-oxide and 
becomes activated in the absence of oxygen following one electron reduction by 
29 
 
enzymes such as cytochrome P450 reductase (Shinde et al., 2009). This results in 
the formation of active/ cytotoxic hydroxyl and benzotriazinyl radicals (Shinde et al., 
2009; Wilson and Hay, 2011). It can further undergo a two-electron reduction to form 
a tirapazamine mono N-oxide which is not toxic. Despite displaying very promising 
HAP like properties in the early pre-clinical tests (Brown, 1993; Brown and Wang, 
1998), it became apparent in the clinical phase III studies that this did not offer any 
additional benefits to existing chemotherapeutic drugs alone or chemoradiotherapy 
(Reddy and Williamson, 2009). Tirapazamine also displayed a lot of side effects as 
this HAP required mild hypoxia to become active and activation occurred in the bone 
marrow, gastrointestinal tract and liver which may have contributed to these adverse 
side effects (Spiegelberg et al., 2019). Several different analogues of tirapazamine 
have been developed and tested pre-clinically but have not yet progressed to clinical 
trials (Wardman et al., 1995). Examples of these analogues are SN30000 and 
SN29751 which are both activated under hypoxia by one electron reduction. 
SN30000 in particular displayed high levels of potency and cancer selectivity 
towards the colorectal cancer cell line HT29 in comparison to tirapazamine (Hicks et 
al., 2010). The vascular penetration and diffusion of SN30000 was much greater in 
multi-cell layer models in the HT29 and SiHa cell lines than that of tirapazamine 
which was another limiting factor for its poor clinical outcome. Both these 
tirapazamine analogues were also much more active than tirapazamine in an in vivo 






1.24 TH-302 (Evofosfamide) 
 
 
Figure 1.10 Chemical structure of the HAP TH-302 
TH-302 is a nitrogen mustard (2-nitroimidazole-based nitrogen) which undergoes 
one electron reduction to release the active DNA alkylating isophosphoramide 
mustard (Millis et al., 1995). TH-302 was first described in 2007-2008 through 
clonogenic cytotoxicity studies from a panel of drug candidates (Hart et al., 2007). 
The results demonstrated that TH-302 was active under hypoxic conditions in the 
H460 lung cancer cell lines with clonogenic IC50 values of 0.1, 5 and 30µM at oxygen 
tensions of 0, 6 and 21% respectively (Hart et al., 2007). The advantage of TH-302 
was that this HAP was tested as a monotherapy and in combinatorial studies with 
the likes of doxorubicin, docetaxel and gemcitabine (Liu et al., 2012). It has also 
been tested in conjunction with radiotherapy (Guise et al., 2014). Phase I and Phase 
II clinical safety and efficacy studies with TH-302 has shown promising results 
(Borad et al., 2015; Chawla et al., 2014; Ganjoo et al., 2011; Weiss et al., 2011). 
Moving forward, the next step was phase III clinical studies where two large trials 
consisting of 600 patients with advanced pancreatic cancer and soft tissue sarcoma 
were treated with doxorubicin, gemcitabine with the addition of TH-302 (Tap et al., 
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2017). Unfortunately both trials did not perform well and the overall endpoint of 
improved overall survival was not met (Spiegelberg et al., 2019). The researchers 
tried justifying the overall performance of TH-302 by stating that the placebo group 
had performed better than they initially believed but TH-302 ultimately failed. One of 
the major reasons why TH-302 may have not performed as well as it should have is 
due to a poor understanding of the different oxygen tensions that may be present in 
the tumours. It has been previously reported that pancreatic cancer oxygen tensions 
can fluctuate between 0-26% which may have affected the performance of TH-302 
activation (Dhani et al., 2015). Basic in vitro studies assessing the cytotoxicity of TH-
302 in combination with the classic anti-cancer drugs against a panel of pancreatic 
cancer cell lines with fluctuating or even oxygen cycling from 0-26% may give 
insightful information. Unfortunately however, TH-302 also follows the same 
footsteps as tirapazamine in that clinical activity did not reflect the promising activity 
seen in preclinical models. 
 
1.25 EO9 (Apaziquone) 
 
 




EO9 was synthesised as a derivative of mitomycin C and undergoes activation by 
either one or two electron reduction. This creates DNA damaging species under both 
normoxic and hypoxic conditions (Oostveen and Speckamp, 1987; Phillips, 2016). 
The one electron reduction route generates a semi-quinone intermediate which can 
recycle back to the parent quinone in the presence of oxygen. This generates toxic 
reactive oxygen species in the presence of oxygen but in hypoxia, the semi-quinone 
is stabilised which can lead to further reduction to form the hydroquinone. The semi-
quinone or the hydroquinone moiety could then generate toxic lesions in cells 
leading to hypoxia selectivity. These reactions are carried out by one electron 
oxidoreductases such as cytochrome P450 reductase (Plumb and Workman, 1994; 
Workman, 1994). The quinone can be directly converted to the hydroquinone by the 
2 electron oxidoreductase NAD(P)H:quinone oxidoreductase 1 (NQO1) which is also 
known as DT-diaphorase. This bypasses the semi-quinone step and this reaction is 
effectively oxygen insensitive. The generation of the hydroquinone leads to the 
formation of DNA damage which is typically in the form of single strand breaks in the 
DNA although alkylation of DNA has also been reported (Workman, 1994).  
There is a complex relationship between the enzymology of cells and the ability of 
EO9 to eradicate hypoxic cells. In the case of NQO1 rich cells, NQO1 tends to 
dominate over one electron oxidoreductases and this leads to both aerobic and 
hypoxic cell kill with low hypoxic cytotoxicity ratios (HCR). In cells that have low 
levels of NQO1, one electron reductases predominate and as this is an oxygen 
sensitive reaction, preferential activity against hypoxic cells has been reported 
(Plumb and Workman, 1994). EO9 was selected for clinical trials in the 1990’s but 
failed to show any efficacy when administered intravenously (Boyer, 1997). 
Reasoning behind this was due to poor/ impaired pharmacokinetics and poor 
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penetration through avascular tissue (Phillips et al., 2013). Connors et al., 1996 went 
on to further discuss other limitations and design flaws of the phase II clinical trial by 
noting that levels of NQO1 and hypoxia were not measured from the patient 
samples. The pHe also has an effect on the cytotoxic ability of EO9 under normoxic 
conditions. A study carried out by Phillips et al., (1992) demonstrated that when EO9 
was tested against the colorectal cancer DLD-1 cell line under pHe 7.4 resulted in 
40% cell death, however when the pHe was reduced to 5.8 this enhanced the 
cytotoxic ability of EO9 killing 95% of the cells (Phillips et al., 1992).   
Based on an understanding of the reasons why EO9 failed following intravenous 
administration, a further clinical trial of EO9 against non-muscle invasive bladder 
cancer was proposed (Phillips et al., 2013). The rational being that intravesical 
administration directly into the bladder would circumvent the drug delivery problem 
and any drug reaching the systemic circulation would be rapidly eliminated (EO9’s 
poor pharmacokinetic properties would paradoxically be favourable in terms of 
reducing the risk of systemic side effects). Both phase I and II clinical trials 
demonstrated substantial anti-cancer activity (Puri et al., 2006) and EO9 entered 
phase III clinical trials. The results of these trials have been reported recently 
(Hendricksen et al., 2008) and both trials failed to reach their primary endpoint of 
delayed two-year recurrence rates. There were significant changes to the protocols 
used in the phase III and phase II trials and these ultimately contributed to its failure. 
In particular, the administration of EO9 immediately after surgery when haematuria 




1.26 AQ4N (Banoxantrone) 
 
Figure 1.12 Chemical structure of the HAP AQ4N 
AQ4N is an aliphatic N-oxide that is activated under low oxygen concentrations by 
sequential 1-electron reduction by cytochrome p450 resulting in the generation of the 
potent topoisomerase II inhibitor alkylaminoanthraquinone (AQ4) (Steward et al., 
2007). AQ4N has shown promise in in vivo studies where it has good activity against 
mouse models (Loadman et al., 2001). AQ4N was also very effective in a phase I 
clinical trials where it demonstrated hypoxic selectivity in head and neck cancer 
patients (Albertella et al., 2008). In total there have been three clinical phase I 
studies where 2 have been as a single drug study and the other in combination with 
radiation (Albertella et al., 2008; Papadopoulos et al., 2008; Steward et al., 2007). 
Despite promising results from the clinical phase I studies, AQ4N did not progress 
any further than the clinical phase II trials which was initially carried out in 2006 
(NCT00394628) where the results have not been published (Mistry et al., 2017). The 
reason for its lack of progression was commercial rather than performance based 
results and novel analogues of AQ4N are being developed to circumvent this issue 




1.27 Current status of HAPs and the need for new therapeutic approaches to 
targeting the physiological TME of solid tumours 
As described above, the development of HAPs has been an active area of research 
for many years but the attractive concepts underpinning this approach have so far 
proved difficult to translate into clinical activity. The reality of the situation is that 
despite 4 decades of research, no HAP has so far been approved for use in humans. 
Nevertheless, HAPs remain an active area of research and it is hoped that the new 
generation of drugs under development will perform better in clinical trials. In view of 
the lack of success of the HAP programme, it is also prudent to investigate 
alternative approaches to the development of drugs that target the physiological 
TME. The majority of HAPs that have been developed focus almost exclusively on 
tumour hypoxia but as described earlier, tumour hypoxia is only one component part 
of the physiological TME. Cells that reside in these regions are exposed to other 
environmental challenges including low pHe. The majority of preclinical studies 
conducted in this field only focus on hypoxia and the importance of both hypoxia and 
acidic pHe combined has largely been overlooked. It is therefore possible that better 
effects may be obtained if preclinical models reflected the complexity of the TME 
more closely that just looking at hypoxia in isolation. The hypothesis that will be 
tested in this thesis therefore is that novel molecules will be discovered that exploit 





1.3 Aims of this thesis 
The aim of this study is to determine whether or not a phenotypic screen based on 
the evaluation of compounds under hypoxic and acidic pHe conditions will identify 
compounds that have superior activity compared to hypoxia alone. The phenotypic 
screen described here is based on testing compounds under (i) aerobic (ii) hypoxic 
(iii) aerobic plus acidic pHe and (iv) hypoxic plus acidic pHe conditions. These 
experiments will be conducted in a range of cell lines including cancer and non-
cancer cells with the additional aim of determining selectivity indices (by comparing 
the response of cancer and non-cancer cells), hypoxic cytotoxicity ratios (comparing 
the response of tumour cells under aerobic and hypoxic conditions) and a 
microenvironment enhancement ratio (comparing the response of cells under 
aerobic and neutral pHe with hypoxic and acidic pHe conditions). A range of test 
compounds was obtained from collaborators from various institutions across the 
world and these are listed below;    
i. Ruthenium, Iridium and Rhodium based napthyridines, thiourea 
derivatives, benzylthiourea ligands and aroylthiourea compounds  
ii. Bromo-hexitol prodrugs 
iii. NHC-Ag based  complexes 
iv. Minor groove binders 







Chapter 2: General Materials and Methods 
2.1 Cell lines and cell culture conditions  
The following cell lines were all obtained from American Type Culture Collection 
(ATCC): HCT116 p53+/+, HCT116 p53-/-, HCT116 KRAS mutant, HCT116 KRAS 
wildtype, HT29, Mia-PaCa-2, MDA-MB-231 and H460. In addition to these cancer 
cell lines, a non-cancer cell line (ARPE-19) was also included in order to assess 
selectivity in vitro. All the cells were routinely cultured in base media (table 2.1) 
containing 10% v/v foetal bovine serum (FBS) (Sigma), 2mM L-glutamine (Sigma) 
and 1mM sodium pyruvate (Sigma). Non-essential amino acids were used for some 
cell lines (H460 and ARPE-19). The final composition of media plus supplements 
used was termed ‘complete media’ and this terminology is widely used throughout 
the thesis. Cells were maintained at 37°C in a CO2 enriched (5%) and humidified 













Table 2.1 List of all the different types of cancerous cell lines used throughout 
this PhD study, type of disease and media used.  
2.2 Sub culturing of cells 
Cells were grown as 2D monolayers and were sub-cultured upon reaching 
confluency. This was carried out by washing cells with 10mL phosphate buffered 
saline (PBS) solution (Sigma) followed by the addition of 3-4mL of trypsin-EDTA 
(Sigma). Cells were placed in a humidified incubator for approximately 2 minutes. 
Cells were further checked under the light microscope to ensure cells were detached 
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from the surface of the flask. Occasionally the flask would be gently tapped to ensure 
all the cells have detached. To stop the trypsinisation process, complete media 
containing 10% FBS was added to the flask (10mL per flask). Cells were collected in 
a 25mL universal tube (Sarstedt) and centrifuged for 3 minutes at 1200 rpm. Upon 
completion, media containing trypsin was removed and the cell pellet was re-
suspended in complete media. The cell suspension was diluted 1:3 or 1:10 
depending on cell type and new cultures were established. 
2.3 Cell counting and determination of cell number 
Cells were counted using an improved Neubauer haemocytometer following the 
procedure recommended by ThermoFisher, 
(www.thermofisher.com/uk/en/home/references/gibco-cell-culture-basics/cell-culture-
protocols/counting-cells-in-a-hemacytometer.com). 
Briefly, the cell suspension (10µL) was loaded onto the haemocytometer and cells 
were counted in each of the chambers (n=5 for each chamber). The average cell 
number was determined and multiplied by 104 to obtain the number of cells/mL.  
2.4 Cryo-preservation 
To protect the cultures from genetic drift, cells were routinely frozen down and stored 
in liquid nitrogen. Cell suspensions obtained from cultures in mid to late exponential 
growth were placed into media containing 20% FBS and 10% DMSO and aliquoted 
into cryo-tubes (1mL per tube). A Mr Frosty (Nalgene) was filled with isopropanol 
and each cryo-vial was labelled, inserted into the Mr Frosty and placed in the -80°C 
freezer overnight. The following day the cryo-vials were removed and placed into the 
liquid nitrogen Dewer storage system.  
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To defrost cells and establish fresh cultures, cells were rapidly thawed at 37°C and 
transferred to universal tubes containing 9mL of media. Cells were centrifuged for 3 
minutes at 1200rpm and the cell pellet was re-suspended in complete media before 
being placed into a T25 flask and cultured as described above. Cells were routinely 
passaged up to ten times after which they were discarded and fresh cultures 
established from the liquid nitrogen bank.  
2.5 Compounds 
All of the drugs were made up in DMSO with the exception of cisplatin which was 
dissolved in PBS solution. The stock concentration of each compound varied 
between 10 and 100mM, details of which are described in the results chapters for 
each of the compounds evaluated. 
2.6 Chemosensitivity studies under aerobic conditions 
Upon completion of cell counting, the cells were inoculated into a 96 well plate at a 
cell density of 1.5 x 103 cells per well in a volume of 100µL complete media. Lane 
one had no cells but just contained media (100µL) as a blank. 96 well plate 
containing cells were placed at 37°C with 5% CO2 in a humidified incubator for 
24hours to allow cells to adhere to the base of the wells. The media was aspirated, a 
serial dilution of the drug was made and 200µL was added to each well. Where 
compounds were dissolved in DMSO, one lane was used as a vehicle control at a 
concentration of 0.1%v/v which is known not to be toxic to the cells. The layout of the 














Figure 2.1 Representation of the layout of a standard 96 well plate for 
chemosensitivity studies. 
Cells were exposed to the test compound for 96 hours before the addition of 20µL 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5mg/mL) and 
incubated further for four hours at 37°C in a CO2 enriched atmosphere (5%) in a 
humidified incubator. All media and MTT was removed and the formazan crystals 
formed were dissolved in 150µL of DMSO per well. 96 well plates were then inserted 
into a Tecan microplate photometer to measure absorbance which was set at 
540nm. The true absorbance of the solution was obtained by subtracting the blank 
absorbance and % cell survival was determined as the true absorbance of treated 
lanes divided by the true absorbance of the control and expressed as a percentage. 
Dose response curves were plotted and each assay was performed in triplicate. IC50 
values were determined directly from the dose response curve and the results were 


















Serial dilution of 
compound from low to 
high (left to right)  
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2.7 The MTT assay – chemosensitivity studies under hypoxic conditions 
This was carried out as described above with the exception that the 96 well plates 
were placed in a Whitley H35 Hypoxystation which is humidified at 37°C with 5% 
CO2, and 0.1% oxygen tension. An oxygen tension of 0.1% oxygen was chosen to 
mimic severe hypoxia. Appropriate stocks of complete media were placed in the 
Hypoxystation 24h prior to carrying out any work to ensure the media was fully 
equilibrated to the hypoxic conditions. All subsequent steps of the procedure were 
carried out in hypoxic conditions up until the step where MTT was added which was 
carried out in a normal class II biological safety cabinet and then further subjected to 
a normal incubator at 37°C with 5% CO2 in a humidified incubator for four hours 
before analysing using a Tecan microplate photometer to measure absorbance at 
540nm. The data was analysed as described previously.  
2.8 pH dependent chemosensitivity studies under aerobic and hypoxic 
conditions 
The chemosensitivity study was carried out as mentioned in 2.6. When treating the 
cells with compound, the pH of the media was adjusted to pH 6.5 using 0.1M HCL in 
conjunction with a Jenway pH calibrator. For all hypoxia work, this was placed in the 
Hypoxystation 24h prior to carrying out any work to ensure the media is equilibrated 
to the hypoxic conditions. Serial dilution of drugs was performed in media at pH 7.4 
or 6.5 and the remaining steps were conducted under hypoxia or normoxic 




2.9 Cell harvesting for Western Blot  
Cells were seeded into T25 flasks at a cell density of 1 x106 cells and placed in 
either a humidified incubator at 37°C with 5% CO2 or the Hypoxystation at 37°C with 
5% CO2, and 0.1% oxygen tension. Cells were exposed to various drug 
concentrations (as described in figure legends) and allowed to recover for 24 hours. 
Media was removed and cells were washed with 5mL of PBS solution and 
trypsinised as described above. All media and PBS including cells with trypsin were 
all placed in a universal tube and centrifuged at 1200rpm for 3 minutes. Media 
containing trypsin and PBS was discarded and the cell pellet was further washed 
with PBS twice to ensure all media and trypsin has been removed. To lyse the cells, 
10µL of phosphatase inhibitor (Sigma) and 25µL of protease cocktail inhibitor 
(Sigma) was added to 965µL RIPA buffer (Sigma) and placed on ice until further use. 
100µL of the RIPA buffer cocktail was added to the cell pellet and gently re-
suspended to ensure all cells have been lysed before putting them into eppendorf 
tubes. Cell lysates were either frozen or used directly for protein quantification by the 
BCA assay. Samples were sonicated using a Ultrasonic cleaner (model: GT sonic G-
2) for 30 seconds and then placed on ice for 2 minutes. This was repeated three 
times. 
2.10 BCA assay 
Protein concentrations in cell lysates were measured using the BCA assay 
(Thermofisher). A set of Bovine Serum Albumin standards was made ranging from 
0.2 to 2mg/mL. 10µL of each of the standards was added to a 96 well plate in 4 wells 
with 10µL of the cell lysates to 4 separate wells. The BCA working solution was 
made up by adding Reagent A to B to a ratio of 50:1 respectively and 190 µL added 
to each well. The 96 well plate was left for 30minutes before the absorbance was 
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measured using a spectrophotometer at 562nm. The unknown concentrations of the 
cell lysates were calculated using the regression equation y=mx+c generated from 
the calibration curve. Any values falling outside of the linear range of the calibration 
curve were either diluted so that absorbance values fell within the linear range or 
were discarded if absorbance values were at or below the limit of detection of the 
assay.  
2.11 SDS-PAGE Gel Electrophoresis  
Laemmli buffer was prepared by adding 900µL 4 x laemmli buffer (Bio-Rad) to 100µL 
of β-mercaptoethanol (355mM). 40µg of protein lysate for each of the samples was 
diluted in laemmli buffer and the cell lysate was vortexed. Samples were heated to 
95°C for 5 minutes and further centrifuged. SDS-PAGE resolving gels at 15% were 
prepared (5.4mL distilled autoclaved water, 5mL 1M Tris pH 6.8, 6ml 40% 
acrylamide (Bio-Rad), 3.2mL 2% bis-acrylamide (Bio-Rad), 200µL 10% SDS 
(InVitrogen), 20µL TEMED (Sigma) and 200µL of ammonium persulfate (APS) 
solution 0.2M) and poured in between two glass plates and allowed to set for 1 hour. 
Isopropanol was added to ensure a clear boundary formed at the surface of the 
resolving gel. Once the resolving gel had fully polymerised, the isopropanol was 
removed and a 4% stacking gel (13.5mL distilled autoclaved water, 2.9mL 1M Tris 
pH 6.8, 2ml 40% acrylamide, 1.2mL 2% bis-acrylamide, 240µL 10% SDS, 20µL 
TEMED and 240µL of APS solution) was poured onto the resolving gel and a 1.5mm 
comb was inserted into each gel. This was further left for an additional 30 minutes to 
allow the gel to set. The combs were removed and the glass plates were transferred 
to a Bio-Rad gel electrophoresis tank. Running buffer (Tris Base, Glycine and water) 
was poured into the tank and protein ladder (Thermofisher Scientific) along with 
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samples were added into each well in a logical order. Samples were run at 70V for 
one hour (until samples had crossed the stacking gel and entered the resolving gel) 
and then at 120V until the tracking dye (bromophenol blue) reached the bottom of 
the gel.   
2.12 Western Blot 
The stacking gel was removed from the resolving gel and the latter was placed 
carefully onto a nitrocellulose transfer membrane (Whatman) in running buffer (10x 
transfer buffer, methanol, 10% SDS and water). 2 filter papers were placed on both 
outer parts of the membrane and 2 further fibre pads were placed on top of this on 
both sides. Finally this was all placed into a ‘sandwich cassette’ which was inserted 
into a Bio-Rad transfer tank. Electrophoretic transfer was performed at 35mA 
overnight. Upon completion of transfer, the nitrocellulose membrane was separated 
from the gel and left on tissue to allow the membrane to dry. The membrane was 
washed with PBST (0.1% Tween and PBS) for 5 minutes and then blocked using 5% 
Marvel in PBST or 5% BSA for 1 hour on a shaker set to 50rpm. The membrane was 
probed using primary antibodies (see table 2.2) in blocking buffer and incubated 
overnight at 4°C on a shaker. Membrane was washed using PBST 3 times for 5 
minutes before adding the secondary (HRP conjugated) antibody (table 2.2) was 
added in blocking buffer for 1 hour. The membrane was washed further using PBST 
3 times for 5 minutes. Chemiluminescent (Roche) reagents were prepared by adding 
reagent a to reagent b at a 1:100 ratio and added to the membrane and kept in the 
dark for 1 minute. The membrane was dried and put onto a Hyper-cassette and 
taken to the dark room immediately for exposure using a hyperfilm ECL (GE 
Healthcare). The duration of film exposure was dependent on the protein of interest. 
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Films were developed and fixed using the instant developer and fixer (Ilford 








ϒH2AX (rabbit) 1:1000 Abcam (ab11174) 
p53 (rabbit) 1:10000 Abcam (ab131442) 
Src (rabbit) 1:1000 Cell signalling (# 2108S) 
pSrc 527 (rabbit) 1:1000 Cell signalling (# 2105S) 
β-actin (mouse) 1:25000 Millipore (MAB1501) 
 
Table 2.2 Primary antibodies used in this PhD with species, dilution and 
supplier. Antibodies ϒH2AX, Src and pSrc 527 were prepared in 5% bovine serum 
albumin (BSA) PBST whereas p53 and β-actin were prepared in 5% marvel PBST. 
 
 
 Table 2.3 Secondary antibodies used in this PhD with species, dilution and 
supplier.  
 
2.13 Immunodetection using the LiCor Odyssey 
The alternative way to read the membranes was by using the LiCor Odyssey 







Rabbit/ IgG 1:10000 Rockland (611-145-122) 
Mouse/ IgG 1:10000 Life Technologies (A21057) 
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body was added and incubated for 1 hour. Upon completion the membrane was 
washed with PBST for 5 minutes before being transferred to the membrane reader. 
A full digital scan of the membrane was taken using the LiCor Odyssey infra-red 
imaging system which was visualised at either 680 or 800nm. 
 
2.14 Statistical analysis 
Statistical analysis was carried out using Graph Prism or Microsoft Excel (data 
analysis). All experiments were done in triplicate (n=3), and results were presented 
as the mean ± SD. Statistical significance was determined by means of a two-tailed 
Student’s t-test for comparing two mean samples or a one-way ANOVA to compare 





Chapter 3: Performance of selected established anti-
cancer drugs and tirapazamine in the phenotypic screen 
3.1 Introduction 
As discussed in the introduction, this thesis will determine whether or not the use of 
a phenotypic screen will identify novel compounds that are preferentially activated 
against cells that reside within the tumour microenvironment. In order to provide a 
‘yardstick’ against which novel compounds can be measured, the performance of 
selected established anti-cancer drugs and a classical HAP in this screen is 
required. The work described in this chapter focuses on cisplatin, 5-fluorouracil (5-
FU) and etoposide which are well known and established classic anti-cancer agents 
that are approved for use against various cancers in humans (Hande, 1998; Longley 
et al., 2003; Wiltshaw, 1979). These three agents all have different mechanism of 
actions and have therefore been selected for this study to provide a ‘baseline 
standard’ for their cytotoxicity under normoxic, hypoxic and mild acidic pHe. In 
addition, tirapazamine has also been selected as a representative example of a 
classical HAP that is designed to work better under hypoxic conditions. Brief details 
of their mechanisms of action are as follows;  
Cisplatin – This is an alkylating agent capable of inducing intra-strand and 
interstrand (albeit less frequent) cross links in DNA. Once inside the cell, the Cl 
groups become hydrated and this leads to nucleophilic attack at the N7 position of 




Etoposide – The mechanism of action involves the inhibition of topoisomerase II 
enzymes that play an important role in DNA replication. Etoposide is known to affect 
mainly the S and G2 phases of the cell cycle (Baldwin and Osheroff, 2005). 
5-FU – This is a thymidylate synthase inhibitor which can enter the cells by either 
active or facilitated diffusion.  Metabolic activation of 5-FU involves conversion into 
three different active metabolites which are, fluorodeoxyuridine monophosphate 
(FdUMP), fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate 
(FUTP). It is FdUMP which inhibits thymidylate synthase which depletes one of the 
nucleotides thymidine triphosphate (TTP) required for DNA synthesis. This 
effectively prevents DNA synthesis and ultimately results in cell death (Longley et al., 
2003). 
Tirapazamine – This compound belongs to the class of drugs known as bioreductive 
drugs or HAPs and has been included in the panel of compounds as a positive 
control. Its mechanism of action involved enzymatic reduction by oxidoreductases 
leading to the generation of free radical species. Preferential activity against hypoxic 
cells has been documented in the literature and this has been described earlier in 
the introduction to this thesis (see section 1.23). Tirapazamine has the ability to 
target DNA producing a single or double stranded break leading to apoptosis 
(Brown, 1993). As this is a phenotypic screening program, the rationale for selecting 
cell lines to use was not based on biochemical characteristics but on pragmatic 
reasons including ease and reliability of growth under aerobic and hypoxic 
conditions. In addition, previous studies from out group have used the HCT116 
P53+/+ colorectal cancer cells for phenotypic screening studies and therefore to 
maintain consistency, this cell line was used. The ARPE-19 non-cancer cells was 
also selected for use in this chapter for the same reasons as outlined above.  
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3.2 Aims and objectives 
The aim of this study is to determine the activity of standard agents and a classic 
HAP against cancer cells under experimental conditions that mimic the hypoxic and 
acidic pHe conditions typically found within the physiological tumour 
microenvironment. This will provide a baseline against which the relative merits of 
novel test compounds can be compared with existing agents, the ultimate aim of 
which is to assess the validity of this approach for identifying novel compounds with 
activity against the TME. In addition, the ability of compounds to selectively target 
cancer cells will be determined by the inclusion of a non-cancer cell line (ARPE-19) 




3.3 Materials and Methods 
3.3.1 Drugs used in this chapter 
Anti-cancer agents were purchased from Sigma Aldrich and their chemical structures 
and molecular weights are presented in figure 3.1. These were prepared in 
dimethylsulphoxide (DMSO) with the exception of cisplatin which was dissolved in 










Figure 3.1 Chemical structures and molecular weights of the drugs used in this 
chapter.  
3.3.2 Validation of the MTT assay 
In order for the MTT assay to provide a valid assessment of cell number, there 
needs to be a linear relationship between cell number and the absorbance of 
formazan. HCT116 p53+/+ cells were inoculated into a 96 well plate ranging from 600-
Cisplatin (RMM = 300.01) 5-Fluorouracil (RMM = 130.07) 
Etoposide (RMM = 588.8) Tirapazamine (RMM = 178.4) 
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12000 cells per well and treated with 20µL of MTT (5 mg/mL) immediately after 
plating. Lane 1 of the plate contained media only to serve as a blank for the 
spectrophotometer readings. The plate was incubated at 37°C and 5% CO2 for 4 
hours. Upon completion, media was carefully removed and the formazan crystals 
formed were dissolved in 150µL of dimethyl sulfoxide (DMSO) and the resulting 
solution mixed. The absorbance of the solution was measured at 540nm using a 
Tecan plate reader. The absorbance of the blank was subtracted from the 
absorbance of other lanes in order to obtain the true absorbance values and the 
results were graphically presented as mean absorbance ± standard deviation vs cell 
number (in each experiment, there were 8 replicates per cell number). 
3.3.3 Cell culture and chemosensitivity  
Cell culture and chemosensitivity studies under normoxic and hypoxic conditions 
were carried out as previously described in the general methods section (section 2.2, 
2.6 and 2.7). Cell lines HCT116 P53+/+ and HCT116 P53-/- were used in this chapter. 
The media was adjusted to the relevant pH and equilibrated to the correct oxygen 
concentration as described in the methods (section 2.8) 24 hours prior to any 
experiment. A series of parameters used to measure the effects of various conditions 
on efficacy were derived as follows: 
 
HCR: This is the hypoxic cytotoxicity ratio defined as the ratio of IC50 values in 
normoxia divided by the IC50 value under hypoxia. Values greater than 1 indicate that 
the test compound has greater activity under hypoxic conditions.  
 
pHR: This is the pH cytotoxicity ratio defined as the ratio of IC50 values under normal 
pHe conditions (pHe 7.4) divided by the IC50 value under acidic pHe (pHe 6.5) 
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conditions. Values greater than 1 indicate that the test compound has greater activity 
under acidic pHe conditions.  
 
TME ratio: This is the tumour microenvironment ratio defined as the ratio of IC50 
values obtained in normoxia (pHe 7.4) divided by the IC50 value under hypoxia (pHe 
6.5). Values greater than 1 indicate that the test compound has greater activity under 
TME conditions.  
 
Selectivity index (SI): This is defined as the IC50 value for the non-cancer ARPE-19 
cell line (under normoxia, pHe 7.4) divided by the IC50 for cancer cells (under various 
experimental conditions of oxygen tension and pHe). Values greater than 1 indicate 
that the test compound has greater activity against cancer cells than non-cancer 
cells in vitro. 
3.3.4 Statistical analysis 
Statistical analysis was carried out using Microsoft Excel and Graph Prism. All 
experiments were done in triplicate (n=3), and results were presented as the mean ± 
SD. Statistical significance was determined by means of a two-tailed Student’s t-test, 
or by One Way ANOVA where significance was only accepted when p ≤ 0.05. The 





3.4.1 Validation of HCT116 for p53 
HCT116 p53+/+ is the main cell line used in this study. To confirm that this cell line 
expressed p53 and the HCT116 p53-/- did not, a western blot was carried out as 
described above. Instead of chemiluminescent detection using ECL reagents, the 




















3.4.2 Validation of the MTT assay 
The relationship between the number of cells and the absorbance of the solution 
obtained from the MTT assay is presented in figure 3.3. This relationship is linear 




Figure 3.3 Validation of the MTT assay carried out on HCT116 p53+/+ cells (n=3). 
HCT116 p53+/+ cells were inoculated into a 96 well plate at different cell densities 
and treated with MTT straight away under normoxic and pHe 7.4. Each result 
represents the mean ± standard deviation of three independent experiments. 
 





























3.4.3 The effect of tirapazamine against the HCT116 p53+/+ cell line under 
normoxic and hypoxic conditions 
 
Tirapazamine, a well-established HAP was tested under both normoxic and hypoxic 
conditions (figure 3.4A). The IC50 values were 11.85 ± 0.63 µM and 1.24 ± 0.39 µM 
respectively (figure 3.4B) giving a HCR of 9.55. These results demonstrate that the 
hypoxic conditions used in this study are appropriate to identify HAPs.  
Figure 3.4 HCT116 p53+/+ cells were drug treated for 96 hours with tirapazamine 
under hypoxic and normoxic conditions (pHe 7.4).  Panel A: Dose response 
curves to tirapazamine under aerobic and hypoxic conditions. Panel B: IC50 value of 
tirapazamine under both normoxic and hypoxic conditions. Each result represents 
the mean ± standard deviation of three independent experiments. A students t-test 
was carried out to determine any significance when comparing hypoxia to normoxic 













































3.4.4 The effect of cisplatin, 5-FU and etoposide against the HCT116 p53+/+ cell 
line under TME conditions  
Dose response curves representing the response of HCT116 p53+/+ under normoxic 
conditions (pHe 7.4) and under hypoxic (pHe 6.5) (TME conditions) are presented in 
figure 3.5. The response (IC50 values) obtained for all the conditions tested are 
presented graphically in figure 3.6 and numerically in table 3.1.  
The results presented in figure 3.6 and table 3.1 demonstrate that the response of 
HCT116 p53+/+ cells to standard cytotoxic drugs is adversely affected by TME 
conditions. In the case of cisplatin, the IC50 under normoxic conditions (pHe 7.4) was 
2.03 (± 0.08) µM and this increased to 6.75 (± 1.33) µM under hypoxic (pHe 6.5) 
conditions. Similarly, the IC50 for 5-FU under normoxic conditions (pHe 7.4) was 1.01 
(±0.06) µM and this increased to 3.73 (± 0.61) µM under hypoxic (pHe 6.5) 
conditions (table 3.1). Finally for etoposide, IC50 values increased from 0.52 (± 0.05) 
µM under normoxic conditions (pHe 7.4) to 0.91 (± 0.26) under hypoxic (pHe 6.5) 
conditions. The results for tirapazamine are also presented in table 3.1 and as 
mentioned previously, the activity of tirapazamine is significantly enhanced under 
hypoxic conditions (please note that the response of cells to tirapazamine under full 





Figure 3.5 HCT116 p53+/+ cells were drug treated for 96 hours with classic 
cytotoxic compounds under hypoxic (pHe 6.5) and normoxic conditions (pHe 









































































Figure 3.6 The response (IC50) of HCT116 p53
+/+ and ARPE-19 cells to standard 
cytotoxic drugs and tirapazamine. Cells were exposed to test compounds for 96 
hours using drug concentrations ranging from 0.3 to 100µM. Values represent the 
mean and standard deviation of three independent experiments (n=3). Statistical 
significance was worked out using the one-way ANOVA test to make multiple 
comparisons. The black asterisks show comparisons of different conditions to the 
normoxia pH 7.4 control, whilst the red asterisks show comparisons of different 
































































HCT116 p53+/+ cells ARPE-19 
Cisplatin 2.03 (± 0.08) 2.68 (± 1.24) 4.52 (± 1.59) 6.75 (± 1.33) 3.75 (± 0.72) 
5-FU 1.01 (±0.06) 1.82 (± 0.26) 2.5 (± 0.82) 3.73 (± 0.61) 2.13 (± 0.66) 
Etoposide  0.52 (± 0.05) 0.68 (± 0.02) 0.85 (± 0.16) 0.91 (± 0.26) 0.31 (± 0.005) 
Tirapazamine 11.85 (± 0.63) 18.41 (± 1.09) 1.23 (± 0.39) n/a 27.63 (± 4.00) 
 
Table 3.1 The response of HCT116 p53+/+ and ARPE-19 cells to standard 
cytotoxic drugs and tirapazamine under various experimental conditions. All 
cells were exposed to test compounds for 96 hours over a concentration range from 
0.3-100µM under normal and TME conditions. Each result represents the mean ± 
standard deviation of three independent experiments. N/a refers to no data available. 
 
3.4.5 Analysis of the effect of the TME on cellular response to standard 
cytotoxic drugs and tirapazamine 
Using the data presented in table 3.1, a series of parameters were derived to 
illustrate the effect that individual changes to experimental conditions had on the 
activity of the drugs tested. These results are presented in table 3.2. In the case of 
all compounds tested including tirapazamine, reducing the pHe to 6.5 reduced the 
efficacy of compounds tested under normoxic conditions with pHR values ranging 
from 0.55 to 0.76. In the case of cisplatin and 5-FU (and to a lesser extent 
etoposide), hypoxia (0.1% oxygen) has a more profound effect than pHe on cellular 
response with HCR values of 0.44 and 0.40 respectively. When both hypoxia and 
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acidic pHe conditions are combined, the response of cells is reduced further (TME 
values ranged from 0.27 to 0.57, table 3.2). When compared to the response of non-
cancer ARPE-19 cells, the TME causes a clear and significant decrease in the 
selectivity ratios for cisplatin, 5-FU and to a lesser extent etoposide (table 3.2)  
 
Compound pHR HCR TME ratio SI  SI (TME) 
Cisplatin 0.75 0.44 0.3 1.84 0.55 
5-FU 0.55 0.40 0.27 2.10 0.57 
Etoposide  0.76 0.61 0.57 0.59 0.34 
Tirapazamine 0.61 9.55 n/a 2.33 22.28* 
 
Table 3.2 The effect of the TME on the response of cells to standard cytotoxic 
drugs and tirapazamine. pHR, HCR and TME represent the pH ratio, the hypoxic 
cytotoxicity ratio and tumour microenvironment ratio as defined in the methods 
section 3.3.3. * refers to the SI value for the hypoxic data only and not the combo of 






The study was designed to test a novel phenotypic screening strategy utilising the 
physiological parameters of the TME which are normally not present in vitro. The 
screen was deployed on the classic chemotherapeutic compounds cisplatin, 5-FU 
and etoposide with the aim of generating some parameters that could be used as a 
‘yardstick’ to measure the relative merits of the novel agents evaluated in this thesis. 
Initially, two validation experiments were conducted. The first was to demonstrate 
that HCT116 cells either possessed p53 or not. The results of western blot analysis 
(figure 3.2) demonstrate that p53 is present in HCT116 p53+/+ cells and absent from 
HCT116 p53-/- cells. The second was to validate the MTT assay. This validation 
assay was carried out to establish the relationship between cell number and 
absorbance. Figure 3.3 displays a linear relationship with an R2 value of 0.9932 and 
demonstrates that the MTT assay is a reliable method for conducting 
chemosensitivity studies. This finding is similar to (Ahmadi et al., 2014) study where 
a linear relationship was also observed under both normoxic and hypoxic conditions 
which verifies the suitability of this method under both working conditions.  
Before conducting experiments on the established drugs, initial studies were 
conducted on the HAP tirapazamine to ensure that the hypoxic conditions used in 
the H35 hypoxystation were suitable for subsequent studies. The results presented 
in figure 3.4 and table 3.1 and 3.2 clearly demonstrate that tirapazamine is 
preferentially cytotoxic under hypoxic conditions compared to aerobic conditions with 
IC50 values of 1.23µM (±0.39) and 11.85µM (±0.63) respectively. The HCR value of 
9.55 is comparable to previously published values (Ahmadi et al., 2014) and 
therefore the conditions used in the hypoxystation are satisfactory. This was also 
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statistically proven by ways of a student’s t-test where p<0.01. The results 
demonstrate that the hypoxic chamber was functioning correctly and the 
chemosensitivity testing continued under hypoxic conditions for the remainder of this 
PhD. 
The results also demonstrates good cytotoxicity of the classic chemotherapy 
compounds against the HCT116 p53+/+ cell lines under normoxic pHe 7.4 conditions. 
When the same compounds are subjected to hypoxia (pHe 7.4) there was notable 
resistance with HCR values all below 1 (table 3.2) reflecting an underlying problem 
of current anti-cancer chemotherapeutic compounds, namely ineffective efficacy 
against hypoxic cells. Furthermore, the increased IC-50 values under hypoxia reduce 
the selectivity index when the response of ARPE-19 cells are taken into account 
(Ahmadi et al., 2014; Nichol et al., 2019). The resistance of cisplatin to hypoxia 
displayed here is consistent with that of Song et al., 2006. They also demonstrate 
that manipulation of HIF in non-small cell lung cancer (NSCLC) cells by a lentiviral 
vector-mediated HIF-1α RNA interference (RNAi) strategy reverses the resistance 
exhibited by hypoxia (Song et al., 2006).  
HCT116 p53+/+ cells treated with classic chemotherapeutic compounds under pHe 
6.5 under normoxic conditions also displayed resistance with a pHR ratio all below 1. 
The data expressed here is similar to the findings of Wachsberger et al. (1997) 
where Chinese hamster ovary (CHO) cells that were adapted in growth medium at 
pH 6.7 displayed resistance to cisplatin when compared to pH 7.3 (Wachsberger et 
al., 1997). The highest difference observed in treating HCT116 p53+/+ cells with the 
chemotherapeutic compounds was in the combination of hypoxia and the pHe of 6.5. 
The TME ratio for all three classic chemotherapeutic compounds was below 1 and 
this is indicative that none of these compounds showcased any preferential activity 
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under the physiological TME conditions. This was statistically proven by the one way 
ANOVA parametric test between the classic compounds tested under normoxia pHe 
7.4 vs hypoxia and pHe 6.5 combined (figure 3.4).  
The classic chemotherapeutic compounds were also screened against the ARPE-19 
cells where cisplatin and 5-FU (SI 1.84 and 2.10 respectively) displayed some levels 
of selectivity towards the HCT116 P53+/+ cells. This was not the case for etoposide 
which was below 1. Under hypoxic or acidic pHe conditions, the SI values decrease 
even further and under TME conditions (combined hypoxia and acidic pHe), tumour 
cells are substantially more resistant than non-cancer ARPE-19 cells (SI values 
ranging from 0.34 to 0.57, table 3.2). In contrast, tirapazamine under hypoxic 
conditions has a substantially enhanced SI value of 22.46 which is consistent with 
the compound’s mechanism of action.  
Whilst the mechanistic reasons for the reduction in cellular response to cytotoxic 
drugs under hypoxia, acidic pHe or combinations of hypoxia and acidic pHe have not 
been explored in this thesis, the results provide a valuable baseline or yardstick for 
future studies. The results demonstrate that both hypoxia and acidic pHe can reduce 
the efficacy of the selected cytotoxic drugs and in the context of a phenotypic 
screening approach to drug discovery, these results are interesting. When combined 
with the results for tirapazamine, this approach has the potential to identify 
compounds that will (i) suffer a similar fate to the established anti-cancer drugs 
tested here in terms of resistance under TME conditions and (ii) be preferentially 
active under hypoxic, acidic pHe or combined TME conditions. In conclusion 
therefore, this chapter demonstrates that the phenotypic approach to drug discovery 
described here could identify compounds with preferential activity against cells that 
reside within the TME. Subsequent chapters of this thesis will explore this in detail 
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using a diverse range of novel compounds. The results presented in table 3.2 will be 
used in each of the subsequent chapters as the yardstick to judge the relative merits 
of each compound tested, the ultimate aim of which is to select promising lead 





Chapter 4: Bromo-Hexitols as a novel class of hypoxia-
activated prodrugs for cancer therapy 
4.1 Introduction 
The basic design for a HAP is the ‘trigger-linker-warhead’ structure as described by 
Denny et al (Denny et al., 1996). There are many ‘warheads’ available which are 
capable of causing cell death but the general issue with these is lack of selectivity. 
One example of this is a class of compounds known as bromo-hexitols which are 
potent cytotoxins. The well-known bromo carbohydrate compounds which have been 
around for 40 years are dibromomannitol (DBM), dibromogalacticol (DBG) and 
threosulfane (figure 4.1). These compounds are designed to be cytotoxic under 
normal physiological conditions and are activated by the reduction of bromine in vivo. 
This releases the active DNA-alkylating agent bis-epoxide which are marked by the 






Figure 4.1 DNA-alkylating chemotherapeutics, treosulfan, DBM and DBG. 
Dianhydrogalactitol (DAG) is the DNA alkylating agent formed by the in vivo 




Irrespective of the small structural differences between  DBM and DBG the cytotoxic 
activity of these are considerably different (Chiuten et al., 1981). These were not 
developed further because of toxicity to normal tissues (Chiuten et al., 1981). The 
most promising set of compounds were the bromo-hexitols and despite their 
cytotoxic properties, these compounds have been largely ignored in the past decade. 
There have been no attempts at exploring the correlation between structural activity 
of bromohexitols or in developing prodrugs which may be selective towards the 
hypoxic fraction of the tumour microenvironment. 
The Pederson group (University of Copenhagen) have synthesised a total of 13 
compounds (as shown in methods section 3.2.1) and have used a starting material 
known as endoperoxides which makes the synthesising process easier (Johansson 
et al., 2019). The endoperoxide is a closed ring carbohydrate structure consisting of 
bromine and due to the susceptibility of the endoperoxide linkage (O-O). It is 
hypothesised that this maybe cleaved under hypoxic conditions by way of one or two 
electron reduction which releases an activated form of the prodrug di-bromohexitol 









Figure 4.2 Schematic diagram indicating the hypoxic release of dibromohexitol 
from the endoperoxide. This is further activated to the active DNA-alkylating 
chemotherapeutic agent. The active sites are highlighted in red. 
The synthesised compounds by Pedersons team are divided into two groups. The 
first group are all endoperoxides – DS1, DS2, DS3, DS4, DS5, DS6, DS9 and DS10 
and these set of compounds are hypothesised to become activated by hypoxia and 
converted into the di-bromohexitol prodrug. The second group – DS11, DS12, DS13, 
DS14 and DS15 (see methods section 4.3.1) have been synthesised as the di-
bromohexitols and therefore should not be activated by hypoxic conditions. As this is 
a phenotypic screening program, the rationale for selecting cell lines to use was not based 
on biochemical characteristics but on pragmatic reasons including ease and reliability of 
growth under aerobic and hypoxic conditions. In addition, previous studies from our group 
have used the HCT116p53+/+ colorectal cancer cells for phenotypic screening studies and 
therefore to maintain consistency, this cell line was used. The ARPE-19 non-cancer cells 







4.2. Aims and objectives 
 
The aim of this study is to evaluate whether or not a series of bromo-hexitol 
derivatives are preferentially active under (i) hypoxia (0.1% oxygen), (ii) acidic 
extracellular pH (pHe 6.5) or (iii) a combination of hypoxia and acidic pHe. These 
studies were conducted on HCT116 p53+/+ (human colorectal cancer cells) cells with 
the aim of identifying ‘hit compounds’. To determine selectivity, these compounds 
were also evaluated against the non-cancer ARPE-19 cell line under conditions that 
reflect the ‘normal conditions’ found in healthy tissue (i.e. oxygenated and pHe 7.4). 
Following the identification of ‘hit compounds’, western blot analysis was conducted 
to determine if biomarkers of DNA damage induction (phosphorylated H2AX and 
p53) are induced under different experimental conditions.  
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4.3 Material and methods 
4.3.1 Compounds  
All bromosugar HAPs were kindly provided by Professor Daniel Sejer Pederson 
(University of Copenhagen). These were prepared in dimethylsulphoxide (DMSO) at 















Figure 4.3 Chemical structure of bromosugar based compounds and molecular 
weight. Panel A: Endoperoxides and panel B: Di-bromohexitols 
DS1 (RMM 271.94) DS2 (RMM = 305.95) DS3 (RMM = 287.94) 
DS4 (RMM = 287.94) DS5 (RMM = 368.85) DS6 (RMM = 346.02) 
DS9 (RMM = 319.98) DS10 (RMM = 360.04) 
A 
DS15 (RMM = 289.95) DS14 (RMM = 289.95) DS13 (RMM = 370.86) 




4.3.2 Cell culture and chemosensitivity 
Cell culture, adjusting the pH of the media, drug dilutions and chemosensitivity 
studies were carried out as previously described in the general methods section 
(section 2.6-2.8). The HCT116 P53+/+ cell line was used in this chapter. Any variation 
from these methods are indicated in the figure legends and described in the results 
section. 
4.3.3 Western blot analysis 
Cells were treated with hit compound for a duration of 24 hours at a drug 
concentration of 20µM (this concentration was chosen as it is a therapeutically 
relevant concentration (IC50 under hypoxic conditions was 25.93 ± 3.17 µM) and a 24 
hour duration of drug exposure was selected as minimal cell death had occurred at 
this time point (as illiustrated in figure 4.6). Controls were treated with media alone or 
with vehicle control (DMSO 0.1% which has been previously reported not to be toxic 
to the cells) under the following conditions: (i) normoxia pHe 7.4, (ii) normoxia pHe 
6.5, (iii) hypoxia pHe 7.4 and (iv) hypoxia pHe 6.4. Upon completion of treatment, 
cells were harvested for western blot analysis for DNA damage induction 
(phosphorylated H2AX or p53 dependency). Details of western blot methodology 
and antibody dilutions are described in methods (section 2.9-2.13 and table 2.2).  
4.3.4 Statistical analysis 
Statistical analysis was carried out using Microsoft Excel and Graph Prism. All 
experiments were done in triplicate (n=3), and results were presented as the mean ± 
SD. Statistical significance was determined by means of a two-tailed Student’s t-test, 
or by One Way ANOVA where significance was only accepted when p ≤ 0.05. The 




4.4.1 Chemosensitivity studies 
The response of HCT116 p53+/+ and ARPE-19 cells following continuous exposure to 
test compounds under normoxic and hypoxic (pHe 7.4) are presented in table 4.1. 
Responses ranged from inactive at the highest dose tested (IC50 > 100 µM; DS6 and 
DS12) to active with the most potent compound (DS3) having an IC50 against 
HCT116 p53+/+ cells of 4.50 ± 0.58 µM. The hypoxic cytotoxicity ratio (HCR) and 
selectivity index (SI) values are presented in table 4.2.  
Of these compounds, only DS10 and surprisingly DS15 demonstrated statistically 
significant greater activity under hypoxic compared to normoxic conditions (HCR = 
2.56 and 6.83 respectively (table 4.2)). Whilst the HCR was less than that of 
tirapazamine (HCR = 9.55), DS10 was the only endoperoxide compound to exhibit 
HAP like properties in vitro and was therefore the only compound subjected for 
further testing. It is not known why DS15 showed preferential activity under hypoxic 
conditions as it is in its inactive linear form under both conditions. Further studies are 
required to explore the mechanism(s) underpinning the hypoxia selectivity of DS15 
but these were not possible due to a shortage of compound supply. In the context of 
selectivity for cancer as opposed to non-cancer cells, DS1, DS3, DS4 and DS14 
showed a >2 fold selectivity towards HCT116 p53+/+ cells compared to ARPE-19 
cells under normoxic conditions (table 4.2). Under hypoxic conditions, DS10 also 
showed a degree of selectivity for HCT116 cells (SI = 1.65) compared to normoxic 
conditions (SI = 0.64). Based on the HCR and SI data (under hypoxia), a decision 




















Table 4.1 The response of HCT116 p53+/+ and ARPE-19 cells to endoperoxides, 
di-bromohexitols and tirapazamine under normoxic (pHe 7.4) and hypoxic (pHe 
7.4) conditions. All cells were exposed to test compounds for 96 hours over a 
concentration range from 0.3-100µM under normal and hypoxic conditions. Each 
result represents the mean ± standard deviation of three independent experiments. A 
student’s t-test was carried out to determine any significance when comparing 
















DS1  7.05 ± 1.74 13.26 ± 0.98 17.31 ± 5.96 
DS2  27.70 ± 10.05 47.54 ± 3.82 34.18 ± 5.24 
DS3  4.50 ± 0.58 21.56 ± 1.38 15.02 ± 4.32 
DS4  4.90 ± 1.88 12.36 ± 1.02 9.85 ± 1.54 
DS5  12.19 ± 2.17 19.16 ± 0.53 13.59 ± 1.43 
DS6  IC50 >100 IC50 >100 77.22 ± 3.82 
DS9  87.59 ± 5.37 72.15 ± 9.33 N/A 
DS10  66.39 ± 8.10 25.93 ± 3.17* 42.95 ± 5.03 
DS11  15.63 ± 4.30 25.90 ± 3.50 3.20 ± 0.89 
DS12  IC50 >100 IC50 >100 IC50 >100 
DS13  18.59 ± 3.00 16.18 ± 1.65 25.80 ± 9.75 
DS14  22.02 ± 0.46 71.73 ± 5.20 35.93  ± 0.55 
DS15  14.20 ± 2.32 2.08 ± 0.70** 15.13 ± 6.87 
















Table 4.2 The SI and HCR of endoperoxides, di-bromohexitols and 
tirapazamine against the HCT116 p53+/+ cells. The selectivity index (SI) is defined 
as the ratio of IC50 values for ARPE-19 divided by HCT116 p53
+/+ with values >1 
indicating selectivity towards HCT116 p53+/+ cancer cells. The HCR is defined as the 
ratio of IC50 values under normoxic conditions divided by the IC50 under hypoxic 
(0.1% oxygen) conditions. Values >1 indicate that compounds have selective toxicity 
towards cells under hypoxic conditions.  






DS2  1.23 0.71 0.58 
DS3  3.34 0.69 0.21 
DS4  2.01 0.79 0.39 
DS5  1.11 0.70 0.63 
DS6  - 0.77 - 
DS9  - - 1.21 
DS10  0.64 1.65 2.56 
DS11  0.20 0.12 0.60 
DS12  - - - 
DS13  1.38 1.59 1.14 
DS14  1.43 0.50 0.30 
DS15  1.06 7.27 6.83 
Tirapazamine 2.33 22.28 9.55 
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4.4.2 The effect of DS10 against the HCT116 p53+/+ cell line under TME 
conditions 
Under mildly acidic pHe conditions (pH 6.5), the activity of DS10 was significantly 
enhanced under normoxic conditions with IC50 values of 26.52 ± 7.01 and 66.39 ± 
8.10 µM respectively (figures 4.4 and 4.5). Under both hypoxic and acidic pHe 
conditions, the potency of DS10 increased further (IC50 = 16.3 ± 4.11 µM) 
demonstrating that both hypoxia (0.1% oxygen) and acidic pHe (pH 6.5) generate 
additive effects when combined (figure 4.4 and 4.5). 
Microenvironment enhancement ratios are presented in table 4.3 and this clearly 
shows the enhanced activity of DS10 under the combination of hypoxic and acidic 
pHe. This has a significant effect on the selectivity index (SI) which increases from 
0.64 in normoxic pHe 7.4 to 2.63 in hypoxia pHe 6.5. The pHR is similar to the HCR 
(2.5 and 2.63 respectively) which may be indicative of DS10 potentially having a dual 
trigger mechanism, one under the activation of hypoxic conditions and secondly 
DS10 sensitivity under low pHe conditions. 
DS10 displayed superiority over the classic compounds tested with preferential 
activity towards all of the physiological TME conditions tested for in this phenotypic 
screen (table 4.3). DS10 displayed a TME ratio of 4.07 which is more than 7 fold 
greater than etoposide and approximately 15 fold greater than 5-FU and cisplatin 





Figure 4.4 Dose response curve of HCT116 p53+/+ cells exposed to DS10 under 
normoxic and tumour microenvironmental conditions. Cells were continuously 
exposed (96 hour exposure) to DS10 over a wide range of concentrations (0.3-
100µM). HCT116 p53+/+ cells were exposed to DS10 under the following conditions: 
(i) normoxia pHe 7.4, (ii) normoxia pHe 6.5, (iii) hypoxia pHe 7.4 and (iv) hypoxia 








































Figure 4.5 Response of HCT116 p53+/+ cells to DS10 under normoxic and 
tumour microenvironmental conditions. IC50 values are presented in different 
combinations of oxygen concentration and pHe. Each value represents the mean 



























































Compound pHR HCR TME ratio SI  SI (TME) 
Cisplatin 0.75 0.44 0.3 1.84 0.55 
5-FU 0.55 0.40 0.27 2.10 0.57 
Etoposide  0.76 0.61 0.57 0.59 0.34 
Tirapazamine 0.61 9.55 n/a 2.33 22.28* 
DS10 2.50 2.56 4.07 0.64 2.63 
 
Table 4.3 The effect of the TME on the response of cells to standard cytotoxic 
drugs, tirapazamine and DS10. pHR, HCR and TME represent the pH ratio, the 
hypoxic cytotoxicity ratio and tumour microenvironment ratio as defined in the 
methods section (see section 3.3.3). * refers to the SI value for the hypoxic data only 
and not the combo of hypoxia and acidic pHe. The IC50 values for the classic 






4.4.3 Early signs of DNA damage by DS10 under hypoxic conditions in the 
HCT116 p53+/+ cell line  
 
As briefly discussed earlier, these set of compounds are designed to be activated to 
yield DNA damaging metabolites capable of alkylating DNA. To assess whether 
DS10 is activated under hypoxic conditions to generate DNA damage, western blot 
analysis for the detection of phosphorylated ϒH2AX, a protein marker which is used 
to determine the early signs of DNA damage, was used. The role of p53 dependency 
















Figure 4.6 Post 24 hour treatment of HCT116 P53+/+ cells treated with DS10 
under the physiological and TME conditions. A. HCT116 p53+/+ cells were treated 
with DS10 (20µM) for a duration of 24hours under the following conditions, normoxia 
pHe 7.4/ pHe 6.5 and hypoxia pHe 7.4/ pH 6.5. The vehicle control DMSO 0.1% was 
used as a control under each condition. B. HCT116 p53+/+ cells were treated with 
DS10 (100µM) for a duration of 96hours under the following conditions, normoxia 
and hypoxia (both at pHe 7.4). 
Choosing the correct concentration was important to determine whether DS10 was a 
DNA damaging agent or not. HCT116 p53+/+ cells were subjected to 20µM of DS10 
under both normoxic (pHe 7.4/ 6.5) and hypoxic (pHe 7.4/ 6.5) conditions. There was 
No cell death occurs after 24hours under normoxic or 
hypoxic conditions with either 0.1% DMSO or 20µM of DS10 
Poor cell death 




Significant cell death 






no difference in cell morphology between drug treated and untreated under these 
conditions after 24hours (figure 4.6A). When a higher drug concentration of DS10 
(100µM) was used there is a distinct difference in cell morphology between normoxic 
and hypoxic conditions indicating that cell death is imperative within 24hours (figure 
4.6B). For a fair assessment of early signs of DNA damage by DS10, 20µM was 
used to verify if ϒH2AX was phosphorylated under hypoxic conditions.  
Cells were immediately lysed and western blot analysis was carried out as described 
in the methodology section (see section 2.9-2.13). As depicted in figure 4.7, western 
blot analysis demonstrated that p-ϒH2AX is induced in cells treated with DS10 under 
hypoxic conditions only at pHe 7.4 and 6.5. No p-ϒH2AX was detected in DS10 
treated cells under aerobic conditions. This would suggest that DS10 is being 
activated to a DNA damaging species under hypoxic conditions although the 






















Figure 4.7 Influence of hypoxia and DS10 on induction of p-ϒH2AX and p53. 
Colorectal cancer HCT116 p53+/+ cells were exposed to DS10 for 24 hours under 
normoxic and hypoxic (0.1% O2) conditions, cell lysates prepared and subjected to 





























































































































4.5 Discussion  
In this chapter, a series of bromosugars that were designed as potential HAPs were 
evaluated in the phenotypic screen. Chemosensitivity studies with the bromosugar 
HAPs were carried out using HCT116 p53+/+ and the normal human retinal epithelial 
cell line ARPE-19 was used to provide an indication of selectivity. The most potent 
bromo-sugars under normoxic conditions with IC50 less than 10µM were the 
endoperoxides, DS1 (IC50 = 7.05µM ± 1.74), DS3 (IC50 = 4.50µM ± 0.58) and DS4 
(IC50 = 4.90µM ± 1.88) (table 4.1). From the compounds tested, the only 
endoperoxide that displayed preferential toxicity under hypoxic conditions was DS10 
with a HCR value of 2.56 (table 4.2 and figures 4.4 - 4.5). A further chemosensitivity 
study carried out with DS10 under normoxic conditions at pHe 6.5 showed a similar 
increase in toxicity as that of DS10 under hypoxic conditions IC50 26.53µM (±1.66) 
(figure 4.4 – 4.5). This warranted a final chemosensitivity study with DS10 under 
hypoxic conditions at pHe 6.5 to ascertain a TME ratio and the results were striking. 
Not only was this more toxic to the cancer cell line (2 fold decrease in IC50 values), 
the selectivity index had also increased by 4 fold (from 0.64 to 2.63). This is a 
desirable property for any new emerging chemotherapeutic compound as to be 
successful, it must have minimum or little toxicity to normal cells when compared to 
cancerous cells (Connors, 1982).  
From the endoperoxides DS6 is the only compound which is structurally identical to 
DS10 with the exception of a methyl functional group attached to it. However both 
these compounds exhibit different levels of cytotoxicity. DS6 did not display any level 
of potency towards the HCT116 p53+/+ cell line with IC50 values both greater than 
100µM under normoxic and hypoxic conditions. With the removal of the methyl group 
to form DS10, not only is cytotoxic activity enhanced but hypoxia selectivity also 
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occurs. This data demonstrates that subtle changes to the compound can have an 
significant impact on the potency of these and how they behave under both normoxic 
and hypoxic conditions. Similar observations were made with compounds DBM, 
DBG and treosulfan under normoxic conditions (Chiuten et al., 1981; Mischler et al., 
1979).  
From the di-bromohexitols only DS12 displayed no toxicity against both cell lines and 
conditions tested with IC50 values all greater than 100µM. The other di-bromohexitols 
DS11 and DS14 were also less active under hypoxic conditions (HCR 0.6 and 0.3 
respectively) and DS13 was slightly more toxic under hypoxic conditions (HCR 1.14). 
One interesting finding from this study was with the compound DS15 and its ability of 
behaving like a HAP. This may not be as potent (IC50 14.20µM ± 2.32) as the classic 
chemotherapeutic drugs tested in chapter 3 under normoxic conditions but it was 
very toxic under hypoxic conditions (HCR 6.83). The HCR observed with this 
compound is less than the classic HAP agent tirapazamine (HCR 9.55) but 2 fold 
greater than DS10. With DS10 being a endoperoxide and DS15 a dibromohexitol (in 
conjunction with its limited supply), it was decided that DS10 will be subjected for 
further studies as this project investigates the roles of endoperoxides becoming 
active under hypoxic conditions. Further studies are nevertheless warranted to 
explore the unusual and unexpected observation of hypoxia selectivity for DS15.  
When compared to the standard classic chemotherapeutic agents in results chapter 
3 and table 4.3, the HCR of DS10 (2.56) is much greater than that of cisplatin, 5-FU 
and etoposide (0.44, 0.40 and 0.61 respectively). The SI under normoxic conditions 
at pHe 7.4 for DS10 is 0.64 which is similar to etoposide (0.59), but less than 
cisplatin and 5-FU (1.84 and 2.10). When DS10 is tested under hypoxic conditions at 
pHe 6.5 the SI is 2.63 which is much improved compared to the classic agents 
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cisplatin (SI = 0.55), 5-FU (SI = 0.57) and etoposide (SI = 0.34). This demonstrates 
that DS10 is more active and selective under tumour microenvironmental conditions 
in comparison to the leading classic chemotherapeutic drugs. Similar results were 
obtained with a 2,4-dinitrobenzamide mustard which showed that lowering the 
extracellular pH (6.5) enhanced the cytotoxicity of this compound under normoxic 
conditions in the KHT sarcoma cell line, an effect that was further enhanced when 
acidic pHe conditions were combined with hypoxia (Denny et al., 1996). 
To further investigate the mechanism of action of DS10 under hypoxic conditions, 
western blot analysis was carried out for the screening of ϒH2AX and p53. Damaging 
the DNA, particularly the induction of double stranded DNA breaks, trigger the onset 
of several cellular response functions. One of these is the phosphorylation of the 
histone ϒH2AX to p-ϒH2AX (Podhorecka et al., 2010). P-ϒH2AX analysis is widely 
used to determine genotoxic effects of experimental compounds (Podhorecka et al., 
2010) and has been used in a clinical setting where cancer patients receiving certain 
anti-cancer treatments are monitored for both toxicity and selectivity towards tumour 
cells (Downs, 2007; Taneja et al., 2004). As depicted in figure 4.7, ϒH2AX 
phosphorylation was only observed in HCT116 p53+/+ cells treated with DS10 under 
hypoxic conditions with no ϒH2AX phosphorylation under normoxic conditions. This 
suggests that DS10 may be a DNA alkylating agent which is only active under 
hypoxic conditions. There was also no p53 dependency observed (figure 4.7). 
Further studies are warranted to explore the mechanism(s) of action of DS10 but the 
results presented here illustrates how endoperoxide linkage may be an important 
source of novel hypoxia triggers, the activity of which is further enhanced by acidic 
pHe conditions (figure 4.4 – 4.5 and table 4.3). 
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It is important to state that the results presented here have been conducted in 
monolayer cultures and further studies are required using experimental models that 
better mimic the tumour microenvironment. This includes the use of multi-cell layers 
to assess drug penetration (Phillips et al., 1998) and the use of multi-cell spheroids 
(Phillips, 2016). Due to the fact that limited supplies of the compounds were 
available (Prof Pederson’s group moved to the Pharmaceutical Industry during the 
course of this study), further studies of this nature were not possible. However, if this 
was not the case then further studies assessing the role of DS10 to penetrate 
through a multi-cell layer or in 3D spheroids where both gradients of hypoxic and 
acidic pHe conditions exist would be the next step in their preclinical evaluation.  
In conclusion, the phenotypic screen utilised in this results chapter has successfully 
identified a new novel di-bromohexitol prodrug DS10 which has shown preferential 
activity under all of the TME parameters tested. Within the broader context of current 
approaches to drug discovery, the US National Cancer Institute (NCI) 60 human 
tumour cell line screen plays a major role in random or phenotypic screening 
approaches. As stated previously, the NCI60 was developed in the late 1980’s and 
has been used as a platform for screening compounds by the research community 
(Shoemaker, 2006). This screen essentially uses panels of cell lines exposed to test 
compounds under normoxic and neutral pHe conditions only. If the same screening 
strategy was implemented with these endoperoxides then the ability of DS10’s to 
preferentially target cells under hypoxic and acidic pHe conditions would not be 
discovered. These results therefore demonstrate for the first time that the phenotypic 
approach to drug screening described in this study can identify novel compounds 
that are selectively toxic to cancer cells under conditions that partially mimic the 
TME.   
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Chapter 5: Performance of dasatinib and a HAP dasatinib 
derivative in the phenotypic screen 
5.1 Introduction 
Tyrosine kinase inhibitors (TKI’s) are one of the most promising and most 
extensively studied class of targeted drugs for cancer treatment. Cancer therapy has 
changed significantly over the past two decades with the emergence of TKI’s as a 
major ‘weapon’ in the war on cancer. These TKIs have continued to evolve over the 
past decades and we are currently on the third generation of TKI’s. (Arora and 
Scholar, 2005; Minari et al., 2016). Most established cytotoxic anti-cancer agents 
present a narrow therapeutic index, resulting in undesirable and unwanted side 
effects (Arora and Scholar, 2005). The development of the TKI’s was initially 
designed to circumvent these issues by targeting specific molecules and signalling 
pathways. TKI’s are generally given in conjunction with other cytotoxic agents as well 
as radiotherapy (Arora and Scholar, 2005). 
 
 
Figure 5.1 Chemical structure of Dasatinib (De Francia et al., 2009). 
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Dasatinib (figure 5.1) is a 2nd generation TKI which was developed by Bristol Myers 
Squibb (Kantarjian et al., 2006) and works by inhibiting the Src kinase family which 
are important proteins involved in the development of metastasis, angiogenesis, 
invasion, adhesion, growth and progression in human cancers (Frame, 2002; 
Schlessinger, 2000). In addition, dasatinib is widely used for the treatment of imatinib 
refractory chronic myeloid leukaemia (CML) by targeting the BCR-ABL oncogene. 
This 2nd generation TKI was developed as a successor to imatinib, a 1st generation 
TKI which is used in the treatment of CML. In vitro studies have clearly demonstrated 
that dasatinib is a highly potent ATP-competitive inhibitor and is 300 times more 
potent than imatinib. This could be because some patients can typically get a 
secondary resistance which is known to be linked to a mutation of the BCR-ABL 1 
kinase domain referred to as the T315I mutation (Apperley, 2007). This mutation of 
the T315I site changes the conformation of the specific site where Imatinib would 
bind resulting in steric hindrance and reduced activity. TKIs such as dasatinib were 
designed to target imatinib resistant CML (Perrotti et al., 2010).  
As stated previously, hypoxia has been shown to trigger a set of biochemical 
processes which are facilitated by the induction of the HIF factors (Rohwer and 
Cramer, 2011). Pham et al., (2009) has demonstrated this in cancer model 
xenografts by the up regulation of Src and phosphorylated Src proteins in the 
hypoxic regions of tumours (Pham et al., 2009). This has stimulated interest in this 
area to determine whether TKI’s do possess HAP like abilities in cancer cells. A 
study carried out by Ahmadi et al., (2014) investigated this by testing a series of 
TKI’s such as, sunitinib, sorafenib, gefitinib, masatinib, dasatinib, nilotinib, imatinib 
and erolitinib across a panel of cancer cell lines. The results demonstrated that 
dasatinib had increased potency under hypoxic conditions when compared to 
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normoxic in the MCF-7 and the triple negative MDA-MB-231, MDA-MB-468 and 
MDA-MB-453 breast cancer cell lines. In some cell lines this was not the case such 
as the non-small cell lung cancer cell line H460 which did not display any difference 
in potency (Ahmadi et al., 2014). The cell lines MDA-MB-231 and H460 were 
therefore chosen for this study. The selection of cell lines was based on previous 
studies within our group (Ahmadi et al 2014) which demonstrated that MDA-MB-231 
was more sensitive to dasatinib under hypoxic conditions whereas H460 was not. 
The ARPE-19 non-cancer cells was also selected for use in this chapter for the same 
reasons as outlined above. 
N-oxides have been previously used to increase potency under hypoxic conditions. 
AQ4N (a well-established HAP under clinical trials) has an N-oxide terminal group 
attached to the warhead AQ4 which undergoes a two electron reduction by 
metabolic processes under hypoxia thereby releasing AQ4 and increasing the 
potency of AQ4N up to 1000 times in the absence of air (Patterson, 1993). 
Consistent with this theory and rationale, nitroimidazole groups could also be used 
as bio-reductive triggers when combined with TKI agents such as dasatinib. 
Associate professor Adam Patterson from Auckland Cancer Society Research 
Centre, New Zealand has synthesised many novel compounds with the most well-
known example being TH-4000 (tarloxotinib bromide). This compound releases a 
highly toxic EGFR-TKI under hypoxic conditions and is currently under phase 2 
clinical studies (Patterson et al., 2015). As well as TH-4000, Patterson has also 
synthesised dasatinib which consists of an nitroimidazole trigger group as shown in 









Figure 5.2 Chemical structure of DAS-HAP. The region outlined in blue is the 
hypoxia sensitive nitroimidazole ‘trigger’ group with the black region being dasatinib.  
Dasatinib has previously demonstrated HAP like abilities (Ahmadi et al 2014) and to 
further test these inhibitors with the addition of nitroimidazole triggers could be 
beneficial in terms of providing an additional level of selectivity for targeting those 






The aim of this study is to evaluate whether the addition of an nitroimidazole terminal 
to dasatinib is cytotoxic towards the triple negative breast cancer MDA-MB-231 and 
the non-small cell lung cancer H460 cell lines under TME conditions by determining 
preferential activity under (i) hypoxia (0.1% oxygen), (ii) acidic extracellular pH (pHe 
6.5) and (iii) a combination of hypoxia and acidic pHe. To determine the selectivity, 
these compounds will also be evaluated against the non-cancerous ARPE-19 cell 
line under conditions that reflect the ‘normal conditions’ found in healthy tissue (i.e. 





5.3.1 Compounds  
DAS-HAP was kindly provided by Associate Professor Adam Patterson (Auckland 
Cancer Society Research Centre, New Zealand). This compound along with 
dasatinib was dissolved in dimethylsulphoxide (DMSO) at 100mM and aliquots 
(20µL) were stored at -20°C.  
5.3.2 Cell culture and chemosensitivity 
Cell culture, adjusting the pH of the media, drug dilutions and chemosensitivity 
studies were carried out as previously described in methods (see section 2.6-2.8). 
The cell lines used in this study are the non-small cell lung cancer cell line H460 and 
the triple negative breast cancer cell line MDA-MB-231. Any variation from these 
methods are indicated in the figure legends and described in the results section. 
5.3.3 Western blot analysis 
Cells were treated with hit compounds for a duration of 24 hours at a drug 
concentration of 0.005, 0.05 and 0.5µM. These concentrations were chosen as it is a 
therapeutically relevant concentration (IC50 under hypoxic conditions was 0.036 ± 
0.008 µM and 0.084 +/- 0.03 µM for dasatinib and DAS-HAP respectively as shown 
in table 5.12). A 24 hour duration of drug exposure was selected as minimal cell 
death had occurred at this time point. Controls were treated with media alone or with 
DMSO 0.1% vehicle control (which has been previously reported not to be toxic to 
the cells). Dasatinib was used as the positive control and these were carried out 
under the following tumour microenvironment conditions, normoxia pHe 7.4, 
normoxia pHe 6.5, hypoxia pHe 7.4 and hypoxia pHe 6.4. Upon completion of 
treatment, cells were harvested for western blot analysis for Src, and pSrc at tyrosine 
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527. Details of western blot methodology and antibody dilutions are described in the 
general methods (see section 2.9-2.13). 
 
5.3.4 Statistical analysis 
Statistical analysis was carried out using Microsoft Excel and Graph Prism. All 
experiments were done in triplicate (n=3), and results were presented as the mean ± 
SD. Statistical significance was determined by means of a two-tailed Student’s t-test, 
or by One Way ANOVA where significance was only accepted when p ≤ 0.05. The 





5.4.1 The effect of dasatinib against the H460 cell line under normoxic pHe 7.4 
The non-small cell lung cancer H460 cell line was treated with a dose concentration 
range of dasatinib over 96 hours and achieved an IC50 value of 9.71µM ± 1.06 which 
is graphically displayed below (figure 5.3). 
 
 
Figure 5.3 Response of H460 cells following a 96hour exposure to dasatinib 
under normoxic pHe 7.4. Each data point represents the mean ± standard 




















Dasatinib normoxia pH 7.4
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5.4.2 The effect of dasatinib and DAS-HAP against the H460 cell line under 
normoxic and hypoxic pHe 7.4 conditions  
The H460 cell line was treated with a dose concentration range of dasatinib and 
DAS-HAP under normoxic and hypoxic pHe 7.4 conditions over 96 hours. An IC50 
value of 9.71µM ± 1.06 was ascertained for dasatinib and no IC50 value was reached 
for DAS-HAP (IC50 > 100µM) under normoxic pHe 7.4 conditions and this is 











Figure 5.4 Response of H460 cells following a 96hour exposure to dasatinib 
and DAS-HAP under normoxic pHe 7.4. Each result represents the mean ± 
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DAS-HAP normoxia pH 7.4
DAS-HAP hypoxia pH 7.4
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Under hypoxic pHe 7.4 conditions, the IC50 generated for the two compounds was 
9.96µM ± 4.78 and 0.44 µM ± 0.02 (table 5.1) and an HCR ratio of 0.97 and 227.27 
respectively. A comparison between dasatinib and DAS-HAP under these conditions 
is graphically shown in figure 5.4 and table 5.1. 
 
 
Normoxia pHe 7.4 
H460 IC50 (µM) 
Hypoxia pHe 7.4 
H460 IC50 (µM) 
HCR 
Dasatinib 9.71 (± 1.06) 9.96 (± 4.78) 0.97 
DAS-HAP IC50 > 100 0.44 (± 0.02) >222.27 
 
Table 5.1. IC50 values and HCR for DAS-HAP and dasatinib against the H460 
cell line. These are presented in different combinations of oxygen tension and 
extracellular pH. Each value represents the mean IC50 ± SD for three independent 
experiments. 
5.4.3 The effect of dasatinib and DAS-HAP against the H460 cell line under 
normoxic pHe 7.4 and pHe 6.5 conditions 
H460 cells were treated with a dose concentration range of dasatinib and DAS-HAP 
over 96 hours under normoxic conditions at pHe 7.4 and 6.5. The IC50 values for 
both compounds under physiological pH conditions have been reported below with 
IC50 values of 9.96µM ± 4.78 for dasatinib and >100 µM for Das-HAP. Under acidic 
pHe conditions, the IC50 generated for dasatinib was 10.34µM ± 0.94 for dasatinib 
but an IC50 value was not reached for DAS-HAP IC50 > 100µM (figure 5.5 and table 
5.2). The pHR ratio for dasatinib and DAS-HAP are 0.93 and 1 respectively (table 
5.2). A comparison between dasatinib and DAS-HAP under these conditions is 




Figure 5.5 Response of H460 cells following a 96hour exposure to dasatinib 
and DAS-HAP under normoxic pHe 7.4 and pHe 6.5. Each result represents the 
mean ± standard deviation of three independent experiments.  
 
 
Normoxia pHe 7.4 
H460 IC50 (µM) 
Normoxia pHe 6.5 
H460 IC50 (µM) 
pHR 
Dasatinib 9.71 (± 1.06) 9.96 (± 4.78) 0.97 
DAS-HAP IC50 >100 IC50 >100 n/a 
 
Table 5.2 IC50 values and pHR for DAS-HAP and dasatinib against the H460 cell 
line. These are presented in different combinations of extracellular pH under 
normoxic conditions. Each value represents the mean IC50 ± SD for three 




















Dasatinib normoxia pH 7.4
DAS-HAP normoxia pH 7.4
Dasatinib normoxia pH 6.5
DAS-HAP normoxia pH 6.5
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5.4.4 The effect of dasatinib and DAS-HAP against the H460 cell line under 
normoxic pHe 7.4 and hypoxia pHe 6.5 conditions 
H460 cells were treated with a range of dasatinib and DAS-HAP concentrations over 
96 hours under hypoxic and pHe 6.5 conditions. The IC50 generated for the two 
compounds was 6.76µM ± 1.31 for dasatinib and 67.73µM ± 0.003 for DAS-HAP 
(table 5.3). The TME enhancement ratio for dasatinib and DAS-HAP are 1.43 and 
1.47 respectively (table 5.3) and demonstrates similar a potential for the TME 
conditions. A comparison between dasatinib and DAS-HAP under these conditions is 
graphically displayed below (figure 5.6). 
 
 
Normoxia pHe 7.4 
H460 IC50 (µM) 
Hypoxia pHe 6.5 
H460 IC50 (µM) 
TME 
Dasatinib 9.71 (± 1.06) 6.76 ± 1.31 1.43 
DAS-HAP IC50 >100 67.73 ± 0.003 ~ 1.47 
 
Table 5.3 IC50 values and the TME ratio for DAS-HAP and dasatinib against the 
H460 cell line. These are presented in different combinations of oxygen tension and 
extracellular pH including the combination of hypoxia and acidic pHe. Each value 






Figure 5.6 Response of H460 cells following a 96hour exposure to dasatinib 
and DAS-HAP under normoxic pHe 7.4 and hypoxia pHe 6.5. Each result 
represents the mean ± standard deviation of three independent experiments.  
5.4.5 The effect of dasatinib and DAS-HAP against the H460 and ARPE-19 cell 
line under normoxic pHe 7.4  
Dasatinib and DAS-HAP were also exposed to the normal human retinal epithelial 
cell line ARPE-19 cells under normoxic pHe 7.4 conditions for 96 hours. The IC50 
values of these compounds towards this cell line were 0.12µM ±0.02 for dasatinib 
and 3.636µM ±0.56 for DAS-HAP (table 5.4). The SI index for dasatinib and DAS-
HAP are 0.01 and 0.03 respectively (table 5.4). This indicates that DAS-HAP is less 
toxic towards the normal cells and more selective towards the H460 cancerous cell 




















Dasatinib normoxia pH 7.4
DAS-HAP normoxia pH 7.4
Dasatinib hypoxia pH 6.5
DAS-HAP hypoxia pH 6.5
100 
 
Table 5.4 IC50 values, SI for DAS-HAP and dasatinib against the H460 and 
ARPE-19 cell line. These are presented in different combinations of extracellular pH 
under normoxic conditions. Each value represents the mean IC50 ± SD for three 
independent experiments. 
 
Figure 5.7 Response of H460 and ARPE-19 cells following a 96hour exposure 
to dasatinib and DAS-HAP under normoxic pHe 7.4. Each result represents the 




















Dasatinib normoxia pH 7.4





Normoxia pHe 7.4 




Dasatinib 9.71 (± 1.06) 0.12 (± 0.02) 0.01 







































Table 5.5 IC50 values for DAS-HAP and dasatinib against the H460 and ARPE-
19 cell line. These are presented in different combinations of oxygen concentration 
and pHe. Each value represents the mean IC50 ± SD for three independent 
experiments 
 
Compound Cell pHR HCR TME ratio SI  SI (TME) 
Dasatinib H460 0.93 0.97 1.43 0.01 0.01 
DAS-HAP H460 1 227.27 1.47 0.03 0.05 
Table 5.6 The effect of the TME on the response of H460 cells to dasatinib and 
DAS-HAP. pHR, HCR and TME represent the pH ratio, the hypoxic cytotoxicity ratio 
and tumour microenvironment ratio as defined in the methods section 3.3.3.   
 
5.4.6 The effect of dasatinib against the MDA-MB-231 cell line under normoxic 
pHe 7.4 
The triple negative MDA-MB-231 breast cancer cell line was treated with a dose 
concentration range of dasatinib over 96 hours and reached an IC50 value of 
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0.037µM ± 0.009. This is graphically displayed below (figure 5.8). This is more toxic 
towards the MDA-MB-231 in comparison to the H460 cell line. 
 
Figure 5.8 Response of MDA-MB-231 cells following a 96hour exposure to 
dasatinib under normoxic pHe 7.4. Each result represents the mean ± standard 
deviation of three independent experiments.  
5.4.7 The effect of dasatinib and DAS-HAP against the MDA-MB-231 cell line 
under normoxic and hypoxic pHe 7.4 
MDA-MB-231 cells were treated with a dose concentration range of DAS-HAP over 



















Dasatinib normoxia pH 7.4
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0.037µM ± 0.009 for dasatinib under normoxia pHe 7.4 and is graphically displayed 
below (figure 5.9). 
 
Figure 5.9 Response of MDA-MB-231 cells following a 96hour exposure to 
dasatinib and DAS-HAP under normoxic and hypoxic pHe 7.4. Each result 
represents the mean ± standard deviation of three independent experiments.  
The IC50 generated for the two compounds under hypoxic pHe 7.4 conditions was 
0.036µM ± 0.008 and 0.084µM ± 0.03 for dasatinib and DAS-HAP respectively. The 
HCR ratio for dasatinib and DAS-HAP was 1.02 and 19.57 respectively. A 
comparison between dasatinib and DAS-HAP under these conditions is graphically 




















Dasatinib normoxia pH 7.4
DAS-HAP normoxia pH 7.4
Dasatinib hypoxia pH 7.4





Normoxia pHe 7.4 
MDA-MB-231 IC50 (µM) 
Hypoxia pHe 7.4 
MDA-MB-231 IC50 (µM) 
HCR 
Dasatinib 0.037 (± 0.009) 
 
0.036 ± 0.008 1.02 
DAS-HAP 1.644 (± 0.22) 0.084 ± 0.03 19.57 
 
Table 5.7 IC50 values and HCR for DAS-HAP and dasatinib against the H460 cell 
line. These are presented in different combinations of oxygen tension and 





5.4.8 The effect of dasatinib and DAS-HAP against the MDA-MB-231 cell line 
under normoxic pHe 7.4 and pHe 6.5 conditions 
MDA-MB-231 cells were treated with a dose concentration range of dasatinib and 
DAS-HAP over 96 hours under normoxic and pHe 6.5 conditions. The IC50 generated 
for the two compounds was 0.02µM ± 0.001 for dasatinib and 0.821µM ±0.18 for 
DAS-HAP (table 5.8). The pHR for dasatinib and DAS-HAP are 1.85 and 2 
respectively (table 5.8). A comparison between dasatinib and DAS-HAP under these 
conditions is graphically displayed below (figure 5.10). 
 
Figure 5.10 Response of MDA-MB-231 cells following a 96hour exposure to 
dasatinib and DAS-HAP under normoxic pHe 7.4 and pHe 6.5. Dose response 
curves to dasatinib and DAS-HAP (0.001-100µM) under normoxic pHe 7.4 and pHe 




















Dasatinib normoxia pH 7.4
DAS-HAP normoxia pH 7.4
Dasatinib normoxia pH 6.5





Normoxia pHe 7.4 
H460 IC50 (µM) 
Normoxia pHe 6.5 
H460 IC50 (µM) 
pHR 
Dasatinib 0.037 (± 0.009) 0.02 (± 0.001) 1.85 
DAS-HAP 1.644 (± 0.22) 0.821 (±0.18)   2 
 
Table 5.8 IC50 values and pHR for DAS-HAP and dasatinib against the H460 cell 
line. These are presented in different combinations of extracellular pH under 
normoxic conditions. Each value represents the mean IC50 ± SD for three 
independent experiments. 
 
5.4.9 The effect of dasatinib and DAS-HAP against the MDA-MB-231 cell line 
under normoxic pHe 7.4 and hypoxia pHe 6.5 conditions 
MDA-MB-231 cells were treated with a dose concentration range of dasatinib and 
DAS-HAP over 96 hours under hypoxic pHe 6.5 conditions. The IC50 generated for 
the two compounds was 0.016µM ± 0.004 for dasatinib and 0.02µM ± 0.003 for DAS-
HAP (table 5.9). The TME enhancement ratio for dasatinib and DAS-HAP are 2.31 
and 82.2 (table 5.9) respectively and demonstrates that DAS-HAP although not as 
toxic as dasatinib, but has a much higher selectivity for the TME conditions. A 
comparison between dasatinib and DAS-HAP under these conditions is graphically 






Normoxia pHe 7.4 
H460 IC50 (µM) 
Hypoxia pHe 6.5 
H460 IC50 (µM) 
TME 
Dasatinib 0.037 (± 0.009) 0.016 ± 0.004 2.31 
DAS-HAP 1.644 (± 0.22) 0.02 ± 0.003 82.2 
 
Table 5.9 IC50 values and the TME ratio for DAS-HAP and dasatinib against the 
H460 cell line. These are presented in different combinations of oxygen 
concentration and pHe. Each value represents the mean IC50 ± SD for three 
independent experiments. 
 
Figure 5.11 Response of MDA-MB-231 cells following a 96hour exposure to 
dasatinib and DAS-HAP under normoxic pHe 7.4 and hypoxia pHe 6.5. Each 



















DAS-HAP normoxia pH 7.4
DAS-HAP normoxia pH 6.5
Dasatinib hypoxia pH 6.5
DAS-HAP hypoxia pH 6.5
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5.4.10 The effect of dasatinib and DAS-HAP against the MDA-MB-231 and 
ARPE-19 cell line under normoxic pHe 7.4  
The SI index for dasatinib and DAS-HAP are 3.33 and 43.28 respectively (table 
5.10). This indicates that DAS-HAP is less toxic towards the normal cells and more 
selective towards the MDA-MB-231 cancerous cell lines in comparison to dasatinib. 
 
Figure 5.12 Response of MDA-MB-231 and ARPE-19 cells following a 96hour 
exposure to dasatinib and DAS-HAP under normoxic pHe 7.4. Each result 
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Table 5.10 IC50 values, SI for DAS-HAP and dasatinib against the H460 and 
ARPE-19 cell line. These are presented in different combinations of extracellular pH 
under normoxic conditions. Each value represents the mean IC50 ± SD for three 
independent experiments. 
 
5.4.11 Summary on the effect of dasatinib and DAS-HAP against the H460 and 








































Table 5.11 Summary of IC50 values for DAS-HAP and dasatinib against the 
H460 cell line. These are presented in different combinations of oxygen tension and 
extracellular pH including the combination of hypoxia and acidic pHe. Each value 
represents the mean IC50 ± SD for three independent experiments. 
 
 
Normoxia pHe 7.4 




Dasatinib 9.71 (± 1.06) 0.12 (± 0.02) 0.01 













































Table 5.12 Summary of IC50 values for DAS-HAP and dasatinib against the 
MDA-MB-231 cell line. These are presented in different combinations of oxygen 










0.75 0.44 0.3 1.84 0.55 
5-FU 0.55 0.40 0.27 2.10 0.57 
Etoposide  0.76 0.61 0.57 0.59 0.34 
Tirapazamine 0.61 9.55 n/a 2.33 22.46* 
Dasatinib MDA-MB-231 1.85 1.02 2.31 3.33 7.5 
H460 0.93 0.97 1.43 0.01 0.01 
DAS-HAP MDA-MB-231 2.00 19.57 82.2 43.28 181.8 
H460 1 227.27 1.47 0.03 0.05 
 
Table 5.13 The effect of the TME on the response of cells to standard cytotoxic 
drugs, tirapazamine, dasatinib and DAS-HAP. pHR, HCR and TME represent the 
pH ratio, the hypoxic cytotoxicity ratio and tumour microenvironment ratio as defined 
in the methods section 3.3.3.  * refers to the SI value for the hypoxic data only and 
not the combo of hypoxia and acidic pHe. 
Although DAS-HAP was not as active as dasatinib, it did however display 
preferential activity towards all the TME parameters tested in this phenotypic screen 
in the MDA-MB-231 cells and this is defined by the high TME ratio of 82.2. In 
comparison, this is 35 fold greater than dasatinib and when compared to the classic 
chemotherapeutic compounds, it is 144 fold greater than etoposide, 274 fold greater 
than cisplatin and 304 fold greater than 5-FU (table 5.13). With regards to the 
selectivity indices, the DAS-HAP is superior to dasatinib alone with a SI value of 
181.8 compared to 7.5 in the MDA-MB-231 cell line. In H460 cells however, the 
unexpected observation of reduced cytotoxicity under full TME conditions (both 
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hypoxia and acidic pHe) complicates matters and further experiments are required to 
explore this observation.   
 
5.4.12 Western blot analysis for the detection of Src induction by dasatinib and 
DAS-HAP under TME condition  
For further investigation of dasatinib and DAS-HAP on Src and pSrc only the MDA-
MB-231 cells were used as dasatinib and the DAS-HAP showcased much more 
selectivity towards this cancer cell line under all the tumour microenvironment 
conditions tested. MDA-MB-231 cells were treated with either dasatinib or DAS-HAP 
with a concentration range of 0.005-0.5µM under the following conditions: (i) 
normoxia pHe 7.4, (ii) normoxia pHe 6.5, (iii) hypoxia pHe 7.4 and (iv) hypoxia pHe 
6.5 (these conditions were the same as those used in the chemosensitivity studies). 
Following a 24 hour drug exposure, the cells were lysed in either the biological class 
II safety cabinet for normoxic conditions or the H35 hypoxystation for hypoxic 
conditions and Western blot analysis conducted for both Src and p527-Src, the 
results of which are presented in figures 5.13 and 5.14 respectively.  
The western blot data for Src expression did not display much of a difference in 
activity under all concentrations tested for both dasatinib and the DAS-HAP. In 
general, the expression levels of Src were similar in treated samples and the DMSO 
0.1% vehicle control (figure 5.13). In contrast however, dasatinib did inhibit pSrc 527 
under normoxic conditions at pHe 7.4 at a concentration of 0.05µM. In comparison 
the concentration of DAS-HAP required to inhibit pSrc 527 was much higher (0.5µM) 
which is consistent with the prodrug nature of the DAS-HAP compound. Under 
hypoxic conditions, inhibition of pSrc 527 by DAS-HAP occurred at much lower 
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concentrations (figure 5.16). The results for DAS-HAP under hypoxic combined with 
acidic pHe conditions are less clear cut with evidence of inhibition of pSrc 527 at 
0.005 µM conflicting with a much stronger band at 0.05 µM (figure 5.14). Further 
studies are required to address this but they were not possible due to time 
constraints in this project.   
 
Figure 5.13 Western blot analysis of the effect of dasatinib or DAS-HAP (24 
hour drug exposure) on SRC phosphorylation induction in MDA-MB-231 







Figure 5.14 Western blot analysis of the effect of dasatinib or DAS-HAP (24 
hour drug exposure) on SRC 527 phosphorylation induction in MDA-MB-231 





The purpose of this study was to evaluate the preferential TME activity of DAS-HAP 
that was provided by Associate Professor Adam Patterson (Auckland Cancer Society 
Research Centre, New Zealand) on the MDA-MB-231 and H460 cell lines by utilising 
the phenotypic screening strategy.  
Structurally dasatinib and DAS-HAP are very similar; the only difference is that DAS-
HAP has the addition of an 2-nitroimidazole as a hypoxia trigger. Dasatinib inhibits 
both the Src family tyrosine kinases and the BCR-ABL oncogene and is approved for 
the use of patients with imatinib refractory CML (Chen and Chen, 2015). As the 
tumour cell lines used in this study are MDA-MB-231 and H460 cell lines, then the 
main focus shall be on targeting of the Src tyrosine kinases. Dasatinib is a very 
potent TKI with IC50 values within the range of 0.037-0.016µM under the different 
parameters tested against the MDA-MB-231 cell lines as demonstrated in this study 
(table 5.12). This compound was more sensitive towards the MDA-MB-231 cell line 
in comparison to the H460 cell line under normoxic pHe 7.4 conditions. This data is 
in line with a study carried out by Ahmadi et al (2014) who tested the response of a 
panel of tumour cell lines to a series of well-established 1st and 2nd generation TKI’s. 
The results displayed that the TKI’s had a much more favourable response towards 
the triple negative breast cancer cell lines in comparison to the lung cancer cells 
(Ahmadi et al., 2014).  
When both dasatinib and DAS-HAP were tested under hypoxic conditions, it was 
clear that these displayed HAP like properties. One of the most striking results was 
the response of DAS-HAP towards the H460 cells under the pHe 7.4 conditions 
which was 0.44µM with a HCR of 227.2 which is much higher than all of the 
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compounds tested in this study and those classic chemotherapeutic agents tested 
(table 5.13) including tirapazamine. This demonstrates that DAS-HAP is undergoing 
bioreductive activation under hypoxic pHe 7.4 conditions. Unfortunately, the 
significant increase in potency under hypoxia and pHe 7.4 was not observed under 
hypoxia combined with mild acidic conditions and in this case, it appears that DAS-
HAP is becoming inactive under mild acidity. The TME enhancement ratio of DAS-
HAP against the H460 and MDA-MB-231 cell line was 1.47 and 82.2 respectively 
which was much greater than dasatinib especially against the MDA-MB-231 cell line 
(1.43 and 2.31 – table 5.13). The reasons for the inhibitory effect of acidic pHe and 
hypoxia on DAS-HAP efficacy against H460 cells is not known and further studies 
are required to (i) confirm that this result is correct and not an experimental artefact 
and (ii) to understand the mechanism responsible for this observation. The results of 
this study nevertheless demonstrated that DAS-HAP has preferential activity towards 
the H460 cell line under hypoxic conditions although the inhibitory effects of acidic 
pHe results are a cause for concern.  
A different picture emerged however when the same set of experiments were 
conducted against MDA-MB-231 cells. Although DAS-HAP is very potent, it is not as 
toxic as dasatinib towards the MDA-MB-231 cells (table 5.12). The enhancement 
ratios collectively put things into perspective by demonstrating its superior 
enhancement ratios compared to dasatinib. These were pHR of 2 against 1.85, a 
HCR of 19.57 against 2.31, a TME ratio of 82.2 against 2.31, a SI at pHe 7.4 of 
43.28 against 3.33 and a SI (TME) of 181.8 against 7.5. This was not only superior 
against dasatinib which is a well-established TKI but also all of the classic 
chemotherapeutic compounds tested earlier (table 5.13). It is worth noting that the 
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inhibitory effect of acidic pHe observed with the H460 cell line was not observed in 
the MDA-MB-231 cell line.  
Src plays many pivotal roles as intermediates in tumourigenesis such as, adhesion, 
invasion, metastasis, angiogenesis and proliferation (Frame, 2002). It was important 
to further understand the role of dasatinib and DAS-HAP on the Src kinases and its 
ability to inhibit these under TME conditions. The western blot data for MDA-MB-231 
cells demonstrated that there was no major difference in Src expression between 
dasatinib and the DAS-HAP (figure 5.13). In contrast, there was a notable difference 
in the inhibition of pSrc 527 between normoxic and hypoxic conditions. Dasatinib 
showcased this at concentrations of 0.05µM for normoxic and 0.005µM for hypoxia 
conditions. In comparison, DAS-HAP showed inhibition of pSrc (527) at 
concentrations of 0.5µM for normoxic and 0.05µM for hypoxic (figure 5.14). This data 
is in line with the chemosensitivity studies carried out earlier (table 5.11 and 5.12) 
which demonstrate that dasatinib was more active than DAS-HAP. However this 
cannot be concluded with the investigation of pSrc 527 alone as pSrc 527 only 
inactivates c-Src. For full activation there is another Src which need to be 
phosphorylated which is Src 419 (Ahmadi et al., 2014) and further studies are 
required to assess the effects of these compounds on pSrc 419. The 
chemosensitivity data also demonstrated the selectivity of DAS-HAP towards the 
MDA-MB-231 cells and this could be due to the high expression of Src in cancer 
cells in comparison to the normal cells (Frame, 2002).  
Through this phenotypic screening strategy, MDA-MB-231 cell line was considered 
for further studies as this compound displayed preferential activity towards all of the 
TME conditions tested for. The selectivity of DAS-HAP towards the MDA-MB-231 
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cells is much higher than those in comparison to classic chemotherapeutic drugs 
tested which demonstrates that this type of phenotypic screen is able to find new 
novel compounds which have more favourable towards cancer cells (the selectivity 
index) and preferential activity against cells under conditions that mimic the 





Chapter 6: Phenotypic evaluation of novel organometallic 
compounds under TME conditions 
6.1 Introduction 
The previous chapters have described the establishment of a phenotypic screen to 
identify compounds with preferential activity against the tumour microenvironment. 
The work reported in the previous two chapters have focused on compounds that 
were designed to be preferentially activated under hypoxia but in this chapter and 
subsequent chapters will evaluate compounds that had not been designed to exploit 
the tumour microenvironment. This therefore this represents the first attempt to 
identify novel TME active agents in the true spirit of phenotypic screening. These 
compounds were synthesised by Professor Mohan Rao (North Eastern Hill 
University, Shillong, India) and they are all organometallic compounds. Brief details 
of the various types of compounds that have been evaluated are summarised below.  
 
6.1.1 Napthyridines 
Napthyridine consist of two pyridine rings which are fused together through two 
adjacent carbon atoms where each ring contains one nitrogen atom (Madaan et al., 
2015).  
 




There are six different isomers of napthyridines with the 1,8-napthyridine derivatives 
gaining the most interest for their numerous biological activities such as, anti-
microbial, anti-viral, as well as anti-cancer properties (Brown, 1965; Daniels et al., 
2007; Srivastava et al., 2007). There are only a few napthyridine metal compounds 
which consist of the half-sandwich metal platinum groups reported to date 
irrespective of its interesting chemistry and bonding modes (Sinha et al., 2013; 
Suzuki, 2006). Upon reflection on the different bonding modes corresponding with 
the napthyridine ligands it was hypothesised that if pyridine, phenol and aniline was 
substituted at the 2-position of the 1,8-napthyridine consisting of either ruthenium, 







Figure 6.2 Ligands used in the synthesis process for napthyridine ligands with 
either phenol (PHNp), anailine (AnNp) or pyridine (PyNp), consisting of either 
ruthenium, iridium or rhodium which are known as KMR-SA-21-29 and KMR-





6.1.2 Thiourea derivatives 
Thiourea are a class of organic compounds having sulphur with the general formula 
(R1R2N)(R3R4N)C=S (Shakeel et al., 2016).  
 
Figure 6.3 The general structure of Thiourea  (Lapasam et al., 2019; Shakeel et 
al., 2016). 
 
Half-sandwich arene d6 compounds have been extensively researched for their 
organometallic metal based anti-cancer properties (Habtemariam et al., 2006). This 
has ‘opened the lid’ for new research into the synthesis of such compounds which 
consist of a half sandwich compound with an organometallic metal base for its anti-
cancer properties.  
Much interest has been paid towards the synthesis and development of transition 
metal compounds which consist of thiourea ligands due to their interesting binding 
modes (Lapasam et al., 2019). Thiourea derivatives are also known to exhibit a wide 
range of biological activities such as anti-bacterial, anti-fungal, anti-malarial and anti-
tumour activities which is dependent on their ligands (Lin et al., 2013; Mahajan et al., 
2007).  
Professor Rao used 3 different pyridyl ligands with each one consisting of ruthenium, 




Figure 6.4 Ligands used in the synthesis process for transition metal half-
sandwich compounds of pyridyl thiourea derivatives, consisting of either 
ruthenium, iridium or rhodium which are known as KMR-SA-1-9 and KMR-L1-
L3 (Adhikari et al., 2018b). 
 
6.1.3 Benzylthiourea 
Benzolylthiourea ligands are of interest in regards to coordination chemistry due to 
their interesting behaviour towards various transition metals. In this particular study 
rhodium, iridium and ruthenium half-sandwich compounds consisting of pyrimidyl 
and pyridyl thiourea derivatives are tested for their chemotherapy like properties 
under TME conditions. 
 
Figure 6.5 Ligands used in the synthesis process for transition metal half-
sandwich compounds of pyrimidyl and pyridyl thiourea derivatives. These 
consist of either ruthenium, iridium or rhodium. These are known as KMR-SA-




Aroylthiourea are versatile in coordinating with a wide range of metal ions as neutral, 
dibasic or monobasic ligands (Lapasam et al., 2019). Therefore, the biological 
relevance of ruthenium-arene and aroylthiourea has warranted the biological 
evaluation of ruthenium-arene complexes which consist of the aroylthiourea ligand 
for their cytotoxic ability and selectivity towards cancer cells. 
 
Figure 6.6 Ligands used in the synthesis process for aroylthiourea 
compounds. These consist of either ruthenium, iridium or rhodium. These are 
known as KMR-AL-9-17 (Lapasam et al., 2019).  
The compounds described above in this chapter were all used to treat the following 
different cell lines: colorectal cancer HCT116,  HT29 and the pancreatic cancer Mia-
PaCa-2. As in previous chapters, the selection of cell lines was not based on any 
biochemical rationale but for pragmatic reasons of easy and reliable growth in cell 






The purpose of this chapter is the phenotypic evaluation of a series of organometallic 
compounds synthesised by Professor Mohan Rao (Eastern Hill University, India) with 
the aim of identifying novel compounds with preferential activity against cells under 
tumour microenvironmental conditions. The compounds evaluated included novel 
metal ruthenium, iridium and rhodium based napthyridines, thiourea derivatives, 
aroylthiourea ligands and benzoylthiourea compounds. All of the different 
compounds will be tested for their cytotoxic ability and selectivity towards the 
colorectal cancer HCT116, HT29 and the pancreatic cancer Mia-PaCa-2 cell lines 
compared to non-cancer ARPE-19 cells. The ability to become activated under 
hypoxic, mild pHe acidity or a combination of the two conditions using the HCT116 
cell line will be determined and preliminary studies looking at the potential 














All synthesised compounds were synthesised by Professor Mohan Rao and his 
students (Eastern Hill University, India) and all compounds were dissolved in 
(DMSO) at 100mM (which are shown below in figures 6.7 to 6.10), aliquoted and 
stored at -20°C.  
 











































KMR-L10 (RMM = 258.31) KMR-L11 (RMM = 271.33) KMR-L12 (RMM = 271.33) 
KMR-SA-30 (RMM = 564.50) KMR-SA-31 (RMM = 567.33) KMR-SA-32 (RMM = 656.64) 
KMR-SA-33 (RMM = 577.53) 
KMR-SA-36 (RMM = 577.53) 
KMR-SA-34 (RMM = 579.03) KMR-SA-35 (RMM = 669.68) 
KMR-SA-37 (RMM = 579.03) KMR-SA-38 (RMM = 669.68) 
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6.3.2 Cell culture and chemosensitivity 
Cell culture, adjusting the pH of the media, drug dilutions and chemosensitivity 
studies were carried out as previously described in the general methods chapter 
(see sections 2.2, 2.6-2.8). The following cell lines were used for this study which 
were the colorectal cancer HCT116, HT29 and the pancreatic cancer Mia-PaCa-2 
cell line. Any variation from these methods are indicated in the figure legends and 
described in the results section. 
6.3.3 Western blot analysis 
Cells were treated with hit compounds for a duration of 24 hours at a drug 
concentration of 12.5, 25 and 50µM. These concentrations were chosen as it is a 
therapeutically relevant concentration (IC50 under hypoxic conditions was 34.53 ± 
13.86 µM) and a 24 hour duration of drug exposure was selected as minimal cell 
death had occurred at this time point (as illustrated in figure 6.12). Controls were 
treated with media alone or with DMSO (0.1% v/v) vehicle control (which has been 
previously reported not to be active to the cells). These were carried out under the 
following tumour microenvironment conditions, normoxia pHe 7.4, and hypoxia pHe 
7. Upon completion of treatment, cells were harvested for western blot analysis of 
phosphorylated γH2AX (as a marker of DNA damage). Details of western blot 
methodology and antibody dilutions are described in methods (see sections 2.12 and 
table 2.2). 
6.3.4 Statistical analysis 
Statistical analysis was carried out using Microsoft Excel data analysis. All 
experiments were done in triplicates (n=3) unless specified in the figure legend, and 
results were presented as the mean ± SD. Statistical significance was determined by 
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6.4.1 Chemosensitivity testing of thiourea ligand derivatives under normoxic 
pHe 7.4 conditions  
Compounds KMR-L1 to KMR-L3 represent the ligand only (do not contain metal) and 
under standard cell culture conditions, these did not display any activity towards the 
cancer cell lines HCT116 and Mia-PaCa-2 tested with IC50 values all greater than 
100µM (table 6.1).  
Table 6.1 The response of HCT116, Mia-PaCa-2 and ARPE-19 cells following a 
96hour exposure to thiourea ligand compounds under normoxic pHe 7.4 
conditions. Each result represents the mean ± standard deviation of three 
independent experiments.  
 
IC50 (µM) Selectivity index 
Compound HCT116  Mia-PaCa-2  ARPE-19  HCT116   Mia-PaCa-2  
KMR-SA-1 17.53 ± 2.96 10.05 ± 0.17 21.31 ± 3.53 1.21 2.12 
KMR-SA-2 9.69 ± 0.97 10.18 ± 0.38 19.47 ± 2.57 2.00 1.91 
KMR-SA-3 15.38 ± 3.21 9.97 ± 0.11 24.14 ± 8.33 1.56 2.49 
KMR-SA-4 68.44 ± 5.83 77.45 ± 2.71 67.52 ± 16.98 0.98 0.87 
KMR-SA-5 44.83 ± 11.70 33.67 ± 3.97 84.41 ± 16.51 1.88 2.50 
KMR-SA-6 35.60 ± 7.35 33.18 ± 0.40 66.28 ± 3.97 1.86 1.99 
KMR-SA-7 18.23 ± 3.26 16.76 ± 0.42 20.82 ± 0.57 1.14 1.24 
KMR-SA-8 9.16 ± 0.85 9.49 ± 0.33 15.75 ± 2.87 1.69 1.66 
KMR-SA-9 16.03 ± 2.13 9.11 ± 0.09 19.78 ± 1.80 1.23 2.17 
KMR-L1 IC50 > 100 IC50 > 100 IC50 > 100 - - 
KMR-L2 IC50 > 100 IC50 > 100 IC50 > 100 - - 
KMR-L3 IC50 > 100 IC50 > 100 IC50 > 100 - - 
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All the remainder thiourea compounds (KMR-SA-1-9) displayed varying degrees of 
activity towards the HCT116 and Mia-PaCa-2 cell lines. Thiourea ligands consisting 
of the L2 configuration (KMR-SA-4-6) were moderately active against both cell lines 
exhibiting an IC50 range of 33.18 (± 0.40) to 77.45µM (± 2.71). Compounds KMR-SA-
1-3 (ligand 1) and KMR-SA-7-9 (ligand 2) also had IC50 values that were moderately 
active towards the HCT116 and Mia-PaCa-2 cell lines with IC50 values of 9.16 (± 
0.85) – 18.23µM (± 3.26) respectively. The classic chemotherapeutic drugs tested 
earlier in chapter 3 were much more active than the thiourea ligand compounds 
tested in this study (KMR-SA-1-9). Although the selectivity of the thiourea ligand 
compounds was not high, these were much more selective towards the HCT116 and 
Mia-PaCa-2 cell lines in comparison to etoposide (table 6.1 and table 6.10). Only 
compounds KMR-SA-2 and KMR-SA-5 displayed a higher selectivity index than 
cisplatin towards the HCT116 cell line. All the thiourea ligand compounds displayed 
higher selectivity towards the Mia-PaCa-2 cell line (apart from KMR-SA-4). 
Compounds KMR-SA1, KMR-SA-3, KMR-SA-5 and KMR-SA-9 displayed a higher 
selectivity towards the Mia-PaCa-2 cell line in comparison to all of the classic 
compounds tested earlier (table 6.1 and table 6.10). Unfortunately these compounds 




6.4.2 Chemosensitivity testing of 1,8 napthyridine under normoxic pHe 7.4 
conditions  
KMR-LA displayed some moderate activity towards the HCT116 and Mia-PaCa-2 
cell lines 39.90 (± 1.60) and 62.45µM (± 26.28) respectively. KMR-LB-LC did not 
display any activity (IC50 > 100µM). 
1, 8 napthyridine compounds 






ARPE-19 cells HCT116   
Mia-
PaCa-2  
KMR-SA-21 82.09 ± 3.55 IC50 > 100 IC50 > 100 1.21 - 
KMR-SA-22 61.28 ± 13.80 25.13 ± 6.07 IC50 > 100 >1.61 >3.97 
KMR-SA-23 37.80 ± 4.90 52.13 ± 12.28 IC50 > 100 >2.64 >1.91 
KMR-SA-24 210.32 ± 3.44 IC50> 100 678.55 ± 3.77
† 3.22 - 
KMR-SA-25 84.20 ± 7.30 IC50 > 100 436.53 ± 22.12
† 5.18 - 
KMR-SA-26 31.33 ± 12.93 82.09 ± 2.55 IC50 > 100 >3.19 >1.21 
KMR-SA-27 IC50 > 100 IC50 > 100 IC50 > 100 - - 
KMR-SA-28 IC50 > 100 61.36 ± 3.25 IC50 > 100 - 1.62 
KMR-SA-29 IC50 > 100 IC50 > 100 IC50 > 100 - - 
KMR-LA 39.90 ± 1.6 62.45 ± 26.28 IC50 > 100 >2.50 >1.60 
KMR-LB IC50 > 100 IC50 > 100 IC50 > 100 - - 
KMR-LC IC50 > 100 IC50 > 100 IC50 > 100 - - 
Table 6.2 The response of HCT116, Mia-PaCa-2 and ARPE-19 cells following a 
96hour exposure to 1,8 napthyridine compounds under normoxic pHe 7.4 
conditions. Each result represents the mean ± standard deviation of three 
independent experiments. † refers to compounds that were re-screened using a 
wider concentration range (0.3-1000µM).  
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Napthyridines consisting of the KMR-LA configuration (KMR-SA-21-23) exhibited 
mild activity in contrast to napthyridines consisting the KMR-LC configuration which 
did not display any activity IC50 > 100µM. KMR-SA-26 was the most active 
napthyridine tested against the HCT116 cell line where as KMR-SA-22 was the most 
active towards the Mia-PaCa-2 cell line 31.33 (± 12.93) and 25.13 (± 6.07) 
respectively. All of the napthyridine compounds tested displayed different levels of 
activities against both the HCT116 and Mia-PaCa-2 cell lines which could be 
indicative of different biochemical processes occurring. Although the napthyridine 
compounds are not as active as the classic compounds tested earlier i.e cisplatin, 5-
FU and etoposide as shown in table 6.10, what was an interesting finding was their 
selective ability for the cancer cell lines which was not the case for the classic 
chemotherapeutic drugs. So where the napthyridines lack in potency, they excel in 





6.4.3 Chemosensitivity testing of 1,8 napthyridine against the HCT116 cells 
under hypoxic pHe 7.4 conditions  
HCT116 cells were treated with a dose concentration range of 1,8 napthyridines over 
96 hours under hypoxic pHe 7.4 conditions and the results are presented below 
(table 6.3). 











   
pHe 7.4 
KMR-SA-21 82.098 ± 3.55 IC50 > 100 0.82 - 
KMR-SA-22 61.282 ± 13.80 51.58 ±6.51 1.19 1.93 
KMR-SA-23 37.80 ± 4.90 37.60 ± 11.32 1.01 2.65 
KMR-SA-24 210.32 ± 3.44 34.53 ± 13.86** 6.09 19.65 
KMR-SA-25 84.20 ± 7.30 39.67 ± 13.34* 2.12 11.00 
KMR-SA-26 31.333 ± 12.93 26.44 ± 3.14 1.18 3.78 
KMR-SA-27 IC50 > 100 IC50 > 100 - - 
KMR-SA-28 IC50 > 100 86.30 ±10.43 1.16 1.15 
KMR-SA-29 IC50 > 100 IC50 > 100 - - 
KMR-LA 39.908 ± 1.6 26.75 ± 5.28* 1.49 3.73 
KMR-LB IC50 > 100 IC50 > 100 - - 
KMR-LC IC50 > 100 IC50 > 100 - - 
Table 6.3 The response of HCT116 cells following a 96hour exposure to 1,8 
napthyridine compounds under normoxic pHe 7.4 and hypoxic pHe conditions. 
A two-tail students t-test was applied where p values of ≤0.05 and ≤0.01 are 
represented as * and ** respectively. The SI hypoxia pHe 7.4 is defined as the ratio 
between the ARPE-19 IC50 value divided by the hypoxia pHe 7.4 IC50. Each result 
represents the mean ± standard deviation of three independent experiments.  
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This aspect of the study was to ascertain if these compounds behaved as HAPs or 
not. Strikingly compounds KMR-SA-22-26, KMR-SA-28 and KMR-LA all exhibited 
HAP like properties with HCR all above 1 as shown in table 6.3. Compounds KMR-
LA, KMR-SA-24 and 25 exhibited the best HAP like properties (HCR = 1.49, 6.09 
and 2.12 respectively) which was statistically significant when comparing normoxia 
IC50 values against hypoxia IC50 as shown in figure 6.11 and table 6.3. KMR-SA-24 
and 25 were also both selective towards the HCT116 cells under normoxic 
conditions (SI = 3.22 and 5.18 respectively). This shifts the selectivity indices 
drastically when comparing the IC50 with SI values increasing to 19.65 for KMR-SA-
24 and 11.00 for KMR-SA-25. Cisplatin, etoposide and 5-FU displayed no HAP like 
properties as shown in table 3.2 and reproduced in table 6.10 and therefore novel 
compounds with HAP like activity have been identified.  
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6.4.4 Chemosensitivity testing of aroylthiourea ligand compounds under 
normoxic pHe 7.4 conditions  
Chemosensitivity studies carried out under normoxic pHe 7.4 conditions with the 
aroylthiourea ligand compounds are displayed in table 6.4. The compounds tested 
were not as active as any of the classic compounds tested earlier and shown in table 
6.10. From all the aroylthiourea ligand compounds only KMR-AL-11 was the most 















Table 6.4 The response of HCT116 cells following a 96hour exposure to 
aroylthiourea compoundsunder normoxic pHe 7.4 conditions. Each result 
represents the mean ± standard deviation of three independent experiments.  
 
Compounds KMR-AL-13-14 and KMR-AL-17 displayed no activity. All of the 
compounds were more potent towards the normal human epidermal ARPE-19 cell 
line therefore displaying no selectivity for the cancer cell lines beside KMR-AL-11. 
Aroylthiourea ligand compounds 
IC50 (µM) 




HCT116  ARPE-19   
KMR-AL-9 52.94 ± 4.81 33.52 ± 1.24 0.63 
KMR-AL-10 63.18 ± 1.91 36.60 ± 1.07 0.57 
KMR-AL-11 35.17 ± 1.17 37.94 ± 0.96 1.07 
KMR-AL-12 43.75 ± 2.48 36.77 ± 0.16 0.84 
KMR-AL-13 IC50 > 100 80.27 ± 1.21 0.80 
KMR-AL-14 IC50 > 100 78.25 ± 1.50 0.78 
KMR-AL-15 75.22 ± 4.73 46.91 ± 2.04 0.64 
KMR-AL-16 IC50 > 100 IC50 > 100 - 
KMR-AL-17 78.21 ± 8.66 69.30 ± 1.61 0.80 
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KMR-AL-11 had a selectivity index of 1.07 which is greater than etoposide and close 
to of cisplatin (selectivity = 1.83). This makes KMR-AL-11 the most promising 

















6.4.5 Chemosensitivity testing of aroylthiourea ligand compounds under 
hypoxic pHe 7.4 conditions  
HCT116 cells were treated with a dose concentration range of aroylthiourea ligands 










Table 6.5 The response of HCT116 cells following a 96hour exposure to 
aroylthiourea compounds under normoxic pHe 7.4 conditions. A two-tail 
students t-test was applied where p values of ≤0.05 and ≤0.01 are represented as * 
and ** respectively. Each result represents the mean ± standard deviation of three 
independent experiments.  
When carrying out chemosensitivity studies under hypoxic conditions, compounds 
KMR-AL-9, KMR-AL10, KMR-AL14, KMR-AL 15 and KMR-AL17 all displayed HAP 
like properties with HCR values all above 1. The aroylthiourea compound which 
exhibited the most HAP-like property from this group were KMR-AL9 and 10 (HCR = 





pHe 7.4  
 




KMR-AL-9 52.94 ± 4.81 28.22 ± 6.35* 1.88 1.18 
KMR-AL-10 63.18 ± 1.91 40.83 ± 0.69** 1.54 0.89 
KMR-AL-11 35.17 ± 1.17 39.03 ± 2.40 0.90 0.97 
KMR-AL-12 43.75 ± 2.48 48.60 ± 4.59 0.90 0.75 
KMR-AL-13 IC
50
 > 100 IC
50
 > 100 - 0.80 
KMR-AL-14 IC
50
 > 100 71.80 ± 11.6 1.39 1.08 
KMR-AL-15 75.22 ± 4.73 74.00 ± 11.4 1.01 0.63 
KMR-AL-16 IC
50
 > 100 IC
50
 > 100 - - 
KMR-AL-17 78.21 ± 8.66 76.77 ± 2.83 1.01 0.90 
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1.88 and 1.54 respectively) which were both statistically significant p= ≤ 0.05 and 
0.01 respectively). The trend towards the selectivity of ARPE-19 cells continued 
when comparing data with hypoxia pHe 7.4 values. Only KMR-AL-9 and KM4-AL-14 





6.4.6 Chemosensitivity testing of benzoylthiourea compounds under normoxic 
pHe 7.4 conditions  
Chemosensitivity studies were carried out using the benzoylthiourea derivatives 
which were tested on the following cell lines, HCT116, HT29, Mia-PaC-2 and ARPE-
19. The IC50 data is displayed in table 6.6. Due to their hygroscopic nature 
compounds KM R-SA-30 and KMR-SA-33 were not tested. Compounds KMR-L10 to 






























 > 100 IC
50
 > 100 IC
50
 > 100 IC
50
 > 100 
KMR-L11 IC
50
 > 100 IC
50
 > 100 IC
50
 > 100 IC
50
 > 100 
KMR-L12 IC
50
 > 100 IC
50
 > 100 IC
50
 > 100 IC
50
 > 100 
KMR-SA-30 N/A N/A N/A N/A 
KMR-SA-31 24.9 ± 1.91 11.23 ± 0.49 23.27 ±3.57 47.23 ± 0.63 
KMR-SA-32 1.37 ± 0.09 14.33 ± 0.79 4.89 ±0.56 18.26 ± 0.58 
KMR-SA-33 N/A N/A N/A N/A 
KMR-SA-34 6.98 ± 0.50 4.01 ± 0.12 4.91 ±0.09 11.72 ± 0.30 
KMR-SA-35 5.18 ± 0.10 4.48 ± 0.18 6.99 ±0.51 9.79 ± 0.05 
KMR-SA-36 11.42 ± 1.86 9.02 ± 0.13 13.47 ±1.66 15.72 ± 0.83 
KMR-SA-37 11.96 ± 2.19 6.21 ± 0.57 10.37 ±0.17 16.24 ± 1.16 
KMR-SA-38 5.50 ± 1.86 6.22 ± 0.07 8.09 ±1.06 18.25 ± 0.48 
Table 6.6 The response of HCT116, Mia-PaCa-2, HT29 and ARPE-19 cells 
following a 96hour exposure to benzoylthiourea compounds under normoxic 
pHe 7.4 conditions. Each result represents the mean ± standard deviation of three 
independent experiments.  
Compounds KMR-SA-31, KMR-SA-36 and KMR-SA-37 were all moderately active 
against all the cell lines tested. KMR-SA-32, KMR-SA-34, KMR-SA-35 and KMR-SA-
38 all displayed a good levels of activity. KMR-SA-32 was the most potent compound 
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tested with an IC50 value of 1.37 ± 0.09 µM against the HCT116 cell line. This was 
also the most selective compound exhibiting a selectivity index of 13.33 (table 6.7). 
Interestingly KMR-SA-32 is not only more potent than cisplatin (IC50 2.03µM ± 0.08 
and SI = 1.84) but also much more selective than all three classic compounds tested 
in chapter 3 and displayed in table 6.10. Another interesting finding was that all of 
these compounds displayed some level of selectivity towards all three cancer cell 












      
Table 6.7 The selective indices of benzoylthiourea compounds for HCT116, 
Mia-PaCa-2, HT29 cells under normoxic pHe 7.4 conditions. Each result 























KMR-L10 - - - 
KMR-L11 - - - 
KMR-L12 - - - 
KMR-SA-30 - - - 
KMR-SA-31 1.89 4.21 2.02 
KMR-SA-32 13.33 1.27 3.73 
KMR-SA-33 - - - 
KMR-SA-34 1.68 2.92 2.39 
KMR-SA-35 1.89 2.18 1.40 
KMR-SA-36 1.37 1.74 1.17 
KMR-SA-37 1.36 2.62 1.56 
KMR-SA-38 3.32 2.93 2.25 
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6.4.7 Chemosensitivity testing of benzoylthiourea compounds under hypoxic 
pHe 7.4 conditions  
Further chemosensitivity studies were carried out under hypoxic conditions against 
the HCT116 cancer cells to determine if any of these compounds showcased HAP 
like properties. Unfortunately, despite their promising ability in terms of potency and 
selectivity, none of these set of compounds displayed any HAP like properties (SI 
=<1 for all compounds tested) and in the majority of cases, resistance under hypoxia 
was observed (table 6.8). 
 
Table 6.8 The response of HCT116 cells following a 96hour exposure to 
benzoylthiourea compounds under hypoxic pHe 7.4 conditions, with HCR and 
hypoxia SI pHe 7.4. Each result represents the mean ± standard deviation of three 




 Compounds Normoxia Hypoxia HCR Hypoxia SI 
pHe 7.4 
 HCT-116 cells   
KMR-L10 IC50 > 100 IC50 > 100 - - 
KMR-L11 IC50 > 100 IC50 > 100 - - 
KMR-L12 IC50 > 100 IC50 > 100 - - 
KMR-SA-30 - - - - 
KMR-SA-31 24.92 ± 1.91 34.39 ± 1.16 0.72 1.37 
KMR-SA-32 1.37 ± 0.09 33.47 ± 2.35 0.04 0.54 
KMR-SA-33 - - - - 
KMR-SA-34 6.98 ± 0.50 9.81 ± 1.26 0.71 1.19 
KMR-SA-35 5.18 ± 0.12 12.04 ± 0.24 0.43 0.81 
KMR-SA-36 11.42 ± 1.86 18.01 ± 0.76 0.63 0.87 
KMR-SA-37 11.96 ± 2.19 24.99 ± 1.34 0.48 0.64 
KMR-SA-38 5.50 ± 1.86 14.85 ± 2.17 0.37 1.22 
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KMR-SA-32 was the most selective compound to come out of this set, but displayed 
resistance under hypoxic conditions with a HCR of 0.04 and hypoxia pHe 7.4 of 0.54. 
These set of compounds were more selective than the classic chemotherapeutic 
drugs tested earlier but had a similar HCR. None of these compounds demonstrated 
any preferential activity towards cells under hypoxic  TME conditions. 
 
6.4.8 Chemosensitivity testing of transition metal complexes under TME 
conditions 
After thorough phenotypic screening of all the compounds tested in this results 
chapter, only those compounds which exhibited the best HAP like properties were 
further screened to assess the role of mild acidic pHe of 6.5. The short listed 
compounds were: the aroylthiourea ligand complexes KMR-AL-9 and 10 and the 1, 8 
napthyridine complexes KMR-SA-24 and 25. These compounds displayed HCR 






























Figure 6.11 The response of HCT116 cells following a 96hour exposure to 
KMR-AL-09, KMR-AL-10, KMR-SA-24 and KMR-SA-25 under TME conditions. 





















KMR-SA-24 normoxia pHe 7.4
KMR-SA-24 normoxia pHe 6.5





















KMR-SA-25 normoxia pHe 7.4
KMR-SA-25 normoxia pHe 6.5





















KMR-AL-09 normoxia pHe 7.4
KMR-AL-09 normoxia pHe 6.5
KMR-AL-09 hypoxia pHe 7.4




















KMR-AL-10 normoxia pHe 7.4
KMR-AL-10 normoxia pHe 6.5
KMR-AL-10 hypoxia pHe 7.4














 pH 6.5 
 
Hypoxia  
pH 7.4  
 
Hypoxia 
 pH 6.5  
 
HCT116 cells ARPE-19 
KMR-AL-9 52.93 ± 4.81 15.09 ± 1.01 28.22 ± 6.35 38.94 ± 0.96 33.52 ± 1.24 
KMR-AL-10 63.18 ± 1.91 28.58 ± 3.88 40.83 ± 0.69 43.66 ± 1.71 36.60 ± 1.07 
KMR-SA-24 210.32 ± 3.44 73.69 ± 1.54 34.53 ± 13.86 N/A 678.55 ± 3.77 
KMR-SA-25 84.20 ± 7.30 38.68 ± 1.68 39.67 ± 13.34 N/A 436.53 ± 22.12 
 
Table 6.9 Response of HCT116 cells following a 96 hour exposure to KMR-AL-
9, KMR-AL-10, KMR-SA-24 and KMR-SA-25 under normoxic and tumour 
microenvironment conditions. Each result represents the mean ± standard 
deviation of three independent experiments.  
Chemosensitivity studies were carried out using the colorectal cancer cell line 
HCT116 cells. KMR-AL-9 and KMR-AL-10 both had an increase in activity under 
normoxic pHe 6.5 in comparison to pHe 7.4 as shown in figure 6.11 and table 6.9. 
Interestingly however, when KMR-AL-9 was evaluated under hypoxic and acidic pHe 
conditions, antagonistic effects were observed with the IC50 value increasing form 
15.09 ± 1.01 µM under hypoxic conditions (pHe 7.4) to 38.94 ± 0.96 µM (table 6.9). 
Similar results were obtained for KMR-AL-10 albeit the magnitude of the effect was 





6.4.9 Summary of chemosensitivity testing of lead transition metal complexes 
under TME conditions 
The activity of selected complexes increased significantly when evaluated under mild 
acidic conditions (pHe 6.5) under normoxic conditions with pHR was 3.50, 2.21, 2.85 
and 2.29 for KMR-AL-9 and 10 and KMR-SA-24 and 25 respectively. Reducing the 
extracellular pH therefore significantly enhance the activity of these complexes, the 
magnitude of the pH enhancement being much greater than the chemotherapeutic 
complexes tested in the previous chapters. 
Compound pHR HCR TME ratio SI  SI 
(TME) 
Cisplatin 0.75 0.44 0.3 1.84 0.55 
5-FU 0.55 0.40 0.27 2.10 0.57 
Etoposide  0.76 0.61 0.57 0.59 0.34 
Tirapazamine 0.61 9.55 n/a 2.33 22.46* 
KMR-AL-09 3.50 1.87 1.44 0.63 0.86 
KMR-AL10 2.21 1.54 1.82 0.57 0.83 
KMR-SA-24  2.85 6.09 n/a 3.22 n/a 
KMR-SA-25 2.29 2.12 n/a 5.18 n/a 
 
Table 6.10 The effect of the TME on the response of cells to standard cytotoxic 
drug. Tirapazamine, KMR-AL-09-10 and KMR-SA-24-25. pHR, HCR and TME 
represent the pH ratio, the hypoxic cytotoxicity ratio and tumour microenvironment 
ratio as defined in the methods section (chapter 3 – 3.3.3). * refers to the SI value for 
the hypoxic data only and not the combo of hypoxia and acidic pHe.  
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Furthermore, all of the selected complexes displayed HAP like properties under 
hypoxia pHe 7.4 (particularly KMR-SA-24) which again was greater than the classic 
compounds tested earlier (table 6.10).  Intriguingly however, when subjected to 
further testing of compounds under hypoxia combined with mildly acidic pHe of 6.5, 
both KMR-AL-9 and KMR-AL-10 compounds were not as active. Unfortunately, 
chemosensitivity studies on the 1, 8 napthyridine complexes KMR-SA-24 and KMR-
SA-25 were not completed for the hypoxic combined with pHe 6.5 studies due to 
shortage of compound supplied. Nevertheless, only KMR-SA-24 and 25 displayed SI 
values greater than all of the classic chemotherapeutic complexes and based on this 
data in conjunction with its HAP-like properties, KMR-SA-24 was selected for further 





6.4.10 Western blot analysis for the early signs of DNA damage by KMR-SA-24  
under normoxic and hypoxic and pHe 7.4 conditions  
To assess whether there are any early signs of DNA damage under hypoxic 
conditions, western blot analysis for ϒH2AX, a protein marker which is 
phosphorylated in the early stages of DNA damage was carried out. The results 
presented in figure 6.12A demonstrate that a 24 hour exposure to KMR-SA-24 at 
doses up to 50µM does not induce any noticeable change in cell morphology 
indicating that cell death has not occurred at this time point. By 96 hours however, 
cell kill is apparent under both normoxic and hypoxic conditions (figure 6B and C). 
Cells were therefore harvested for western blot analysis following a 24 hour drug 







Figure 6.12 HCT116 cell images post 24h hour treatment with KMR-SA-24 
under normoxic and hypoxic pHe 7.4. A. HCT116 cells were treated with KMR-
SA-24 using a wide concentration range (12.5-50μM) for a duration of 24hours under 
the following conditions normoxia/pHe 7.4 and hypoxia/pHe 7.4. DMSO at 0.1% (v/v) 
was used as a control under each condition. B. HCT116 cells were treated with 































C. HCT116 cells were treated with KMR-SA-24 (100μM) for a duration of 96hours 
under hypoxic pHe 7.4 conditions. 
 
HCT116 Cells were treated for 24 hours over a drug concentration range that fit 
approximated to the IC50 value for KMR-SA-24 under hypoxic conditions (34.53µM ± 
13.86). Cells were immediately lysed and western blot analysis was carried out as 
described in the methods (see sections 2.9 to 13). As depicted in figure 6.13, 
western blot analysis, displayed a positive band for those HCT116 cells which were 
treated with KMR-SA-24 at 50μM under hypoxic conditions and pHe 7.4. These 
results suggest that KMR-SA-24 could be working as a HAP leading to DNA 









Figure 6.13 Influence of hypoxia and KMR-SA-24 on p-ϒH2AX. Colorectal cancer 
HCT116 cells were exposed to KMR-SA-24 for 24 hours under normoxic and 
hypoxic (0.1% O2) conditions. Cells were lysed and screened for γH2AX. Β-actin was 
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This chapter focuses on Professor Rao’s compounds which have been synthesised 
at the Eastern Hill University, India. The compounds were categorised in accordance 
to their chemical ‘type’ and tested through the phenotypic screen for (i) their selective 
activity under TME conditions and (ii) their selectivity for cancer  cells  (HCT116, 
HT29, Mia-PaCa-2) as opposed to non-cancer ARPE-19 cells.  
The first set of compounds tested were the thiourea derivatives, these compounds 
have the chemical formula R1R2N)(R3R4N)C=S and the addition of either 
ruthenium, iridium or rhodium as their core transition metal base. Compounds KMR-
L1, KMR-L2 and KMR-L3 displayed no signs of activity towards those entire cell lines 
tested (table 6.1). Interestingly these 3 compounds do not contain a transition metal 
base and therefore demonstrates that the thiourea ligands alone do not induce cell 
death (IC50 > 100µM). This is further supported from a study carried out by Pommier 
et al (1983) who demonstrated that thiourea is a well-known and potent scavenger of 
the hydroxyl radical groups and managed to reduce the cytotoxic ability of DNA-
intercalating agents in mouse leukaemia L1210 cells (Pommier et al., 1983). All of 
the remainder compounds (KMR-SA-1-9) did express some degree of activity 
towards the HCT116 and Mia-PaCa-2 cell lines. This is indicative that the 
combination of the metal base to the thiourea ligand is what causes the compound to 
behave like an anti-cancer agent. Compounds KMR-SA-1-3 and KMR-SA-7-9 were 
more active than compounds KMR-SA-4-6, which is interesting as complexes which 
consisted of rhodium were more active than those with ruthenium and iridium. 
Previous reports have stated that ruthenium is generally the most active out of these 
three metal complexes (Katsaros and Anagnostopoulou, 2002). 
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When compared to cisplatin, 5-FU or etoposide, none of these compounds were as 
potent, however their selectivity for cancer as opposed to non-cancer cell lines was 
much better than classic chemotherapeutic drugs tested. This provides the rationale 
for synthesising further thiourea compounds which can have greater cytotoxicity and 
selectivity towards cancer cells. Unfortunately these compounds were not tested 
under conditions that mimic the TME due to limited time constraints and limited drug 
supply. In this case therefore, the phenotypic screen was primarily based on 
identifying compounds with selective activity against cancer cells under standard 
physiological conditions (normoxia and pHe 7.4). 
From all the 1,8 napthyridine compounds tested, it was apparent that none of these 
were as active as any of the three classic based drugs that are used in this study. 
1,8 napthyridines have been extensively studied for their anti-cancer like properties 
which is demonstrated by Kumar et al (2009) who carried out in vitro based 
chemosensitivity studies by 1,8 napthyridine 3-carboxamide derivatives against a 
panel of 8 cancer cell lines (which also consisted of colon and pancreatic cancer cell 
lines). Kumar et al (2009) demonstrated good levels of cell toxicity towards the 
cancer cell lines which was similair to the chemotherapeutic drugs tested in this 
chapter but not the 1,8 napthyridines. However both sets of compounds displayed 
good levels of selectivity towards the cancer cell lines which was greater than the 
classic chemotherapeutic drugs tested in this chapter which shows some promise for 
these set of compounds. 
The aroylthiourea compounds were not as active as any of the three classic 
chemotherapeutic drugs tested earlier in results chapter 3. Compound KMR-AL-11 
was the most active with an IC50 of 35.17µM ± 1.17 but it had a better selectivity 
index in comparison to cisplatin. This indicates that this compound does show some 
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promise for further development. The remainder of the compounds interestingly were 
more active towards the normal human retinal epithelial ARPE-19 cell line in 
comparison to the colorectal HCT116 cancer cell line. To our knowledge this is the 
first time that the aroylthiourea ligand and ruthenium arene have been tested in its 
biological capacity for anti-cancer properties. Despite not showing much promise in 
our in vitro cancer models, thiourea and ruthenium have been shown to exert anti-
cancer like properties in the past. Therefore it was hypothesised that using an 
aroylthiourea ligand to coordinate a wide range of metal ions (Lapasam et al., 2019) 
may make these set of drugs exert anti-cancer like properties, however this is not the 
case here. It may be of interest to test these set of compounds for their anti-
inflammatory and anti-bacterial properties as thiourea has been previously shown to 
exert these properties (Lin et al., 2013; Mahajan et al., 2007). 
In the following cancerous HCT116, HT29, Mia-PaCa-2 and normal ARPE-19 cell 
lines the benzylthiourea compounds displayed the best activity amongst the thiourea, 
1-8, napthyridines and aroylthiourea drugs. Compounds L1-L3 were inactive with 
IC50 > 100µM across all the cell lines tested which is indicative that the arene/cp* 
alone is not active. The iridium based benzylthiourea complexes were found to be 
more active towards all the cell lines tested which is indicative that the metal base 
type also has a crucial role as well as the arene/cp* ring alone. Apart from being the 
most active set of compounds, these were also all selective towards the cancer lines 
tested.  
A similar study carried out by Jeyalakshmi et al (2016) assessed the cytotoxicity of 
Ru-p-cymene complexes against the cancerous MCF7 (breast), A549 (lung) and the 
normal L929 (murine fibrosarcoma) cell lines. These set of complexes were selective 
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towards the cancer cell lines and is similar to our findings which is promising 
(Jeyalakshmi et al., 2016).  
From all the compounds tested in this study under normoxic conditions it is evident 
that the majority of the compounds tested do not have a similar activity profile to 
cisplatin, 5-FU or etoposide with the exception of KMR-SA-32 (1.37µM ± 0.09). 
However the selectivity indexes of the majority of the compounds is more favourable 
than all of the classic chemotherapeutic standards in this study.  
From all the drugs tested, only KMR-AL-9 and 10 and KMR-SA-24 and 25 displayed 
the best HAP like properties (tables 6.9 and 6.10) and were therefore subjected to 
further testing under mildly acidic pHe conditions. As the pHe is reduced under 
normoxic conditions there is an increase in activity amongst all the 4 complexes 
tested and this is confirmed by the pHR values (table 6.10). When tested under 
hypoxic conditions all four of the complexes displayed HAP like properties which was 
really striking. KMR-SA-24 displayed the best HAP like properties with a HCR of 6.09 
as shown in table 6.10 which is almost similar to the classic HAP tirapazamine (HCR 
9.55). The HCR of KMR-SA-24 is higher than all of the standard chemotherapy 
compounds which were also tested under these conditions (table 6.10). 
Upon completion of phenotypic screening the 1,8 napthyridine KMR-SA-24 was 
chosen as a lead complex and preliminary studies were conducted to determine the 
mechanism of action. Specifically, it was tested to determine whether or not gamma 
H2AX phosphorylation was induced as a marker of DNA damage. The results in 
figure 6.13 clearly demonstrate that phosphorylation of γH2AX in HCT116 cells by 
KMR-SA-24 occurs under hypoxic conditions (at 50 µM) only thereby suggesting that 
the complex is being activated to a DNA damaging species. This result is consistent 
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with the chemosensitivity studies of KMR-SA-24 against the HCT116 cell line where 
under 50µM there is activity under hypoxic pHe 7.4 compared to normoxic pHe 7.4 
which was poor (figure 6.11 and table 6.9-10).  
To conclude, the results of this study have shown that the phenotypic based screen 
has identified novel compounds that are both selective for cancer cells (as opposed 
to non-cancer cells) in vitro and have HAP like properties. KMR-AL-9, KMR-AL-10, 
KMR-SA-24 and KMR-SA-25 all had enhanced activity under mild acidic pHe under 
normoxic conditions and bio-reductive properties under hypoxia which is something 
that would have not been discovered had this screening test not been employed. 
Additional experiments were planned/ designed for KMR-SA-24 but due to time 
constraints this could not be achieved. Those experiments were to further validate 
the activity profile of KMR-SA-24 under pHe 6.5 and hypoxia and to expand the 
analysis of induction of γH2AX phosphorylation under these conditions. Whilst further 
studies are warranted to explore the mechanisms of action of these complexes, the 
main conclusion of this chapter is that the phenotypic screen has identified novel 
compounds that are selective and have HAP like properties. These would have 







Chapter 7: Performance of NHC-Ag (I) based complexes in 
the phenotypic screen 
7.1 Introduction 
In the search for new anti-cancer drugs, organometallic complexes have enjoyed a 
resurgence of interest in recent years. In particular, gold based N-heterocyclic 
carbenes (NHC) have been extensively evaluated with regards to their cytotoxic and 
cancer targeting properties. These complexes however, showed unfavourable 
toxicity in vivo which includes reproductive effects as well as oxidative damage to the 
heart in rats (Ciftci et al., 2011). An alternative to gold (NHC) complexes are silver 
(Ag) based compounds which were originally investigated for their antimicrobial 
activity and their ability to treat infected wounds and burns (Kalinowska-Lis et al., 
2016). Over the years Ag compounds were disregarded in the first instance despite 
showcasing good levels of cytotoxicity in various cancer cell lines (Kalinowska-Lis et 
al., 2016). Recently however, a lot of interest has focused on their anti-cancer 
properties (Johnson et al., 2017). Numerous Ag (I) compounds have been 
developed which display cytotoxicity against various cancer cell lines and display low 
toxicity to non-cancer cells thereby exhibiting greater selectivity towards cancer cells 
than cisplatin (Kalinowska-Lis et al., 2016). NHC ligands and carboranes are an 
interesting class of organometallic compounds due to their low toxicity and stability 
(Allison et al., 2017; Holmes et al., 2019). Medvetz et al., 2008 were of the first 
researchers to report the anti-cancer properties of Ag (I) based NHC compounds. 
Cell lines such as OVCAR-3 (ovarian), MB157 (breast) and HeLa (cervical) cells 
were used for the basis of their in vitro study and the IC50 values of their Ag based 
compounds ranged between 20-25µM (Medvetz et al., 2008).  
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The mechanism(s) of action of these compounds is complex and there is now a 
considerable body of evidence demonstrating that their mechanism(s) are distinct 
from platinates (not alkylating agents) but involve multiple pathways involved in 
cancer biology. Whilst compounds that exhibit poly-pharmacological properties are 
now very attractive (in the context of tackling tumour heterogeneity), the challenge is 
to identify multi-targeted agents which show selectivity for cancer cells over normal 
cells (Reddy and Zhang, 2013). One Ag complex, which is commonly referred to as 
Ag8 (Ag(NHC)2AgBr2, has emerged as a promising lead compound based on its 
selective anti-cancer like abilities and several mechanism of actions including 
PARP1 inhibition, topoisomerase I and II inhibition, thioredoxin reductase and 
inhibition of glycolysis (Allison et al., 2017). In this study derivatives of Ag8 with the 
addition of carborane which has attracted a lot of attention in medicinal applications 
due to their high catabolic stability are evaluated in the phenotypic screen (Grimes, 
2016; Valliant et al., 2002). Ag-NHC complexes have previously shown excellent 
potency in cancer cells but in vivo stability is a serious problem which needs to be 
addressed. The addition of the carborane to NHC ligands may increase solubility, 
stability and in essence increase the activity of these Ag complexes. In this study the 
cytotoxicity, selectivity and preferential activity of such compounds under 
physiological TME conditions are assessed using 4 genetically different strains of 
HCT116 cell lines. To explore the further potential of the phenotypic screening 
strategy employed, the HCT116 cell line panel was expanded to include HCT116 
p53-/-, HCT116KRAS mutant and HCT116KRAS wildtype. As described in previous chapters, 




7.2 Aims and objectives 
The aim of this study is to evaluate whether or not a series of Ag (NHC) derivatives 
are cytotoxic towards the colon rectal cancer cell lines HCT116 p53+/+, HCT116 p53-
/-, HCT116KRAS mutant, HCT116KRAS wildtype. To determine the selectivity, these 
compounds were also evaluated against the non-cancerous ARPE-19 cell line under 
conditions that reflect the ‘normal conditions’ found in healthy tissue (i.e. oxygenated 
and pHe 7.4). The Ag (NHC) compounds will also be subjected to hypoxia studies to 
determine preferential activity under (i) hypoxia (0.1% oxygen), (ii) acidic 




7.3 Material and methods 
7.3.1 Compounds  
All Ag complexes were kindly provided by Dr Charlotte Willans (University of Leeds) 
and these were dissolved in DMSO (100mM), aliquoted and stored at -20°C. The 
chemical structure and molecular weights of the complexes evaluated are presented 









Figure 7.1 Chemical structure of Ag(NHC) based compounds and molecular 
weights (in parenthesis).  
 
7.3.2 Cell culture and chemosensitivity 
Cell culture, adjusting the pH of the media, drug dilutions and chemosensitivity 
studies under both normoxic and hypoxic conditions were carried out as previously 
described in methods chapter (see sections 2.6 to 2.8). The following cell lines were 
use for this study, HCT116 p53+/+, HCT116 p53-/-, HCT116KRAS Wildtype and 
JH539 (RMM = 900.80) JH533B (RMM = 768.59) 
JH547B (RMM = 532.37) 
JH532 (RMM = 451.23) 
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HCT116KRAS Mutant. All the experiments were carried out using low or no light 
conditions as the silver complexes were light sensitive. 
7.3.3 Statistical analysis 
Statistical analysis was carried out using Microsoft Excel and Graph Prism. All 
experiments were done in triplicate (n=3), and results were presented as the mean ± 
SD. Statistical significance was determined by means of a two-tailed Student’s t-test, 
or by One Way ANOVA where significance was only accepted when p ≤ 0.05. The 





Ag (NHC) complexes JH532, JH547B, JH533B and JH539 were tested against the 
following colorectal cancer cell lines HCT116 p53+/+, HCT116 p53-/-, HCT116KRAS 
Wildtype and HCT116KRAS Mutant for their cytotoxicity and selectivity against normoxic 
and TME conditions. The non-cancer human retinal epithelial cell line APRE-19 was 
used to test for the cytotoxic activity of complexes and their selectivity for cancer 
cells. In this case, the activity of Ag complexes was performed under normoxic 
conditions only.  
7.4.1 The effect of JH532 against the HCT116 p53+/+ and ARPE-19 cell line 
under normoxia pHe 7.4 conditions 
JH532 had IC50 values of, 11.63µM ± 4.61, 11.28µM ± 4.64, 11.18µM and 12.34µM ± 
5.64 across all 4 different colorectal cancer cell lines tested (table 7.1) but it was its 
selectivity towards the ARPE-19 cell line which was the most striking as this was 
above 6 (table 7.2) for all colorectal cancer cell lines tested and much higher than 
the classic chemotherapy agents tested in chapter 3 (table 7.13). 
    




















Table 7.1 The response of HCT116 cell lines following continuous exposure to 
JH532 under normoxic pHe 7.4 conditions. Each result represents the mean ± 




Compound Selectivity index  
 
HCT116        
p53+/+ 
HCT116           
p53-/- 
HCT116                 
KRAS Mut 
HCT116                 
KRAS wt 
JH532 6.61 6.81 6.87 6.23 
Table 7.2 The selective indices of JH532 for the HCT116 cell lines under 
normoxic pHe 7.4 conditions.  
 
Figure 7.2 Response of HCT116 cell lines and ARPE-19 cells following a 96 
hour exposure to JH532 under normoxia and pHe 7.4 conditions. Each result 



























7.4.2 The effect of JH547B against the HCT116 p53+/+ and ARPE-19 cell line 
under normoxia pHe 7.4 conditions 
JH547B was the least active of the Ag(NHC) compounds towards the different type 
of colorectal cancer cell lines tested in comparison to the different complexes from 
this study with IC50 values of 17.26µM ± 2.13, 20.24µM ± 4.95, 12.83µM ± 3.39 and  
24.68µM ± 1.86 (table 7.3). However, there was a significant difference between (p < 
0.05) the HCT116KRAS Wildtype and HCT116KRAS Mutant which may suggest that there is 
KRAS dependency for this complex (figure 7.3).  
 
Figure 7.3 Response of HCT116 cell lines and ARPE-19 cells following a 96 
hour exposure to JH547B under normoxia and pHe 7.4 conditions. Dose 
response curves to JH547B (0.1-100µM) under normoxic pHe 7.4 conditions. Each 




























    

















Table 7.3 The response of HCT116 cell lines following continuous exposure to 
JH547b under normoxic pHe 7.4 conditions. Each result represents the mean ± 
standard deviation of three independent experiments. 
 
Compound Selectivity index  
 
HCT116        
p53+/+ 
HCT116           
p53-/- 
HCT116                 
KRAS Mut 
HCT116                 
KRAS wt 
JH547B 2.49 2.17 3.42 1.77 
Table 7.4 The selective indices of JH532 for the HCT116 cell lines under 
normoxic pHe 7.4 conditions.  
 
7.4.3 The effect of JH533B against the HCT116 p53+/+ and ARPE-19 cell line 
under normoxia pHe 7.4 conditions 
JH533B was cytotoxic but did not display any significant difference between the 
different p53+/+ or p53-/- or the KRASWildtype or KRASMutant cell lines (table 7.5). A 
moderate degree of selectivity to colorectal cancer cell line was observed (SI 2.85-




Figure 7.4 Response of HCT116 cell lines and ARPE-19 cells following a 96 
hour exposure to JH533B under normoxia and pHe 7.4 conditions. Dose 
response curves to JH533B (0.1-100µM) under normoxic pHe 7.4 conditions. Each 
result represents the mean ± standard deviation of three independent experiments. 
    

















Table 7.5 The response of HCT116 cell lines following continuous exposure to 
JH533B under normoxic pHe 7.4 conditions. Each result represents the mean ± 



























Compound Selectivity index  
 
HCT116        
p53+/+ 
HCT116           
p53-/- 
HCT116                 
KRAS Mut 
HCT116                 
KRAS wt 
JH533B 3.31 3.54 4.06 2.85 
Table 7.6 The selective indices of JH533b for the HCT116 cell lines under 
normoxic pHe 7.4 conditions.  
 
7.4.4 The effect of JH539 against the HCT116 p53+/+ and ARPE-19 cell line 
under normoxia pHe 7.4 conditions 
JH539 displayed the highest level of cytotoxicity against all 4 different HCT116 cell 
lines with an IC50 of 1.273µM ± 0.24, 1.463 ± 0.38, 0.99µM ± 0.27 and 1.515µM ± 
0.27 (table 7.7). JH539 also had moderate selectivity when tested against the normal 
cell line (table 7.8). However this complex was not further tested due to limited 
amount of drug available. 
 
    


















Table 7.7 The response of HCT116 cell lines following continuous exposure to 
JH539 under normoxic pHe 7.4 conditions. Each result represents the mean ± 





Figure 7.5 Response of HCT116 cell lines and ARPE-19 cells following a 96 
hour exposure to JH539 under normoxia and pHe 7.4 conditions. Dose 
response curves to JH539 (0.1-100µM) under normoxic pHe 7.4 conditions. Each 
result represents the mean ± standard deviation of three independent experiments. 
 
Compound Selectivity index  
 
HCT116        
p53+/+ 
HCT116           
p53-/- 
HCT116                 
KRAS Mut 
HCT116                 
KRAS wt 
JH539 2.90 2.52 3.73 2.43 
Table 7.8 The selective indices of JH539 for the HCT116 cell lines under 



























7.4.5 Summary of IC50 values for Ag complexes against HCT116 and ARPE-19 
cell lines under normoxia pHe 7.4 conditions 
All 4 Ag complexes displayed high levels of cytotoxicity against all 4 colorectal 
cancer cell lines tested (figure 7.6 and table 7.10). JH532, JH547B and JH533B 
displayed moderate levels of selectivity towards the colorectal cancer cell lines 
tested with SI ranging from 1.77 – 6.87 (table 7.10).  
 
Figure 7.6 Summary of IC50 values following the continuous exposure of 
HCT116 p53+/+, HCT116 p53-/-, HCT116 KRAS mutant, HCT116 KRAS wildtype and the 
normal Human retinal epithelial cells to JH532, JH547B, JH533B and JH539. A 
two-tail students t-test was applied where p values of ≤0.05 and ≤0.01 are 
























    



















































Table 7.9 Summary of the response of HCT116 p53+/+, HCT116 p53-/-, 
HCT116KRAS mutant, HCT116KRAS wildtype and the normal Human retinal epithelial 
cells under normoxic conditions against Ag complexes. Each result represents 












Compound Selectivity index  
 
HCT116       
p53+/+ 
HCT116           
p53-/- 
HCT116                 
KRAS Mutant 
HCT116                 
KRAS Wildtype 
JH532 6.61 6.81 6.87 6.23 
JH547B 2.49 2.17 3.42 1.77 
JH533B 3.31 3.54 4.06 2.85 
JH539 2.90 2.52 3.73 2.43 
 
Table 7.10 Summary of selectivity index values for Ag complexes towards the 
colorectal cancer cell lines. SI is defined as the ratio of IC50 values for ARPE-19 
divided by HCT116 cell lines with values >1 indicating selectivity towards HCT116 
cancer cells.   
 
7.4.6 The effect of JH532, JH533B and JH547B against the HCT116 p53+/+ cell 
line under hypoxia pHe 7.4 conditions 
Complexes JH532, JH547B and JH533B were all subjected for further testing under 
hypoxic (pHe 7.4) conditions using the HCT116 p53+/+ cell line to determine if any of 





















Figure 7.7 HCT116 p53+/+ cell line was drug treated for 96hours with JH532, 
JH533B and JH547B under hypoxia pHe 7.4. Dose response curves to JH539 
(0.1-100µM) under normoxic and hypoxic (pHe 7.4) conditions. Each result 
represents the mean ± standard deviation of three independent experiments.  
 
JH547B displayed no HAP like properties with a HCR of 0.57 as shown in table 7.11. 


































































difference was not statistically significant. JH532 was considered to be the lead 
compound and was therefore subjected for further testing under the TME conditions.  
 
Compound 
HCT116  p53+/+ 
Normoxic 
HCT116  p53+/+            
Hypoxic 





























Table 7.11 The HCR index of Ag complexes towards the colorectal cancer cell 
lines over a continuous 96 hour exposure. The HCR is defined as the ratio of IC50 
values under normoxic conditions divided by the IC50 under hypoxic (0.1% oxygen) 
conditions. Values >1 indicate that compounds have selective toxicity towards cells 




7.4.7 The effect of JH532 against the HCT116 p53+/+ cell line under TME 
conditions 
JH532 was chosen for further studies as this compound displayed the highest HCR 
and selectivity amongst all compounds tested. This was equitoxic under normoxia 
(pHe7.4 and 6.5) and hypoxia (pHe7.4 and 6.5) with IC50 values of 11.63, 13.96, 
9.07 and 8.9µM respectively. Statistical analysis (one-way ANOVA) displayed no 
significant difference between all the different conditions tested and is graphically 
displayed below.  
 
Figure 7.8 Dose response curve of HCT116 p53+/+ cells to JH532 under 
normoxic and tumour microenvironmental conditions. Each result represents 


































Normoxic       
pHe 7.4 
Normoxic        
pHe 6.5 
Hypoxia            
pHe 7.4 
Hypoxia          
pHe 6.5 














Table 7.12 Summary of IC50 values for JH532 are presented in different 
combinations of oxygen concentration and pHe. Each value represents the mean 
IC50 ± SD for three independent experiments.  
 
7.4.8 Summary on the effect of JH532 under TME conditions  
The TME enhancement ratio for JH532 is 1.3 which is indicative that this complex is 
displaying some preferential activity towards the physiological TME conditions albeit 
minor. The TME ratios is also greater than the classic compounds that were tested 
earlier where resistance towards the physiological TME conditions were shown. The 
SI was also greater than all of the classic chemotherapeutic complexes tested. The 
SI (TME) enhancement ratio was 25 fold higher than etoposide and approximately 






Compound pHR HCR TME ratio SI  SI 
(TME) 
Cisplatin 0.75 0.44 0.3 1.84 0.55 
5-FU 0.55 0.40 0.27 2.10 0.57 
Etoposide  0.76 0.61 0.57 0.59 0.34 
Tirapazamine 0.61 9.55 n/a 2.33 22.46* 
JH532 0.83 1.28 1.3 6.61 8.63 
 
Table 7.13 The effect of the TME on the response of cells to standard cytotoxic 
drugs, tirapazamine and JH532. pHR, HCR and TME represent the pH ratio, the 
hypoxic cytotoxicity ratio and tumour microenvironment ratio respectively as defined 
in the methods section 3.3.3. * refers to the SI value for the hypoxic data only and 





Structurally, Ag (NHC) complexes JH547B and JH532 are both similar. These are 
xanthine – derived imidazolium salts where JH547B has a carborane and the JH532 
complex has a phenyl tail group which are distant to the Ag center. Both have similar 
IC50 values across the panel of HCT116 cell lines tested irrespective of their slight 
structural difference which displays the pivotal role of steric factors in the activity of 
these complexes (Holmes et al., 2019). Interestingly JH547B was more toxic towards 
HCT116KRAS Wildtype in comparison to HCT116KRAS Mutant cell line as shown in figure 7.3 
and 7.6. For further confirmation of this, additional downstream signalling studies 
would need to be carried out in both the KRAS wildtype and mutant HCT116 cell line 
with JH547B. As KRAS plays a role in downstream signalling of cell growth and 
proliferation it may be worth carrying out the experiments to determine the effects of 
JH547B on the Ki67 protein which is a marker for cell proliferation (Stuart-Harris et 
al., 2008). JH533B and JH539 are both large planar Ag complexes where JH533B 
has 1 phenyl group attached to the head and tail of the complex whereas JH539 has 
1 carborane attached to the head and tail of its complex. Both were cytotoxic 
towards all the HCT116 cell lines tested with JH539 being the most potent complex 
of all 4 tested. This could be due to the slower release of Ag over the 96 hour drug 
exposure due to the protection provided by the large carboranes and therefore 
maximising its cytotoxicity.  
One of the major issues of chemotherapy drug failure is poor side effects and this is 
still an unmet challenge which is yet to be overcome (Barbuti and Chen, 2015). This 
has been demonstrated earlier in chapter 3 and is further displayed in table 7.13. All 
the Ag (NHC) complexes were screened for their cytotoxic and selective ability under 
both normoxic and TME conditions. The SI index under normoxic conditions was 
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1.84, 2.1, 0.59 and 2.33 for cisplatin, 5-FU, etoposide and tirapazamine respectively. 
One of the key findings in this study is that all 4 Ag (NHC) complexes displayed SI 
ranging from 2.49 – 6.61 which demonstrates that even the poorest Ag (NHC) 
complex JH547B had a better SI against all the classic chemotherapy complexes 
tested. When these Ag (NHC) complexes were subjected for further testing under 
hypoxic conditions, it was apparent that none of these behaved like HAPs with a 
HCR below 1 for JH547B, 1.08 for JH533B and 1.28 for JH532 as shown in figure 
7.7 and table 7.11.  
The results of this study have demonstrated two key points. The first is that the 
compounds evaluated are selective for cancer cells as opposed to non-cancer cells 
in vitro under standard physiological conditions (normoxic and pHe7.4). In the case 
of JH532 where a SI value of 6.61 was obtained, this represents a substantial 
improvement on SI values for the established cytotoxic drugs tested here. In this 
context, these compounds are of interest and further studies are required to 
determine if this observation holds up in a broad panel of cancer cell lines and non-
cancer cells. The second point is that these compounds do not posses any 
significant HAP like properties. Whilst these compounds do not show enhanced 
activity under TME conditions, it is important to state that their activity is not 
diminished by hypoxia or acidic pHe conditions which again marks them out as 
different from the established cytotoxic drugs. In the broader context of phenotypic 
screening, the results of this study have demonstrated that the screen can identify 
compounds that are not adversely affected by TME conditions and this in itself is 
potentially valuable. This is particularly the case when compounds demonstrate 




Chapter 8: Phenotypic evaluation of a series of DNA minor 
groove binders 
8.1 Introduction 
DNA minor groove binders (MGB) are small molecules which specifically bind to the 
minor groove of the DNA (Nanjunda and Wilson, 2012). MGBs are an interesting set 
of compounds which have been studied extensively in the field of infective, bacterial, 
fungal and cancer research (Scott et al., 2016). MGBs mechanistically work by a 
suggested method of inhibiting DNA topoisomerase I (Nanjunda and Wilson, 2012) 
which is further supported by in vitro evidence demonstrating that MGB with differing 
ligands can induce the formation of topoisomerase I mediated DNA breaks (Marchini 
et al., 2001). However previous reports have demonstrated that other mode of 
actions of the MGB may exist and these include sequence specific DNA alkylating 
damage, disruption to the cell cycle and interference with DNA repair (Zimmer et al., 
1971). What also makes MGB of interest is their ability to inhibit DNA binding of 
transcription factors in a sequence dependent manner (Zimmer et al., 1971). 
Arguably the two most common antiviral antibiotics MGB that have been extensively 
researched are netropsin and distamycin (figure 8.1) as these were the first MGB 
compounds discovered which bind selectively to AT rich sequences in the minor 
groove (Bailly and Chaires, 1998). In this study 5 MGB which are based on the 
polyamide natural product of distamycin and netropsin are assessed for their 
cytotoxic, selective and HAP like abilities. These molecules were synthesised by Dr 
Fraser Scott at the University of Huddersfield and the results have been recently 











Figure 8.1 Chemical structure of netropsin and distamycin.  
As described in previous chapters the selection of cell lines used in this chapter was 
based on pragmatic reasons and not on any biochemical rationale. In addition, to 
maintain consistency with other chapters in this thesis, HCT116 p53+/+ and ARPE-19 









The aim of this study is to evaluate whether or not a series of distamycin and 
netropsin MGB derivatives are cytotoxic towards the colon rectal cancer cell lines 
HCT116 p53+/+. To determine their selectivity for cancer cells, these compounds will 
also be evaluated against the non-cancerous ARPE-19 cell line under conditions that 
reflect the ‘normal conditions’ found in healthy tissue (i.e. oxygenated and pHe 7.4). 
The MGB compounds will also be subjected to hypoxia studies to determine 
preferential activity under (i) hypoxia (0.1% oxygen), (ii) acidic extracellular pH (pHe 




8.3 Material and methods 
8.3.1 Compounds  
All MGB were kindly provided by Dr Fraser Scott (University of Huddersfield – now 
University of Strathclyde). These were prepared in dimethylsulphoxide (DMSO) at 













Figure 8.2 Chemical structure of MGB based compounds and their molecular 
weights in parenthesis. 
 
MGB 176 (RMM= 762.7) MGB 364 (RMM= 719.67) 
MGB 372 (RMM= 919.86) MGB 372 (RMM= 936.31 
MGB 4 (RMM= 903.37) 
182 
 
8.3.2 Cell culture and chemosensitivity 
Cell culture, adjusting the pH of the media, drug dilutions and chemosensitivity 
studies were carried out as previously described in the general methods chapter 
(see sections 2.2, 2.6-2.8). The HCT116 P53+/+ cell line was used in this chapter. 
Any variation from these methods are indicated in the figure legends and described 
in the results section. 
8.3.3 Western blot analysis 
Cells were treated with hit compounds for a duration of 24 hours at a drug 
concentration of 0.25, 0.5 and 1µM. These concentrations were chosen as it is a 
therapeutically relevant concentration (IC50 under normoxic conditions was 0.234 ± 
0.005 µM and 4.418 ± 0.41 µM for MGB 4 and MGB 176 resepectively as shown in 
table 6.12). A 24 hour duration of drug exposure was selected as minimal cell death 
had occurred at this time point. 
. Controls were treated with media alone or with DMSO (0.1% v/v) vehicle control 
(which has been previously reported not to be toxic to the cells). Doxorubicin was 
used as the positive control and these were carried out under the following tumour 
microenvironment conditions, normoxia pHe 7.4, normoxia pHe 6.5, hypoxia pHe 7.4 
and hypoxia pHe 6.4. Upon completion of treatment, cells were harvested for 
western blot analysis for DNA damage induction (phosphorylated γH2AX or p53). 
Details of western blot methodology and antibody dilutions are described in methods 
(see sections 2.12 and table 2.2). 
8.3.4 Statistical analysis 
Statistical analysis was carried out using Microsoft Excel and Graph Prism. All 
experiments were done in triplicate (n=3), and results were presented as the mean ± 
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SD. Statistical significance was determined by means of a two-tailed Student’s t-test, 
or by One Way ANOVA where significance was only accepted when p ≤ 0.05. The 
exact statistical analysis performed is mentioned in the figure legend. 
 
8.4 Results 
8.4.1 The effect of MGBs against the HCT116 p53+/+ and ARPE-19 cell lines 
under normoxic pHe 7.4 conditions  
The response of HCT116 p53+/+ and ARPE-19 cells to MGB compounds under 
normoxic and pHe 7.4 conditions is presented in figures 8.3A and B respectively. 
The second most potent MGB tested against the HCT116 cell line was MGB 373 
with an IC50 of 1.286 ± 0.19 µM and a SI of 1.48 (table 8.1). The least potent MGB 
was the 364 which was inactive against the HCT116 p53+/+ cell lines under normal 
physiological conditions (figure 8.1). The MGB 372 compound displayed potency 
with IC50 values of 2.953 ± 0.60 µM and moderate levels of selectivity towards the 
cancerous cell line with a SI of 2.41. MGB 176 displayed moderate level of activity 
towards the HCT116 p53+/+ cell line with an IC50 value of 4.418 ± 0.41 µM.  
 








MGB 364 IC50>10 IC50>10 - 
MGB 176 4.418 ± 0.41 10.94 ± 1.19 2.47 
MGB 372 2.953 ± 0.60 7.135 ± 0.79 2.41 
MGB 373 1.286 ± 0.19 1.909 ± 0.07 1.48 




Table 8.1 The IC50 values and SI for a series of MGBs against the HCT116 and 
ARPE-19 cell lines under normoxic pHe 7.4 conditions. Each result represents 
the mean ± standard deviation of three independent experiments. 
 
The most potent MGB under these set of conditions was the MGB 4 compound with 
an IC50 value of 0.234 ± 0.005 µM which was similar to that of etoposide tested 
earlier in chapter 3. As well as being highly active, MGB 4 also has the highest SI 










Figure 8.3 Response of HCT116 p53+/+ (panel A) and ARPE-19 cells (panel B) 
following a 96 hour exposure to a series of MGBs under normoxic and pHe 7.4 
conditions. Each result represents the mean ± standard deviation of three 



















































8.4.2 The effect of MGBs against the HCT116 p53+/+ cell line under normoxic 
and hypoxic pHe 7.4 conditions 
HCT116 p53+/+ cells were treated with a dose concentration range of MGBs over 96 
hours under hypoxic pHe 7.4 conditions. The IC50 generated for MGB 364, 176, 372, 
373 and 4 was 8.20 ± 0.1, 1.77 ± 0.02, 2.05 ± 0.01, 0.93 ± 0.02 and 7.65 ± 0.57 µM 
respectively (figure 8.4 and table 8.1). All of the MGBs apart from the MGB 4 
displayed HAP like abilities (albeit minor) with HCR values of 1.22, 2.49, 1.44, 1.38 
and 0.003 (MGB 364, 176, 372, 373 and 4) respectively and the data is shown in 




























































































































MGB 176 (µM) 
Normoxia pH 7.4
Hypoxia pH 7.4
Figure 8.4 Response of HCT116 
p53+/+ cells following a 96 hour 
exposure to a series of MGBs 
under normoxic and hypoxic 
conditions (pHe 7.4). Each result 
represents the mean ± standard 













MGB 364 IC50>10 8.20 ± 0.1 >1.22 
MGB 176 4.418 ± 0.41 1.77 ± 0.02 2.49 
MGB 372 2.953 ± 0.60 2.05 ± 0.01 1.44 
MGB 373 1.286 ± 0.19 0.93 ± 0.02 1.38 
MGB 4 0.234 ± 0.005 7.65 ± 0.57 0.003 
 
Table 8.2 The IC50 values and HCR for a series of MGBs against the HCT116 
cell lines under normoxic and hypoxic pHe 7.4 conditions. Each result 
represents the mean ± standard deviation of three independent experiments. 
 
8.4.3 The effect of MGBs against the HCT116 p53+/+ cell line under normoxic 
pHe 7.4 and pHe 6.5 conditions 
HCT116 p53+/+ cells were treated with a dose concentration range of MGBs over 96 
hours under normoxic pHe 6.5 conditions where only MGB 176 and 364 displayed 
preferential activity under pHe 6.5 conditions with a pHR of 2.06 and 1.04 
respectively. The other MGBs displayed no preferential activity under normoxic pHe 
6.5 conditions with a pHR all <1, 0.78, 0.69 and 0.02 (table 8.3) for MGBs 372, 373 

























Figure 8.5 Response of HCT116 
p53+/+ cells following a 96 hour 
exposure to a series of MGBs 
under normoxic pHe 7.4 and pHe 
6.5. Each result represents the mean 
± standard deviation of three 




















































































































MGB 364 IC50>10 9.60 ± 0.55 >1.04 
MGB 176 4.418 ± 0.41 2.14 ± 0.09 2.06 
MGB 372 2.953 ± 0.60 3.78 ± 0.07 0.78 
MGB 373 1.286 ± 0.19 1.85 ± 0.05 0.69 
MGB 4 0.234 ± 0.005 9.72 ± 1.25 0.02 
 
Table 8.3 The IC50 values and pHR for a series of MGBs against the HCT116 
cell lines under normoxic pHe 7.4 and pHe 6.5 conditions. Each result 
represents the mean ± standard deviation of three independent experiments. 
 
8.4.4 The effect of MGBs against the HCT116 p53+/+ cell line under normoxic 
pHe 7.4 and hypoxic pHe 6.5 conditions 
HCT116 p53+/+ cells were treated with a dose concentration range of MGBs over 96 
hours under hypoxic pHe 6.5 conditions. The IC50 generated for the compounds was 
2.35 ± 0.02, 3.66 ± 0.16, 1.46 ± 0.05 µM and TME ratios were 1.88, 0.80, 0.88 for 
MGB 176, 372 and 373 respectively (figure 8.6 and table 8.4). There was no IC50 






























Figure 8.6 Response of HCT116 
p53+/+ cells following a 96 hour 
exposure to a series of MGBs 
under normoxic pHe 7.4 and 
hypoxic pHe 6.5. Each result 
represents the mean ± standard 



















































































































Hypoxia TME (SI) 
MGB 364 IC50>10 IC50 > 10 - 
MGB 176 4.418 ± 0.41 2.35 ± 0.02 4.65 
MGB 372 2.953 ± 0.60 3.66 ± 0.16 1.94 
MGB 373 1.286 ± 0.19 1.46 ± 0.05 1.29 
MGB 4 0.234 ± 0.005 IC50
 
> 10 1.30* 
 
Table 8.4 The IC50 values and TME (SI) for a series of MGBs against the 
HCT116 cell lines under normoxic pHe 7.4 and hypoxic pHe 6.5 conditions. 
Each result represents the mean ± standard deviation of three independent 
experiments. * refers to the SI value for the hypoxic data only and not the combo of 
hypoxia and acidic pHe. 
 
 
8.4.5 Summary on the effect of MGBs against the HCT116 cell line under TME 
conditions  
The results of the chemosensitivity studies performed in this chapter are summarised 
in tables 8.5 (IC50 values under different conditions) and 8.6 (various parameters 
derived from the IC50 values in comparison to the standard agents). Under normoxic 
conditions (pHe 7.4), a broad range of activity against HCT116 p53+/+ cells was 
observed with MGB 364 being least active (IC50 > 10 µM) and MGB 4 being most 
potent (IC50 = 0.234 ± 0.005 µM).  When evaluated under both hypoxic conditions, 
acidic pHe 6.5, and both hypoxic and acidic pHe conditions combined, the most 
significant finding was the almost complete loss of MGB 4 activity (table 8.5). This 
has a significant effect on pHR, HCR, TME and SI values as shown in table 8.6. Of 
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all the compounds evaluated, only MGB 176 showed HAP like activity although this 
was modest and below the values established for tirapazamine. This is nevertheless 
a promising lead compound to emerge from the screen which possesses modest 
HAP like activity and selectivity for cancer cells that is superior to the established 
anti-cancer drugs evaluated.  
Based on the results above, MGB 4 displayed the high levels of activity which was 
on par with some of the classic compounds tested and selectivity towards the cancer 
cell lines which was much greater than the classic compounds. Furthermore, MGB 
176 was the only compound evaluated here that showed HAP like activity. It was for 
this reason that both MGB 176 and MGB 4 were both chosen to be further tested in 
western blot analysis for the induction of γH2AX phosphorylation (a marker of DNA 
damage). 
 
















MGB 364 IC50>10 9.60 ± 0.55 8.20 ± 0.1 IC50 > 10 IC50>10 
MGB 176 4.418 ± 0.41 2.14 ± 0.09 1.77 ± 0.02 2.35 ± 0.02 10.94 ± 1.19 
MGB 372 2.953 ± 0.60 3.78 ± 0.07 2.05 ± 0.01 3.66 ± 0.16 7.135 ± 0.79 
MGB 373 1.286 ± 0.19 1.85 ± 0.05 0.93 ± 0.02 1.46 ± 0.05 1.909 ± 0.07 




 > 10 
 
Table 8.5 A summary of the response of HCT116 p53+/+ and ARPE-19 cells 
following continuous exposure to MGB netropsin and distamycin derivatives 
under normoxic and tumour microenvironment conditions. Each result 




Compound pHR HCR TME ratio SI  SI (TME) 
Cisplatin 0.75 0.44 0.3 1.84 0.55 
5-FU 0.55 0.40 0.27 2.10 0.57 
Etoposide  0.76 0.61 0.57 0.59 0.34 
Tirapazamine 0.61 9.55 n/a 2.33 22.46* 
MGB 364 1.04 1.22 n/a n/a n/a 
MGB 176 2.06 2.49 1.88 2.47 4.65 
MGB 372  0.78 1.44 0.80 2.41 1.94 
MGB 373 0.69 1.38 0.88 1.48 1.29 
MGB 4 0.02 0.003 n/a 42.73 1.30* 
 
Table 8.6 The effect of the TME on the response of cells to standard cytotoxic 
drugs and tirapazamine. pHR, HCR and TME represent the pH ratio, the hypoxic 
cytotoxicity ratio and tumour microenvironment ratio as defined in the methods 
section in results chapter (3.3.3). * refers to the SI value for the hypoxic data only 
and not the combination of hypoxia and acidic pHe. 
 
8.4.6 Western blot analysis for the early signs of DNA damage by MGB 4 and 
MGB 176 under normoxic pHe 7.4 
This was carried out by exposing HCT116 p53+/+ cells to a range of concentrations of 
MGB 4 or MGB 176 as shown in figures 8.7 and 8.8. A positive control doxorubicin 
was used as this classic chemotherapy drug possesses several mechanisms of 
action, one of which being the inhibition of topoisomerase II (known to induce double 
stranded DNA breaks). For MGB 4 the level of the tumour suppressor protein p53 
was also analysed. As shown in figure 8.7 the levels of γH2AX phosphorylation and 
p53 was increased substantially for doxorubicin but this was not the case for MGB 4 
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over a 24 hour time period where the levels of these two proteins were not higher 
than the 0.1% DMSO vehicle controls. Similar results were obtained for MGB 176 
(figure 8.8). 
 
Figure 8.7 Analysis of γH2AX phosphorylation following the treatment of 











Figure 8.8 Analysis of γH2AX phosphorylation following the treatment of 












The main objective of this study was to determine whether a group of MGB could 
possess more toxic and selective activity than those of classic chemotherapeutic 
agents tested in results chapter 3 and shown in table 8.6. Also of interest of this PhD 
study is to screen these compounds under those conditions which exist in the tumour 
microenvironment. The most potent compound from this study under normoxic (pHe 
7.4) conditions was MGB 4 and it is hypothesised that this is due to its high 
lipophilicity which is generally correlated with high activity in medicinal chemistry 
(Nichol et al., 2019). MGB 4 was also the most selective (SI - 42.73) compound 
amongst all of the MGBs including the cytotoxic drugs evaluated in chapter 3 
(table8.6) which is a positive result. 
Despite being the most potent MGB 4 under normoxic pHe 7.4 conditions, this was 
not the case under those conditions favouring the TME (pHe and hypoxia) where the 
efficacy of this compound is significantly reduced. This is a major shift in 
chemosensitivity and whilst the mechanistic reasons for this are unknown, it does 
demonstrate the value of the phenotypic screen as it can identify compounds that 
are adversely affected by the TME conditions (table 8.6). MGB 176 displayed some 
HAP like activity (HCR - 2.49, table 8.6) which is modest at best but this is a potential 
lead for further development of these compounds as potential HAP-like agents. 
MGB 176 and MBG 4 were both selected as lead compounds for further testing to 
determine if these are DNA damaging agents by γH2AX phosphorylation. This was 
carried out by western blotting and the data suggests that these compounds are not 
inducing DNA damage. This is however a preliminary conclusion as H2AX is not a 
universal marker of DNA damage and further assays are required to confirm this.  
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The MGBs were screened under various parameters, where MGB 4 initially 
displayed good activity and selectivity under normoxic pHe 7.4 conditions which is 
favourable to those classic chemotherapeutic drugs tested earlier in chapter 3. 
However MGB 4 was adversely affected by the TME conditions and although this is 
a negative outcome it identifies that the screen can also detect compounds that are 
resistant to the TME conditions. This tool allows the researcher to make an informed 
decision whether to develop or not to develop these compounds further only to find 
out later that they are completely ineffective against hypoxic cells that reside within 







Chapter 9: General conclusions 
Drug discovery is a lengthy and complex process that typically follows a target 
orientated or phenotypic screening approach (Jaibu et al., 2018). Whilst often seen 
as lacking significant intellectual input, phenotypic screening has undergone a 
resurgence in interest largely because it is one of the major sources of ‘first in class’ 
drugs that target multiple pathways that are important in cancer biology. In this 
thesis, a phenotypic screen designed to identify compounds that are preferentially 
active in the tumour microenvironment (TME) has been combined with an 
assessment of selectivity for cancer cells. The aim of this is to identify novel 
compounds that are selectively more effective against cancer cells that reside within 
the TME, a region of tumours that is associated with chemotherapeutic limitations 
and poor clinical outcome in patients (Höckel and Vaupel, 2001; Kato et al., 2013). 
To provide a baseline or yardstick, three classic chemotherapeutic drugs, cisplatin, 
etoposide and 5-FU were tested against the colorectal cancer cell line HCT116 
p53+/+ under physiological and TME conditions. These conditions were (i) normoxia / 
pHe 7.4 (ii) normoxia / pHe 6.5, (iii) hypoxia / pHe 7.4 and (iv) hypoxia / pHe 6.5. The 
results demonstrated that TME conditions adversely affected the activity of all three 
compounds (chapter 3). Statistical analysis using one-way ANOVA was significant in 
all cases where data from normoxic / pHe 7.4 was compared to hypoxia / pHe 6.5 (p 
≥ 0.05). The data generated under hypoxic conditions (pHe 6.5) for all three classic 
chemotherapeutic compounds adversely affected selectivity indices with tumour cells 
being less responsive than the non-cancer ARPE-19 cell line. These results are 
consistent with the issue of poor tumour selectivity and lack of efficacy against the 
hypoxic fraction of tumours associated with world leading chemotherapeutic drugs. 
The data generated from the phenotypic screen of the classic chemotherapeutic 
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compounds were used as a comparative baseline standard throughout this PhD. To 
further validate the screen, the HAP tirapazamine was also included and as 
expected, it demonstrated enhanced efficacy under hypoxic conditions (results 
chapter 3, figure 3.4). Further studies are required to assess the response of 
tirapazamine under hypoxic and acidic pHe conditions. To conclude, the results in 
this chapter effectively demonstrate that TME conditions (i) adversely affect the 
activity of established drugs and (ii) promote the activity of compounds designed to 
work better under TME conditions. The screen should therefore be capable of 
identifying compounds with preferential activity and compounds that are adversely 
affected by TME conditions.  
Having established that the TME phenotypic screen is capable of identifying 
compounds that are preferentially active under TME conditions, novel compounds 
were then evaluated in this screen. Compounds were kindly provided from various 
collaborators across the world which were, (i) Ruthenium, Iridium and Rhodium 
based napthyridines, thiourea derivatives, benzylthiourea ligands and aroylthiourea 
complexes, (ii) Bromo-hexitol prodrugs, (iii) NHC-Ag based complexes, (iv) Minor 
groove binders and (v) Tyrosine kinase inhibitor (dasatinib) with the attachment of a 
2-nitroimidazole bioreductive trigger. The compounds above are either novel 
compounds or designed as analogues of existing compounds (with unknown 
mechanisms) and can be broadly segregated into two main groups (i) those that 
were designed to have HAP-like properties (bromo-hexitol prodrugs and DAS-HAP) 
and (ii) completely unknown, novel compounds.  
In total there were 72 (excluding the classis chemotherapeutic compounds) different 
compounds that were phenotypically screened under the TME conditions and from 
these, 40 compounds (55.5%) were selective towards the cancer cell line with a 
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selectivity index > 1. A further 8 compounds (11.1%) were further activated by pHe 
6.5 alone under normoxic conditions. A total of 24 compounds (33.3%) displayed 
HAP like abilities with a HCR value > 1 and finally 3 compounds (4.1%) exhibited 
enhanced toxicity with the combination of pHe 6.5 with hypoxia. Furthermore, 19 
compounds (26.3%) which were not designed as bio-reductive drugs were more 
active under hypoxic (pHe 7.4) conditions (HCR > 1) when compared to normoxia 
(pHe 7.4) and this is something that may have been missed if this phenotypic 
screening strategy was not employed. A prime example of this is the 1-8, 
napthyridine, KMR-SA-24 (not designed as a HAP) which displayed high selectivity 
towards the cancerous cell line and was also further activated under hypoxic (pHe 
7.4) conditions. This compound shows much promise with some refinements to the 
as a potential HAP candidate. In comparison to the classic chemotherapeutic 
compounds, 15 (20.8%) of the compounds screened were more selective (SI > 2.10) 
than the established drugs. A major finding of this thesis therefore is that screening 
compounds under both acidic and hypoxic conditions has identified novel 
compounds that would not have been discovered otherwise. The phenotypic screen 
described in this study therefore represents a novel contribution to the field with the 
potential to identify lead compounds that have the ability to target the physiological 
TME of tumours. 
Looking in more detail at the more specific highlights of this thesis, not all of the 
dibromohexitols exhibited HAP like properties or were influenced by all of the TME 
conditions apart from DS10 which displayed preferential activity under a combination 
of hypoxia and acidic pHe conditions. DAS-HAP although not as toxic as its 
counterpart dasatinib displayed HAP like abilities with superior HCR in comparison to 
dasatinib against the H460 cell line. This is striking as dasatinib has been previously 
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shown to not be as toxic against the H460 cell line under hypoxic conditions when 
compared with normoxic conditions. Here we have demonstrated for the first time 
that the addition of the N-OXIDE attachment to dasatinib makes this a very potent 
HAP. The organometallic compounds were not impressive with regards to toxicity 
alone regardless of their preferential selectivity towards the cancer cells. A major 
finding from this study was the KMR-SA-24 complex which despite not being as toxic 
as the other complexes or compounds in this study, it still possessed good HAP like 
properties.  These compounds were not designed to work against the TME but this 
particular example demonstrates that the phenotypic screen can identify compounds 
that would not have been identified otherwise. Similarly, JH532 from the NHC Ag 
complexes displayed equitoxic activity under the TME conditions. All of the NHC Ag 
complexes however showcased moderate to good levels of selectivity towards the 
cancer cells which is also an important decision point for the selection of potential 
lead compounds. The MGBs were the last set of compounds that were tested in this 
study and from the 5 MGBs that were screened, MGB 4 displayed the most potent 
activity and selectivity towards the cancer cell line under normoxic conditions. MGB4 
when screened further under the TME conditions did not perform as well. This 
screen therefore also demonstrates its ability to identify those compounds that may 
not be suitable under TME conditions. MGB4 is nevertheless an interesting 
compound because of its inherent selectivity for cancer cells under normoxic 
conditions. Therefore the following hit or lead compounds identified using this 
phenotypic screen were DS10, DAS-HAP, KMR-SA-24, JH532, MGB4 and MGB 
176. 
The approach described in this study is effectively a pilot study and there are 
numerous ways in which the screen could be improved or expanded. For example, 
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the phenotypic screen employed in this PhD was not tumour specific and the 
HCT116 cell line was mainly used as an initial model to test the proposed 
hypothesis. A potential improvement therefore would be to utilise different cell lines 
and if this is taken to the extreme, the NCI60 screening approach to screening could 
be implemented. There are obvious cost and time implications associated with 
expanding the number of cell lines and this needs to be carefully considered when 
designing a screen of this nature.  This may however be favourable for compounds 
that hit specific targets such as DAS-HAP where high levels of Src have been 
previously reported in the colorectal cancer cell lines. Whilst DAS-HAP was 
specifically designed, it is conceivable that randomly selected compounds which 
target specific pathways could be missed if the cell lines used don’t express the 
specific target of interest.  
Another area that needs to be expanded is characterisation of existing approved 
anti-cancer drugs in the screen. Due to time constraints, only 3 classic 
chemotherapeutic drugs were tested against the physiological TME screen. By 
enhancing the library of classic chemotherapeutic compounds in this study under the 
physiological and TME conditions, the phenotypic screen may provide a more in 
depth overview as to how these classic compounds behave in the TME conditions. 
A 2D monolayer model was used to screen the number of compounds under TME 
conditions (hypoxia and pHe 6,5) and this provided a quick and robust ‘tool’ to 
assess the effects of the TME on compounds. Whilst high throughput screening in 
drug discovery is also carried out in 2D cell culture models (which is cost and time 
effective), these models do not mimic the complexity of the TME in tumours 
(Langhans, 2018). An area where this approach could be improved therefore would 
be to use a 3D cell culture model such as spheroids which contain a much more 
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complex TME that closely mimics the features which are present in vivo (Ravi et al., 
2015). The use of 3D models however adds further complexity to the conduct of 
experiments, particularly when large numbers of compounds are involved. The 
phenotypic screen employed throughout this PhD provides a platform for the rapid 
testing such compounds under conditions that mimic some aspects of the TME and 
once hit compounds have been identified, further testing using multi-cell layers or 
spheroids would be an appropriate next step prior to in vivo testing. The use of 3D 
models would address the issue of drug penetration which is essential if compounds 
that target the TME are to work effectively (Minchinton and Tannock, 2006). 
In conclusion, the results of the work presented in this thesis have demonstrated that 
a phenotypic approach to the identification of compounds with preferential activity 
against the TME is both technically feasible and effective. Several compounds have 
been identified that are preferentially active under hypoxic, acidic pHe or a 
combination of the two conditions in vitro. These compounds require further 
evaluation in more complex 3D models but they demonstrate that the screen has 
identified new lead compounds that would not have been identified using 
conventional approaches. Furthermore, the screen also picks up compounds that are 
adversely affected (e.g. MGB 4) by the TME and this is equally valuable information 
for drug discovery programs. As with all screening approaches, the experimental 
models can be improved but there is a balance to be struck between increased 
complexity and the cost and efficiency of any changes. To conclude, the phenotypic 
screen described in this thesis is effective at identifying compounds with preferential 
activity against cells in the TME and further studies are required to expand upon this 
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